<SEC-DOCUMENT>0001493152-25-018269.txt : 20251016
<SEC-HEADER>0001493152-25-018269.hdr.sgml : 20251016
<ACCEPTANCE-DATETIME>20251016092026
ACCESSION NUMBER:		0001493152-25-018269
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20251014
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251016
DATE AS OF CHANGE:		20251016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Akari Therapeutics Plc
		CENTRAL INDEX KEY:			0001541157
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				981034922
		STATE OF INCORPORATION:			X0

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36288
		FILM NUMBER:		251396617

	BUSINESS ADDRESS:	
		STREET 1:		22 BOSTON WHARF ROAD
		STREET 2:		FL 7
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		(646) 350-0702

	MAIL ADDRESS:	
		STREET 1:		22 BOSTON WHARF ROAD
		STREET 2:		FL 7
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Celsus Therapeutics Plc.
		DATE OF NAME CHANGE:	20130621

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Morria Biopharmaceuticals PLC
		DATE OF NAME CHANGE:	20120201
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:AKTX="http://akaritherapeuticsplc.com/20251014">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_AKTX_akaritherapeuticsplc.com_20251014 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20251014_20251014 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001541157 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-10-14" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-10-14" id="Fact000004" name="dei:EntityCentralIndexKey">0001541157</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="aktx-20251014.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-10-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001541157</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-14</xbrli:startDate>
        <xbrli:endDate>2025-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-142025-10-14_custom_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001541157</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AKTX:AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-14</xbrli:startDate>
        <xbrli:endDate>2025-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-142025-10-14_custom_OrdinarySharesParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001541157</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AKTX:OrdinarySharesParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-14</xbrli:startDate>
        <xbrli:endDate>2025-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; text-transform: uppercase">Washington,
D.C. 20549</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_909_edei--DocumentType_c20251014__20251014_zq8Xxn44eFr6"><ix:nonNumeric contextRef="AsOf2025-10-14" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
REPORT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Pursuant
to Section 13 or 15(</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d<span style="text-transform: uppercase">)
of the</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Securities
Exchange Act of 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <b><span id="xdx_903_edei--DocumentPeriodEndDate_c20251014__20251014_zKeeGRsWBgpc"><ix:nonNumeric contextRef="AsOf2025-10-14" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">October 14, 2025</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90D_edei--EntityRegistrantName_c20251014__20251014_zKyuaybrlOH"><ix:nonNumeric contextRef="AsOf2025-10-14" id="Fact000011" name="dei:EntityRegistrantName">AKARI
THERAPEUTICS, PLC</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20251014__20251014_zvaqqZiHZXUi"><ix:nonNumeric contextRef="AsOf2025-10-14" format="ixt-sec:edgarprovcountryen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">England
    and Wales</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityFileNumber_c20251014__20251014_zETdn3BvpHb9"><ix:nonNumeric contextRef="AsOf2025-10-14" id="Fact000013" name="dei:EntityFileNumber">001-36288</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20251014__20251014_z0eiBLOhOnOi"><ix:nonNumeric contextRef="AsOf2025-10-14" id="Fact000014" name="dei:EntityTaxIdentificationNumber">98-1034922</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction</span></p>
                                                                             <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
                                                                             <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer</span></p>
                                                                             <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20251014__20251014_zEoqhvKHrZr5"><ix:nonNumeric contextRef="AsOf2025-10-14" id="Fact000015" name="dei:EntityAddressAddressLine1">22
Boston Wharf Road FL 7</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressCityOrTown_c20251014__20251014_zud5ORT5Qt8"><ix:nonNumeric contextRef="AsOf2025-10-14" id="Fact000016" name="dei:EntityAddressCityOrTown">Boston</ix:nonNumeric></span>,
<span id="xdx_90A_edei--EntityAddressStateOrProvince_c20251014__20251014_ztsIBzITpo2b"><ix:nonNumeric contextRef="AsOf2025-10-14" id="Fact000017" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20251014__20251014_zCVSRJEVY1Ea"><ix:nonNumeric contextRef="AsOf2025-10-14" id="Fact000018" name="dei:EntityAddressPostalZipCode">02210</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
including zip code, of Principal Executive Offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_900_edei--CityAreaCode_c20251014__20251014_zsHKnINuil5f"><ix:nonNumeric contextRef="AsOf2025-10-14" id="Fact000019" name="dei:CityAreaCode">(929)</ix:nonNumeric></span> <span id="xdx_902_edei--LocalPhoneNumber_c20251014__20251014_zQiwKEVpZcAj"><ix:nonNumeric contextRef="AsOf2025-10-14" id="Fact000020" name="dei:LocalPhoneNumber">274-7510</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--WrittenCommunications_c20251014__20251014_zRbwOWZZ7z0g"><ix:nonNumeric contextRef="AsOf2025-10-14" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--SolicitingMaterial_c20251014__20251014_zCzMyTeNi66h"><ix:nonNumeric contextRef="AsOf2025-10-14" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20251014__20251014_zEAHNLtPDSs8"><ix:nonNumeric contextRef="AsOf2025-10-14" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20251014__20251014_zOSrKB68Vjvh"><ix:nonNumeric contextRef="AsOf2025-10-14" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20251014__20251014__us-gaap--StatementClassOfStockAxis__custom--AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember_zosRJfuMxBf3"><ix:nonNumeric contextRef="From2025-10-142025-10-14_custom_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember" id="Fact000025" name="dei:Security12bTitle">American
    Depository Shares, each representing 2000 Ordinary Shares</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--TradingSymbol_c20251014__20251014__us-gaap--StatementClassOfStockAxis__custom--AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember_zLlww8I8mm8d"><ix:nonNumeric contextRef="From2025-10-142025-10-14_custom_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember" id="Fact000026" name="dei:TradingSymbol">AKTX</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_903_edei--SecurityExchangeName_c20251014__20251014__us-gaap--StatementClassOfStockAxis__custom--AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember_zoRJYmH48Kj5"><ix:nonNumeric contextRef="From2025-10-142025-10-14_custom_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--Security12bTitle_c20251014__20251014__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesParValue0.0001PerShareMember_zKWrLtzh9qhb"><ix:nonNumeric contextRef="From2025-10-142025-10-14_custom_OrdinarySharesParValue0.0001PerShareMember" id="Fact000028" name="dei:Security12bTitle">Ordinary
    Shares, par value $0.0001 per share*</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_907_edei--NoTradingSymbolFlag_dbT_c20251014__20251014__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesParValue0.0001PerShareMember_z0cIx6NdAV4c"><ix:nonNumeric contextRef="From2025-10-142025-10-14_custom_OrdinarySharesParValue0.0001PerShareMember" format="ixt:booleantrue" id="Fact000029" name="dei:NoTradingSymbolFlag">N/A</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_906_edei--SecurityExchangeName_c20251014__20251014__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesParValue0.0001PerShareMember_zg9eSYlOCFOl"><ix:nonNumeric contextRef="From2025-10-142025-10-14_custom_OrdinarySharesParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000030" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Trading,
but only in connection with the American Depositary Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_908_edei--EntityEmergingGrowthCompany_c20251014__20251014_zLyF7SjC4zY5"><ix:nonNumeric contextRef="AsOf2025-10-14" format="ixt:booleanfalse" id="Fact000031" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry
    into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2025, Akari Therapeutics, Plc (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase
Agreement&#8221;) with certain institutional investors providing for the issuance and sale, in a registered direct offering (the &#8220;Offering&#8221;),
of 3,125,000 American Depositary Shares (&#8220;ADSs&#8221;), each representing 2,000 ordinary shares, par value $0.0001 per share (&#8220;Ordinary
Shares&#8221;), of the Company. The ADSs have been offered and sold together with series E warrants to purchase up to an aggregate of
3,125,000 ADSs (&#8220;Series E Warrants&#8221;) and series F warrants to purchase up to an aggregate of 3,125,000 ADSs (&#8220;Series
F Warrants&#8221;, and, with the Series E Warrants, the &#8220;Warrants&#8221;), which are being issued in a concurrent private placement.
The combined purchase price per each ADS and accompanying Warrants sold in the Offering is $0.80. The aggregate gross proceeds from the
Offering are expected to be approximately $2.5 million, excluding any proceeds from any future exercises of Warrants. The Offering is
expected to close on or about October 16, 2025 (the &#8220;Closing Date&#8221;), subject to the satisfaction of customary closing conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds for working capital, general corporate purposes, and continued research and development (&#8220;R&amp;D&#8221;).
Specifically with regard to its focused R&amp;D work, the Company intends to use these funds to generate differentiated data on the novel
ADC payload that highlights its unique action against cancer and builds on new data being presented at the upcoming Society for Immunotherapy
Cancer Society Annual Meeting in early November.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series E Warrants have an exercise price of $0.98 per share, subject to customary adjustments as set forth therein, are exercisable commencing
on the effective date (the &#8220;Shareholder Approval Date&#8221;) of shareholder approval of the issuance of the ADSs issuable upon
exercise of the Warrants (the &#8220;Shareholder Approval&#8221;), and will have a 5-year term from the Shareholder Approval Date. The
Series F Warrants have an exercise price of $0.98 per share, subject to customary adjustments as set forth therein, are exercisable on
the Shareholder Approval Date, and will have a thirty-month term from the Shareholder Approval Date. If at the time of exercise there
is no effective registration statement registering the ADSs underlying the Warrants, the Warrants may be exercised on a cashless basis.
The Company has agreed to file a registration statement registering for resale the ADSs issuable upon exercise of the Warrants and
the Placement Agent Warrants (defined below) within 30 days of the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has agreed to call a meeting of its shareholders for the purpose of obtaining shareholder approval (the &#8220;Special
Meeting&#8221;) within sixty (60) days of the closing date of this transaction for the purpose of obtaining Shareholder Approval. If
Shareholder Approval is not obtained at the Special Meeting, the Company shall call a meeting every forty (40) days thereafter to seek
Shareholder Approval until Shareholder Approval is obtained or the Warrants are no longer outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of the Warrants will not have the right to exercise any portion of its Warrants if the holder (together with such holder&#8217;s
affiliates, and any persons acting as a group together with such holder or any of such holder&#8217;s affiliates or any other persons
whose beneficial ownership of Ordinary Shares would be aggregated with the holder&#8217;s or any of the holder&#8217;s affiliates), would
beneficially own Ordinary Shares in excess of 4.99% (or 9.99% at the holder&#8217;s election) of the number of the Ordinary
Shares outstanding immediately after giving effect to such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Purchase Agreement, the Company has agreed not to (i) enter into any agreement to issue or announce the issuance or proposed issuance
of any ADSs, Ordinary Shares or ordinary share equivalents, or (ii) file any registration statement or amendment or supplement thereto,
for a period of 30 days following the closing of the Offering, subject to certain customary exceptions. In addition, the Purchase Agreement
provides that for a period of one year following the closing of the Offering, the Company will not effect or enter into an agreement
to effect a &#8220;variable rate transaction&#8221; as defined in the Purchase Agreement, subject to certain customary exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement also contains representations, warranties, indemnification and other provisions customary for transactions of this
nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also entered into a placement agency agreement (the &#8220;Placement Agent Agreement&#8221;) with Ladenburg Thalmann &amp;
Co. Inc. (the &#8220;Placement Agent&#8221;), pursuant to which the Placement Agent agreed to serve as the exclusive placement agent
for the Company in connection with the Offering. The Company agreed to pay the Placement Agent a placement agent fee equal to 7.2% of
the gross proceeds from the sale of the securities in the Offering, a management fee equal to 0.5% of the gross proceeds from
the sale of the securities in the Offering and a non-accountable expense allowance of up to $75,000. The Placement
Agent or its designees will also receive warrants (the &#8220;Placement Agent Warrants&#8221;) on substantially the same terms as the
Series E Warrants in an amount equal to 4.0% of the aggregate number of ADSs sold in the Offering, or Placement Agent warrants
to purchase up to 125,000 ADSs, at an exercise price of $1.00 per share and will have a 5-year term from the commencement of sales
of the Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ADSs to be issued in the Offering are being issued pursuant to a prospectus supplement dated as of October 14, 2025, which was filed
with the Securities and Exchange Commission, in connection with a takedown from the Company&#8217;s shelf registration statement on Form
F-3 (File No. 333-289056) (the &#8220;Registration Statement&#8221;), which became effective on July 31, 2025, and the base prospectus
dated as of July 31, 2025 contained in such Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrants, the Placement Agent Warrants and the ADSs and Ordinary Shares underlying the Warrants and Placement Agent Warrants are
being offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933,
as amended (the &#8220;Securities Act&#8221;) and Rule 506(b) of Regulation D promulgated thereunder. The investors have represented
that they are accredited investors, as that term is defined in Regulation D, or qualified institutional buyer as defined in Rule 144(A)(a),
and have acquired the Warrants and the ADSs and Ordinary Shares underlying the Warrants as principals for their own respective
accounts and have no arrangements or understandings for any distribution thereof. The offer and sale of the foregoing securities is being
made without any form of general solicitation or advertising. The Warrants, the Placement Agent Warrants and the ADSs and Ordinary
Shares underlying the Warrants and Placement Agent Warrants have not been registered under the Securities Act or applicable state
securities laws. Accordingly, the Warrants, the Placement Agent Warrants and the ADSs and Ordinary Shares underlying the Warrants
and Placement Agent Warrants may not be offered or sold in the United States except pursuant to an effective registration statement or
an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Report on Form 8-K shall not constitute an offer to sell or the solicitation to buy, nor shall there be any sale of, any of the securities
described herein in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing descriptions of the Purchase Agreement, the Placement Agent Agreement, the Warrants and Placement Agent Warrants are
not complete and are qualified in their entirety by reference to the full text of such documents, copies of which are filed as exhibits
to this Report on Form 8-K and are incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the opinions of Greenberg Traurig, LLP (U.K.) relating to the legality of the Ordinary Shares underlying the ADSs issued
in the Offering is attached as Exhibit 5.1 hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company previously announced the Offering in a press release issued on October 15, 2025, which is included as an exhibit to a Report
on Form 8-K filed with the SEC on the same day.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Report on Form 8-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed
by the registrant under the Securities Act of 1933.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    3.02.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unregistered
    Sales of Equity Securities.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information under Item 1.01 of this Current Report on Form 8-K regarding the Warrants, Placement Agent Warrants and the ADSs and Ordinary
Shares issuable upon exercise of the Warrants and Placement Agent Warrants is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward
Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Report of on Form 8-K contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company&#8217;s present intent, beliefs
or expectations, but forward looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons
which are beyond the Company&#8217;s control. For example, this Report states that the Offering is expected to close on or about October
16, 2025. In fact, the closing of the Offering is subject to various conditions and contingencies as are customary in securities purchase
agreements in the United States. If these conditions are not satisfied or the specified contingencies do not occur, this Offering may
not close. For this reason, among others, you should not place undue reliance upon the Company&#8217;s forward looking statements. Except
as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order to reflect any event
or circumstance that may arise after the date of this Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
  9.01</b></span></td>
  <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
  Statements and Exhibits.</b></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Document</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">5.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm">Opinion of Greenberg Traurig LLP
    (U.K.)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Form of Securities Purchase Agreement</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-2.htm">Form of Placement Agent Agreement</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-3.htm">Form of Series E Warrant</a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-4.htm">Form of Series F Warrant</a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.5</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-5.htm">Form of Placement Agent Warrant</a></td></tr>


  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Akari
    Therapeutics, Plc</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    October 16, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Torsten Hombeck</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Torsten
    Hombeck</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kNFOwjAUhp+AdzhZvDIE2ibzYnc4kRhBl0mIt2U7QOPWNqcF4ZF8S7vNgRpdmmzrOd93/jaKhtHM3KsKCV5v8zkssbaV9Ag5bpBQFxg60ofHBMI7x61ynqT27W8PpiYwGJibEV+H/bbzoByWCXA25vFYxMBEEseQLaJBU0+N3qgStVeyAqlLyMhYUuglnTrDUh6NNvWpnbRCcsrooBuxrvwBgnEBT+Yg3w29OZjP02gwbJ9BNCOzt6FrevSoGxKmFdZhnOvoy2rTFHvnTZ08U6l0CPCyk4Quk7SS1R7ZiDHGM6R2e4H1GikwnAnB2eQrTo9Cxw7BSoJDg8NVJwAbbso11es/Rk9qJFVIfYfWOOVNH2Iqi12ONnw1d6W3Iqh+xvwnUC+Ei/GcDYMU6JsVGi38OkOf8hPA/6f3 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ex5-1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 50%; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT="">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 50%; padding-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
                                                                                                          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
                                                                                                          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Greenberg
                                            Traurig, LLP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shard, Level 8 | 32 London Bridge Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London
SE1 9SG, United Kingdom</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DX
332903 LONDON BRIDGE 10</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T:
+44 (0) 203 349 8700 | F: +44 (0) 207 900 3632</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Akari
Therapeutics, Plc</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Highdown
House</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeoman
Way</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Worthing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">West
Sussex</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BN99
3HH</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16
October 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Sirs,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BACKGROUND</B></FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.1</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
                                            role</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as English legal advisers to Akari Therapeutics, Plc (the &ldquo;<B>Company</B>&rdquo;), a public company with limited liability
(with registered number 5252842) incorporated under the laws of England and Wales, in connection with its registered direct offering
(the &ldquo;<B>Offering</B>&rdquo;) of 6,250,000,000 ordinary shares of US$0.0001 each in the capital of the Company (the &ldquo;<B>Offer
Shares</B>&rdquo;) represented by 3,125,000 American Depositary Shares (&ldquo;<B>ADSs</B>&rdquo;), to the purchasers thereof (the &ldquo;<B>Purchasers</B>&rdquo;)
on or about the date of this letter (the &ldquo;<B>Transaction</B>&rdquo;) pursuant to the securities purchase agreement between the
Company and the Purchasers dated 14 October 2025 (the &ldquo;<B>SPA</B>&rdquo;) and the Registration Statement on Form S-3 (the &ldquo;<B>Registration
Statement</B>&rdquo;) as filed by the Company with the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) under the Securities
Act 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), and the rules and regulations enacted thereunder (the &ldquo;<B>Rules</B>&rdquo;),
on July 29, 2025 and declared effective by the SEC on July 31, 2025 and the supplementary prospectus of the Company to
be dated on or about the date of this opinion which will form part of the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.2</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Defined
                                            terms and construction</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this opinion letter:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">headings
                                            are for ease of reference only and shall not affect the interpretation of this opinion letter;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">references
                                            to &ldquo;<B>paragraph</B>s&rdquo; are to paragraphs of this letter opinion;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>ADSs</B>&rdquo;
                                            means American Depositary Shares;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Articles</B>&rdquo;
                                            means the Company&rsquo;s articles of association from time to time in force;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(e)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Board</B>&rdquo;
                                            means the board of directors of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Board
                                            Resolution&rdquo; </B>has the meaning given to in in paragraph 2.1(a)(ii);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Companies
                                            Act</B>&rdquo; means the Companies Act 2006 (as amended);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt">This is a legal communication, not a financial communication. Neither this nor any other communication from this firm is intended to be, or should be interpreted as, an invitation or inducement to any person to engage in any investment activity.</P>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Greenberg Traurig, LLP is a limited liability partnership registered in England and Wales under number OC346053 and is regulated by the Solicitors Regulation Authority. The term shareholder is used to refer to a member of the LLP. A list of the members is open to inspection at the above address.</P>

<P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">www.gtlaw.com</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>16 October 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company</B>&rdquo;
                                            has the meaning given to in in paragraph 1.1;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Insolvency
                                            Act</B>&rdquo; means the Insolvency Act 1986 (as amended);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(j)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Ordinary
                                            Shares</B>&rdquo; means ordinary shares of par value $0.0001 per share in the capital of the
                                            Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Officer&rsquo;s
                                            Certificate&rdquo; </B>has the meaning given to in in paragraph 2.1;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Registration
                                            Statement</B>&rdquo; has the meaning given to in in paragraph 1.1;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Rules</B>&rdquo;
                                            has the meaning given to in in paragraph 1.1;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Searches</B>&rdquo;
                                            has the meaning given to in in paragraph 2.2, and &ldquo;<B>Search</B>&rdquo; shall be construed
                                            accordingly;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>SEC</B>&rdquo;
                                            has the meaning given to in in paragraph 1.1;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(p)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Securities
                                            Act</B>&rdquo; has the meaning given to in in paragraph 1.1; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Shareholders&rsquo;
                                            Resolutions&rdquo; </B>has the meaning given to in in paragraph 2.1(a)(i).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">2.</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXAMINATION
                                            AND ENQUIRIES</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.1</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Documents
                                            examined</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of giving this opinion letter, we have examined:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">a
                                            certificate dated 15 October</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025
                                            <FONT STYLE="font-style: normal">and signed by an officer of the Company (the &ldquo;<B>Officer&rsquo;s
                                            Certificate</B>&rdquo;) and the documents attached to it, including</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 70.9pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 28.35pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">a
                                            copy, certified as true and correct by the Officer&rsquo;s Certificate, of resolutions passed at
                                            the Company&rsquo;s annual general meeting on 30 June 2025 authorising the directors of the Company
                                            to allot (and grant rights to subscribe for) Ordinary Shares for the purposes of section
                                            551 of the Companies Act and conferring power on the directors of the Company to do so without
                                            the application of pre-emption rights pursuant to section 570 of the Companies Act (the &ldquo;<B>Shareholders&rsquo;
                                            Resolutions</B>&rdquo;); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 70.9pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 28.35pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            copy, certified as true and correct, of minutes of a meeting of the board of directors of
                                            the Company dated 14 October 2025 approving, inter alia, the issue of the Offer Shares and
                                            related ADSs and other related documents and actions (the &ldquo;<B>Board Resolutions</B>&rdquo;)
                                            certified as true and correct by the Officer&rsquo;s Certificate; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">copies,
                                            certified as true and correct by the Officer&rsquo;s Certificate, of the Articles, the Company&rsquo;s
                                            certificate of incorporation and the Company&rsquo;s last registered certificate of incorporation
                                            on change of name, each as available for free on-line viewing by the public on the website
                                            of Companies House; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            certificate of good standing issued by the Registrar of Companies in England and Wales on
                                            15 October 2025 (the &ldquo;<B>Certificate of Good Standing</B>&rdquo;), </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">together
the &ldquo;<B>Documents</B>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>16 October 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page 3</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.2</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Searches</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
approximately</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.34
                                            a.m.</B> London time on 15 October <B>2025,</B> CRO Info (a third-party search company) carried
                                            out a search of the filing history page of the Companies House on-line database in respect
                                            of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.25
                                            a.m.</B> London time on 15 October <B>2025</B>, CRO Info made an enquiry of the Insolvency
                                            and Companies List (formerly known as the Companies Court) in London in relation to the Company;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.33
                                            a.m.</B> London time on 15 October <B>2025,</B> CRO Info made an enquiry at The Gazette in
                                            relation to the Company,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">together
the &ldquo;<B>Searches</B>&rdquo; and each a &ldquo;<B>Search</B>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.3</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
                                            other examination or enquiry</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of giving this opinion letter, we have only examined and relied on the Documents and made the Searches. We have made no further
enquiries concerning the Company or any other matter in connection with the giving of this opinion letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.4</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Matters
                                            of fact</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have made no enquiry, and express no opinion, as to any matter of fact. As to matters of fact which are material to this opinion letter,
we have relied entirely and without further enquiry on statements made in the Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">3.</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OPINIONS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.1</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
                                            statements regarding opinions</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            opinions set out in the remainder of this paragraph&nbsp;3 are given on the basis of the
                                            examination and enquiries referred to in paragraph&nbsp;2 and the assumptions made in Appendix&nbsp;1
                                            and are subject to the qualifications set out in Appendix 2.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            opinion letter is strictly limited to the matters expressly stated in the remainder of this
                                            paragraph&nbsp;3 and is not to be construed as extending by implication to any other matter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            express no opinion on any taxation matter, and none is implied or may be inferred.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.2</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company is a public company incorporated with limited liability under the laws of England
                                            and Wales and existing under the laws of England and Wales.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            searches and the enquiries referred to in paragraph 2.2 revealed that no order, petition
                                            or resolution for winding-up, no interim or final administration order and notice of the
                                            appointment of a receiver, administrative receiver or administrator has been filed at that
                                            time with respect to the Company and no moratorium pursuant to the Corporate Insolvency and
                                            Governance Act 2020 had been granted in respect of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>16 October 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page 4</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offer
                                            Shares</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
receipt of the aggregate consideration for the Offer Shares in accordance with the SPA, and entry of the names of the appropriate persons
in the Company&rsquo;s register of members, the Offer Shares will be validly issued, fully paid and no further amount may be called thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">4.</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LAW
                                            AND RELIANCE</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.1</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>English
                                            law at today&rsquo;s date</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            opinion letter shall be governed by, and construed in accordance with, English law and relates
                                            only to English law as applied by the English courts as at today&rsquo;s date. We do not undertake
                                            or accept any obligation to update this opinion letter to reflect subsequent changes in English
                                            law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            express no opinion as to, and we have not investigated for the purposes of this opinion letter,
                                            the laws of any jurisdiction other than England and Wales.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            express no opinion on matters of fact.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.2</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reliance</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are furnishing this opinion letter to you, solely for your benefit in connection with the Registration Statement. It may be relied upon
by you and by persons entitled to rely upon it pursuant to applicable provisions of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to your filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not admit
that we are in the category of persons whose consent is required under section 7 of the Securities Act or the Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yours
faithfully</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>/s/
<B>Greenberg Traurig, LLP</B></U></I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Greenberg
Traurig, LLP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>16 October 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page 5</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPENDIX
1<BR>
ASSUMPTIONS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signatures
                                            and Documents</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            genuineness of all signatures (including electronic signatures), seals and stamps.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            authenticity and completeness of all documents submitted to us as originals and that all
                                            deeds and counterparts were executed in single physical form.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            documents dated earlier than the date of this opinion letter which we have reviewed remain
                                            accurate, complete and in full force and effect at the date of this opinion letter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            conformity with the original documents of all documents submitted to us as drafts or copies
                                            and the authenticity and completeness of all such original documents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            documents or extracts of documents submitted to us as copies or received in portable document
                                            format (PDF) conform to the originals, and that the original documents of which such copies
                                            or facsimiles or PDFs have been supplied to us were authentic and complete.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
                                            each of the individuals who claims to be an officer of the Company is the individual whom
                                            he or she claims to be and holds the office he or she claims to hold.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            person whose name and electronic signature appears in the signature block of any Document
                                            is the person who signed and that signature was applied with the intention to authenticate
                                            that document.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Resolutions
                                            and constitutional matters</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Board Resolutions were duly passed by the Board in accordance with the Articles. The Board
                                            Resolution is complete and correct and has not been amended or rescinded and is in full force
                                            and effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Shareholders&rsquo; Resolutions were duly adopted by the requisite shareholders of the Company
                                            and have not been amended or rescinded and are in full force and effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            director of the Company has disclosed any interest which he or she may have in the matters
                                            contemplated by the Board Resolution in accordance with the provisions of the Companies Act
                                            and the Articles and none of the directors of the Company has any interest in such matters
                                            except to the extent permitted by the Articles.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Offer Shares will be duly allotted by a valid resolution of the Board, a duly authorised
                                            Board committee or a duly authorised director, in each case, duly passed, in accordance with
                                            the Articles, the Companies Act 2006 and (in the case of a Board committee or authorised
                                            director) the delegation to that committee or director, and pursuant to: (A) a valid authorisation
                                            under section 551 of the Companies Act 2006; and (B) a valid power under section 570 of the
                                            Companies Act 2006 to allot the Offer Shares as if section 561 of the Companies Act 2006
                                            did not apply to the allotment and that those sections of the Companies Act will continue
                                            in force unamended at all relevant times.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
                                            no pre-emptive or similar rights exist or have been created over or in respect of any Offer
                                            Shares other than pre-emption rights arising under section 561 of the Companies Act 2006.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            at the date on which the Company allots and issues the Offer Shares, the Company will have
                                            received the aggregate consideration payable for those Offer Shares as &ldquo;cash consideration&rdquo;
                                            (as defined in section 583(3) of the Companies Act 2006), such aggregate consideration being
                                            not less than the nominal value of those Offer Shares; and that section 583(3) of the Companies
                                            Act 2006 will continue in force unamended at all relevant times.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>16 October 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page 6</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accuracy
                                            and completeness of information</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
                                            there is no fact, matter (such as a mistake or misrepresentation before or at the time any
                                            document was entered into or a subsequent breach, release, waiver or variation of any right
                                            or provision) or additional document between some or all of the parties which would or might
                                            affect this opinion letter and which was not revealed to us by the documents examined or
                                            the searches and enquiries made by us in connection with the giving of this opinion letter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            factual accuracy of the Officer&rsquo;s Certificate as at the date hereof, and that there have
                                            been no amendments to the Articles since the date of the Officer&rsquo;s Certificate.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            information disclosed by the Searches is true, accurate and complete and up-to-date and there
                                            is no information which should have been disclosed by the Searches which has not been disclosed
                                            for any reason.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            at the date on which the Company allots and issues the Offer Shares, the documents examined
                                            or the searches and enquiries made by us in connection with the giving of this opinion letter
                                            would not be rendered untrue, inaccurate, incomplete or out of date in any relevant respect
                                            by reference to subsequent facts, matters, circumstances or events.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insolvency</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is and will be at all relevant times able to pay its debts when due (within the meaning of the Insolvency Act) and (i) will not
become unable to pay its debts when due, or otherwise insolvent as a matter of applicable law; (ii) no proceedings have been or will
be at any relevant time commenced or steps taken for the winding up of the Company or for the appointment of a receiver, trustee, manager,
administrator, moratorium monitor or similar officer in respect of all or any assets of the Company; and (iii) has not taken and will
not take and no other person has taken or will take analogous procedures or steps in any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
                                            Assumptions</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            applicable laws in force at all relevant times will be complied with in respect of anything
                                            done in relation to the offering, sale, issue and (where applicable) allotment of the Offer
                                            Shares, including, without limitation, all applicable provisions of the Financial Services
                                            and Markets Act 2000 (as amended) and all applicable regulations made under it including
                                            the rules, requirements, directions and guidance issued by the Financial Conduct Authority
                                            and/or the Prudential Regulation Authority in force at all relevant times.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            Ordinary Shares are, or are intended to be, admitted to trading on any market, exchange or
                                            trading platform situated or operating in the United Kingdom.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            consents, licences, approvals, notices, filing, publications and registrations which are
                                            necessary under any applicable laws in connection with the offering, sale, issue and (where
                                            applicable) allotment of Ordinary Shares have been made or obtained or will be made and obtained
                                            within the period permitted by such laws or regulations and are or will be in full force
                                            and effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            agreement, document or obligation to or by which the Company (or its assets) is a party or
                                            bound and no injunction or other court order against or affecting the Company would be breached
                                            or infringed by the performance of the transactions contemplated by the Registration Statement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            is and will be no fact or matter (such as bad faith, coercion, duress, undue influence or
                                            a mistake or misrepresentation before or at the time any agreement or instrument is entered
                                            into, a subsequent breach, release, waiver or variation of any right or provision, an entitlement
                                            to rectification or circumstances giving rise to an estoppel) and no additional document
                                            between any relevant parties which in either case would or might affect this opinion letter
                                            and which was not revealed to us by the documents examined or the searches and enquiries
                                            made by us in connection with the giving of this opinion letter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign
                                            law matters</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no provisions of the laws of any jurisdiction outside England and Wales which would or might affect the opinions given in paragraph
3 of this opinion letter and insofar as the laws of any jurisdiction outside England and Wales may be relevant to such opinions, such
laws have been and will be complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>16 October 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page 7</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>APPENDIX
2<BR>
QUALIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accuracy
                                            and completeness of information</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Certificate of Good Standing and the Searches are not capable of revealing conclusively whether
                                            or not:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 1in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            winding-up order has been made or a resolution passed for the winding up of a company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 1in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            administration order has been made; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 1in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            administrator, liquidator, receiver, administrative receiver or moratorium monitor has been
                                            appointed,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
notice of these matters may not be filed with Companies House or the Insolvency and Companies List immediately and, when filed, may not
be entered on the public record of the relevant company immediately. In addition, the Searches are not capable of revealing whether or
not a winding-up petition or an application for an administration order has been presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Searches relate only to a compulsory winding up and are not conclusively capable of revealing
                                            whether or not a winding-up petition in respect of a compulsory winding up has been presented,
                                            since details of the petition may not have been entered on the records of Companies House
                                            or the Insolvency and Companies List immediately or, in the case of a petition presented
                                            to the County Court, may not have been notified to the Insolvency and Companies List and
                                            entered on such records at all.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Obligations
                                            performed outside England</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
                                            an obligation is to be performed in a jurisdiction outside England, that obligation may not
                                            be enforceable in England to the extent that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 1in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
                                            performance would be illegal under the laws of, or contrary to public policy or to the exchange
                                            control regulations of, the other jurisdiction or the law applicable to the obligation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 1in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            English courts take account of the law of that jurisdiction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
                                            arising from insolvency law</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion letter is subject to all insolvency, bankruptcy, liquidation, receivership, moratorium, reorganisation, compromise or similar
laws affecting the rights of creditors (including secured creditors) generally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Miscellaneous
                                            </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            opinions expressed in this opinion letter are subject to the effects of any United Nations,
                                            European Union or United Kingdom sanctions or other similar measures implemented or effective
                                            in the United Kingdom.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            do not express any opinion as to any taxation (including without limitation stamp duty and
                                            stamp duty reserve tax) which may arise or be incurred as a result of or in connection with
                                            the Ordinary Shares or as to tax matters generally.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
                                            the Articles, the Company may restrict the transferability of the Ordinary Shares or the
                                            rights of holders of such Ordinary Shares to hold or vote them.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of October 14, 2025, between Akari Therapeutics, Plc,
a public company with limited liability incorporated under the laws of England and Wales (the &ldquo;<U>Company</U>&rdquo;), and each
purchaser identified on the signature pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and
collectively the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to (i) an effective registration statement under the Securities
Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;) as to the Shares and (ii) an exemption from the registration requirements
of Section 5 of the Securities Act contained in Section 4(a)(2) thereof and/or Regulation D thereunder as to the Warrants, the Company
desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities
of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>ADS(s)</U>&rdquo;
means American Depositary Shares issued pursuant to the Deposit Agreement (as defined below), each representing 2,000 Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>August
2025 Purchase Agreement</U>&rdquo; means the Ordinary Share Purchase Agreement, dated as of August 29, 2025, by and between the Company
and White Lion Capital LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or London
or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Placed ADSs and the Warrants pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1st) Trading
Day following the date hereof (or the second (2<SUP>nd</SUP>) Trading Day following the date hereof if this Agreement is signed on a
day that is not a Trading Day or after 4:00 p.m. (New York City time) and before midnight (New York City time) on a Trading Day).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
UK Counsel</U>&rdquo; means Greenberg Traurig LLP, with offices located at The Shard, Level 8, 32 London Bridge Street, London SE1 9SG.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
US Counsel</U>&rdquo; means Greenburg Traurig LLP, with offices located at One Vanderbilt Avenue, New York, NY 10017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Deposit
Agreement</U>&rdquo; means the Deposit Agreement dated as of December 7, 2012, among the Company, Deutsche Bank Trust Company Americas,
as Depositary, and the owners and holders of ADSs from time to time, as such agreement may be amended or supplemented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) Ordinary Shares or ADSs, options or RSUs to employees, officers or directors of the Company
pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors
or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company,
(b) securities upon the exercise of the Warrants, warrants to the Placement Agent in connection with the transactions pursuant to this
Agreement and any securities upon exercise of warrants to the Placement Agent and/or other securities exercisable or exchangeable for
or convertible into Ordinary Shares or ADSs issued and outstanding on the date of this Agreement, provided that such securities have
not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange
price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such
securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested
directors of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and
carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition
period in Section 4.12(a) herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person)
which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business
of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction
in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing
in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Lock-Up
Agreement</U>&rdquo; means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors, officers,
and 10% and greater stockholders of the Company, in the form of <U>Exhibit B</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Ordinary
Share(s)</U>&rdquo; means the ordinary shares of the Company, par value $0.0001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Ordinary
Share Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Ordinary Shares or ADSs, including, without limitation, any debt, preferred stock, right, option, RSU, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Ordinary
Shares or ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
ADS Purchase Price</U>&rdquo; equals $0.80, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of ADSs and/or Ordinary Shares that occur after the date of this Agreement, representing $0.0004 per Placed
Share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placed
ADSs</U>&rdquo; means the ADSs deliverable and to be delivered at Closing to the Purchasers pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placed
Shares</U>&rdquo; means Ordinary Shares represented by the Placed ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means Ladenburg Thalmann &amp; Co. Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the final base prospectus filed for the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the
Commission and delivered by the Company to each Purchaser at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission File No. 333-289056 which registers the sale of the Ordinary
Shares represented by the ADSs to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Placed ADSs, the Placed Shares, the Warrants, the Warrant ADSs and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Series
E Warrants</U>&rdquo; means the warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Series
E Warrants shall be exercisable upon Shareholder Approval and have a term of exercise equal to five (5) years from the initial exercise
date, in the form of <U>Exhibit A-1</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Series
F Warrants</U>&rdquo; means the warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Series
F Warrants shall be exercisable upon Shareholder Approval and have a term of exercise equal to thirty (30) months from the initial exercise
date, in the form of <U>Exhibit A-2</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in;"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Shareholder
Approval&rdquo; means such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor
entity) from the shareholders of the Company with respect to issuance of all of the Warrants and the Warrant ADSs and the Warrant Shares
upon the exercise thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Shareholder
Meeting&rdquo; shall have the meaning ascribed to such term in Section 4.11.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing Ordinary Shares and/or ADSs).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Placed ADSs, each Placed ADS representing 2,000 Ordinary
Shares, and Warrants purchased hereunder as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next
to the heading &ldquo;Subscription Amount,&rdquo; in United States dollars and in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the ADSs are listed or quoted for trading on the date in question:
the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange
(or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Lock-Up Agreement, the Warrants, all exhibits and schedules thereto and hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs then listed or quoted on
a Trading Market, the daily volume weighted average price of the ADSs for such date (or the nearest preceding date) on the Trading Market
on which the ADSs then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to
4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the ADSs for such
date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs not then listed or quoted for trading on OTCQB
or OTCQX and if prices for the ADSs are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per ADS so reported, or (d) in all
other cases, the fair market value of an ADS as determined by an independent appraiser selected in good faith by the Purchasers of a
majority in interest of the Placed ADSs and Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
ADSs</U>&rdquo; means the ADSs issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Shares</U>&rdquo; means the Ordinary Shares issuable upon exercise of the Warrants, which will be represented by the Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Series E Warrants and the Series F Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASE AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the
Purchasers, severally and not jointly, agree to purchase an aggregate of $2,500,000.00 of Placed ADSs and Warrants, at the Per ADS Purchase
Price. Each Purchaser shall deliver to the Company, via wire transfer, immediately available funds equal to such Purchaser&rsquo;s Subscription
Amount as set forth on the signature page hereto executed by such Purchaser, which funds shall be made available for &ldquo;Delivery
Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) settlement with the Company or its designee. The Company shall deliver to each Purchaser
its respective Placed ADSs and Warrants as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the
other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections
2.2 and 2.3, the Closing shall occur at such location as the parties shall mutually agree. Unless otherwise directed by the Placement
Agent, settlement of the Placed ADSs shall occur via DVP (i.e., on the Closing Date, the Company shall issue the Placed ADSs registered
in the Purchasers&rsquo; names and addresses and released by the Depositary directly to the account(s) at the Placement Agent identified
by each Purchaser; upon receipt of such Placed ADSs, the Placement Agent shall promptly electronically deliver such Placed ADSs to the
applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
legal opinions of Company UK Counsel and Company US Counsel, in a form reasonably acceptable to the Placement Agent, Purchasers and the
Depositary;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
subject to the last sentence of Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions,
on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
subject to the last sentence of Section 2.1, a copy of the irrevocable instructions to the Depositary instructing the Depositary to deliver
on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) ADSs equal
to such Purchaser&rsquo;s Subscription Amount divided by the Per ADS Purchase Price, registered in the name of such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
a Series E Warrant registered in the name of such Purchaser to purchase up to a number of Ordinary Shares represented by ADSs equal to
100% of such Purchaser&rsquo;s Placed ADSs, with an exercise price equal to $0.98, subject to adjustment therein (such original Series
E Warrant certificate may be delivered within three Trading Days of the Closing Date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
a Series F Warrant registered in the name of such Purchaser to purchase up to a number of Ordinary Shares represented by ADSs equal to
100% of such Purchaser&rsquo;s Placed ADSs, with an exercise price equal to $0.98, subject to adjustment therein (such original Series
F Warrant certificate may be delivered within three Trading Days of the Closing Date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
on the date hereof, the duly executed Lock-Up Agreements; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such Purchaser&rsquo;s Subscription Amount, which shall be made available for DVP settlement with the Company or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a
specific date therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
as of a specific date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
from the date hereof to the Closing Date, trading in the ADSs shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall
be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the
corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All of the direct and indirect subsidiaries of the Company are set forth on <U>Schedule 3.1(a)</U>. The Company
owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and
all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and
free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references
to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and, if such concept is applicable, in good standing under the laws of the jurisdiction of its incorporation or organization,
with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted.
Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles
of association, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct
business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case
may be, would not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability
of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial
or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability
to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material
Adverse Effect</U>&rdquo;) and, so far as the Company is aware, no Proceeding has been instituted in any such jurisdiction revoking,
limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors or the Company&rsquo;s shareholders in connection herewith or therewith
other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of association, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) application(s)
to each applicable Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required
thereby, (iv) if applicable, the filing of Form D with the Commission and such filings as are required to be made under applicable state
securities laws, (v) the filing of the return of the allotment of the Placed Shares and the Warrant Shares when issued to the UK Registrar
of Companies in accordance with section 555 of the UK Companies Act 2006 (as amended), (vi) the registration of the allottee(s) of the
Placed Shares and the Warrant Shares when issued in the register of members of the Company, (vii) Shareholder Approval with respect to
the Warrants and (viii) such consents, waivers and authorizations that shall be obtained prior to Closing (collectively, the &ldquo;<U>Required
Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Issuance of the Placed Shares; Registration</U>. The Placed Shares are duly authorized and, when issued and paid for in accordance
with this Agreement, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company
other than restrictions on transfer in the Company&rsquo;s articles of association or imposed by applicable securities laws. The Company
has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on
July 31, 2025, including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement.
The Company was at the time of the filing of the Registration Statement eligible to use Form S-3. The Company is eligible to use Form
S-3 under the Securities Act and it meets the transaction requirements with respect to the aggregate market value of securities being
sold pursuant to this offering and during the twelve calendar (12) months prior to this offering, as set forth in General Instruction
I.B.6 of Form S-3. The Company and the Depositary have prepared and filed with the Commission registration statements relating to ADSs
on Form F-6 (File Nos.: 333-185197, File No. 333-234213 and File No: 333-262049) for registration under the Securities Act (the &ldquo;<U>ADS
Registration Statement</U>&rdquo;). The Registration Statement and the ADS Registration Statement are effective under the Securities
Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of
the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the
Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the Prospectus
with the Commission pursuant to Rule 424(b). At the time the Registration Statement, ADS Registration Statement and any amendments thereto
became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed
and will conform in all material respects to the applicable requirements of the Securities Act and did not and will not contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein
not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement
thereto was issued and at the Closing Date, conformed and will conform in all material respects to the applicable requirements of the
Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Capitalization</U>. The issued share capital of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>, which
<U>Schedule 3.1(g)</U> shall also include the number of ADSs issued in relation to Ordinary Shares. Except as set forth in <U>Schedule
3.1(g)</U>, the Company has not issued any Ordinary Shares since its most recently filed periodic report under the Exchange Act, other
than pursuant to the exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance of ADSs and Ordinary
Shares to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise of Ordinary
Share Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right
of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the
Transaction Documents, except as set forth in <U>Schedule 3.1(g)</U>. Except as a result of the subscription for and issuance of the
Securities and as set forth in <U>Schedule 3.1(g)</U>, there are no outstanding options, warrants, scrip rights to subscribe to, calls
or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable
for, or giving any Person any right to subscribe for or acquire, any ADSs and Ordinary Shares or the capital stock of any Subsidiary,
or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional
ADSs, Ordinary Shares or Ordinary Share Equivalents or capital stock of any Subsidiary. The issuance and sale of the Placed Shares will
not obligate the Company or any Subsidiary to issue ADSs and Ordinary Shares or other securities to any Person (other than the Purchasers).
Except as set forth in <U>Schedule 3.1(g)</U>, there are no outstanding securities or instruments of the Company or any Subsidiary with
any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities
by the Company or any Subsidiary. Except as set forth in <U>Schedule 3.1(g)</U>, there are no outstanding securities or instruments of
the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary.
The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement.
All of the outstanding Ordinary Shares of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued
in compliance with English law, and none of such outstanding Ordinary Shares was issued in violation of any preemptive rights or similar
rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others
is required for the issuance and sale of the Placed Shares. There are no shareholders agreements, voting agreements or other similar
agreements with respect to the Company&rsquo;s Ordinary Shares to which the Company is a party or, to the knowledge of the Company, between
or among any of the Company&rsquo;s shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
one year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and
the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements
of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and
regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in
accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and
its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as <U>specifically disclosed in a subsequent SEC Report filed or furnished prior to the date hereof</U>
or as set forth on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development that has had or that could reasonably
be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other
than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities
not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission,
(iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of
cash or other property to its shareholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its Ordinary
Shares and (v) the Company has not issued any Ordinary Shares or ADSs to any officer, director or Affiliate, except pursuant to existing
Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information.
Except for the issuance of the Securities contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>, no event, liability,
fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the
Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would
be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that
has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Litigation</U>. Except as set forth on <U>Schedule 3.1(j)</U>, there is no action, suit, inquiry, notice of violation, proceeding
or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their
respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state,
county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;) which (i) adversely affects or challenges the legality, validity
or enforceability of any of the Transaction Documents or the Securities or (ii) would, if there was an unfavorable decision, have or
reasonably be expected to result in a Material Adverse Effect. Except as set forth on <U>Schedule 3.1(j)</U>, neither the Company nor
any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability
under federal or state securities laws or a claim of breach of fiduciary duty. Except as set forth on <U>Schedule 3.1(j)</U>, there has
not been, and to the knowledge of the Company, there is no pending or contemplated, any investigation by the Commission involving the
Company or any current or former director or officer of the Company that would have or reasonably be expected to result in a Material
Adverse Effect. The Commission has not issued any stop order or other order suspending the effectiveness of any outstanding registration
statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement. The Company and its Subsidiaries are in compliance
with all applicable U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms
and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is in violation of any statute, rule, ordinance or regulation of any governmental authority,
including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health
and safety, product quality and safety and employment and labor matters, except in each case as would not have or reasonably be expected
to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating
to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where in each clause (i), (ii)
and (iii), the failure to so comply or the failure of such receipt could not be reasonably expected to have, individually or in the aggregate,
a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits would not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit which would reasonably expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. Except where the failure to possess could not reasonably be expected to result in a Material Adverse Effect,
the Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable
title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free
and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with
the use made and proposed to be made of such property by the Company and the Subsidiaries, and (ii) Liens for the payment of federal,
state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither
delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by
them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance except where the failure
to comply could not reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights
has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date
of this Agreement, except as would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary
has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim
or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could
not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property
Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company
and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual
properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe that
it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Transactions With Affiliates and Employees</U>. Except as set forth on <U>Schedule 3.1(r)</U>, none of the officers or directors of
the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any
officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee
has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other
than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company
and (iii) other employee benefits, including share option, restricted share unit and other equity-based compensation under any equity
plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in material compliance with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. Except as set forth in
the SEC Reports, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable
assurance that: (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information
required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized
and reported, within the time periods specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have
evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period
covered by the most recently filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The
Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about
the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation
Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the
Company and its Subsidiaries that have materially adversely affected, or is reasonably likely to materially adversely affect, the internal
control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. Except as set forth in the Prospectus Supplement, no brokerage or finder&rsquo;s fees or commissions are or will
be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this
Section that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be required to be registered as or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment
Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo;
subject to registration under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Registration Rights</U>. Except as set forth on <U>Schedule 3.1(v)</U>, no Person has any right to cause the Company or any Subsidiary
to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Listing and Maintenance Requirements</U>. The ADSs are registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the
Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of ADSs
under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.
The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the ADSs are or have
been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading
Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all
such listing and maintenance requirements. The ADSs are currently eligible for electronic transfer through The Depository Trust Company
or another established clearing corporation and the Company is current in payment of the fees to The Depository Trust Company (or such
other established clearing corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s articles of association (or similar charter documents) or the laws
of its jurisdiction of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of
the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or
counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise
disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure
Schedules to this Agreement, is true and correct in all material respects and does not contain any untrue statement of a material fact
or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which
they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement
taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary in order to make the statements therein, in light of the circumstances under which they were made and when made, not misleading.
The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of the
Warrants, Warrant Shares or the Warrant ADSs under the Securities Act, or (ii) any applicable shareholder approval provisions of any
Trading Market on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its
business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)
the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. <U>Schedule 3.1(aa)</U> sets forth as of the date hereof all outstanding
secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For
the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess
of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other
contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s
consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection
or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due
under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to
any material Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves
have been established by the Company in accordance with GAAP, and (iii) has set aside on its books provision reasonably adequate for
the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are
no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company
or of any Subsidiary know of no basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Accountants</U>. The Company&rsquo;s independent registered public accounting firm is BDO USA, LLP. To the knowledge and belief of
the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) has expressed its
opinion with respect to the financial statements included in the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ending
December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
Acknowledgment Regarding Purchaser&rsquo;s Trading Activity. Anything in
this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(f) and 4.13 hereof), it is understood and
acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to
desist from purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities
issued by the Company or to hold the Securities for any specified
term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales
or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
Ordinary Shares and/or ADSs, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s
length counter-party in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y) one
or more Purchasers may engage in hedging activities (in material compliance with applicable laws) at various times during the period
that the Securities are outstanding, including, without limitation, during the periods that the value of the Warrant Shares deliverable
with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing shareholders&rsquo;
equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that
such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&rsquo;s placement agent in connection
with the placement of the Securities or as otherwise set forth in the Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under
the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. Except as set forth on <U>Schedule 3.1 (hh)</U>, there is no pending, completed
or, to the Company&rsquo;s knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory
proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its
Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i)
contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging
of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests
the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to,
any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv)
enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of
permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations
by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect.
The properties, business and operations of the Company have been and are being conducted in all respects in accordance with all applicable
laws, rules and regulations of the FDA except where the failure to be in compliance would not have a Material Adverse Effect. The Company
has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed
to be developed, produced or marketed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Ordinary Shares on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under
the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity
of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>Private Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, no
registration under the Securities Act is required for the offer and sale of the Warrants and the Warrant Shares issuable upon exercise
thereof by the Company to the Purchasers as contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<U>No General Solicitation</U>. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Warrants
or the Warrant Shares or Warrant ADSs issuable upon exercise thereof by any form of general solicitation or general advertising. The
Company has offered the Warrants and the Warrant Shares issuable upon exercise thereof for sale only to the Purchasers and certain other
&ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)
<U>No Disqualification Events</U>. With respect to the Warrants and Warrant Shares and Warrant ADSs issuable upon exercise thereof to
be offered and sold hereunder in reliance on Rule 506 under the Securities Act, none of the Company, any of its predecessors, any affiliated
issuer, any director, executive officer, other officer of the Company participating in the offering hereunder, or, to the knowledge of
the Company, any beneficial owner (as that term is defined in Rule 13d-3 under the Exchange Act) of 20% or more of the Company&rsquo;s
outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405
under the Securities Act) connected with the Company in any capacity at the time of sale (each, an &ldquo;Issuer Covered Person&rdquo;
and, together, &ldquo;Issuer Covered Persons&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described in
Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;Disqualification Event&rdquo;), except for a Disqualification Event covered
by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a
Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has
furnished to the Purchasers a copy of any disclosures provided thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)
<U>Other Covered Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person)
that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)
<U>Notice of Disqualification Events</U>. The Company will notify the Purchasers and the Placement Agent in writing, prior to the Closing
Date of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time,
reasonably be expected to become a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)
<U>Cybersecurity</U>. (i)(x) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any
Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data (including the data of its respective
customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively,
&ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of
any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and
Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders,
rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations
relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use,
access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)
the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material
confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company
and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)
<U>Compliance with Data Privacy Laws</U>. (i) The Company and the Subsidiaries are, and at all times during the last three (3) years
were, in compliance with all applicable state, federal and foreign data privacy and security laws and regulations, including, without
limitation, the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively, &ldquo;<U>Privacy
Laws</U>&rdquo;); (ii) the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to
ensure compliance with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure,
handling and analysis of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii) the Company provides accurate notice
of its applicable Policies to its customers, employees, third party vendors and representatives as required by the Privacy Laws; and
(iv) applicable Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy practices relating to its
subject matter, and do not contain any material omissions of the Company&rsquo;s then-current privacy practices, as required by Privacy
Laws. &ldquo;<U>Personal Data</U>&rdquo; means (i) a natural person&rsquo;s name, street address, telephone number, email address, photograph,
social security number, bank information, or customer or account number; (ii) any information which would qualify as &ldquo;personally
identifying information&rdquo; under the Federal Trade Commission Act, as amended; (iii) &ldquo;personal data&rdquo; as defined by GDPR;
and (iv) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection
or analysis of any identifiable data related to an identified person&rsquo;s health or sexual orientation. (i) None of such disclosures
made or contained in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii) the
execution, delivery and performance of the Transaction Documents will not result in a breach of any Privacy Laws or Policies. Neither
the Company nor the Subsidiaries (i) to the knowledge of the Company, has received written notice of any actual or potential liability
of the Company or the Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy
Laws; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant
to any regulatory request or demand pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement by or with any
court or arbitrator or governmental or regulatory authority that imposed any obligation or liability under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case
they shall be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and
in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by this Agreement and
each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery
of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been
duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such
Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser
in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against
it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business. Specifically, such Purchaser understands that the Warrants and the Warrant Shares issuable upon exercise
thereof are &ldquo;restricted securities&rdquo; and have not been registered under the Securities Act or any other applicable state securities
law and is acquiring such Securities as principal for its own account, not as nominee or agent, and not with a view to or for distributing
or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present
intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no
direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities
in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting such Purchaser&rsquo;s
right to sell such Securities pursuant to a registration statement, if applicable, or otherwise in compliance with applicable federal
and state securities laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each
date on which it exercises any Warrants, it will be either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2),
(a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo; as defined in Rule 144A(a) under
the Securities Act. Such Purchaser is not required to be registered as a broker-dealer under Section 15 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the
Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither
the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect
to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes
any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public
information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the
Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to
such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has
not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales of the securities of the Company during the period commencing as of the time that such Purchaser first received a
term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions
contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by
the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons
party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors, partners,
legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made
to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for
the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>No General Solicitation</U>. Such Purchaser is not purchasing the Securities as a result of the Registration Statement or any advertisement,
article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over
television or radio or presented ay any seminar or any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Beneficial Ownership</U>. Such Purchaser represents that neither such Purchaser nor any group of Purchasers (as identified in a public
filing made with the SEC) of which such Purchaser is a part in connection with the transactions contemplated hereby, acquired, or obtained
the right to acquire, 9.99%, or more of the ADSs (or securities convertible into or exercisable for ADSs) or the voting power of the
Company on a post transaction basis; provided, that the Company acknowledges that such Purchaser is relying on the Ordinary Shares issued
and outstanding as set forth in Section 3.1(g) in calculating the such beneficial ownership.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Removal of Legends.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Warrants and Warrant Shares and Warrant ADSs issuable upon exercise thereof may only be disposed of in compliance with state and
federal securities laws. In connection with any transfer of Warrants or Warrant Shares or Warrant ADSs issuable upon exercise thereof
other than pursuant to an effective registration statement with a current prospectus or Rule 144, to the Company or to an Affiliate of
a Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide
to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which
opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred
Warrant or Warrant Share or Warrant ADS under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Warrant or Warrant Shares
or Warrant ADSs issuable upon exercise thereof in the following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;) AND
ARE &ldquo;RESTRICTED SECURITIES&rdquo; AS DEFINED IN RULE 144 PROMULGATED UNDER THE ACT. THE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED,
OR OTHERWISE DISTRIBUTED OR TRANSFERRED EXCEPT (i) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR (ii) PURSUANT TO
AN EXEMPTION FROM REGISTRATION UNDER THE ACT, AND, IN THE CASE OF A TRANSACTION EXEMPT FROM REGISTRATION, UNLESS THE COMPANY AND DEPOSITARY
HAVE RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO EACH OF THEM THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER
THE ACT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Warrants or Warrant Shares or Warrant ADSs issuable upon exercise thereof
to a financial institution that is an &ldquo;accredited investor&rdquo; as defined in Rule 501(a) under the Securities Act and who agrees
to be bound by the provisions of this Agreement and, if required under the terms of such arrangement, such Purchaser may transfer pledged
or secured Warrants or Warrant Shares or Warrant ADSs issuable upon exercise thereof to the pledgees or secured parties. Such a pledge
or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor
shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser&rsquo;s
expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Warrants and Warrant Shares
and Warrant ADSs issuable upon exercise thereof may reasonably request in connection with a pledge or transfer of the Warrants or Warrant
Shares or Warrant ADSs issuable exercise thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Certificates (or book entry positions) evidencing the Warrant Shares or Warrant ADSs shall not contain any legend (including the legend
set forth in Section 4.1(b) hereof): (i) while a registration statement with a current prospectus covering the resale of such security
is effective under the Securities Act, (ii) following any sale of such Warrant Shares pursuant to Rule 144, (iii) if such Warrant Shares
or Warrant ADSs are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public
information required under Rule 144 as to such Warrant Shares or Warrant ADSs and without volume or manner-of-sale restrictions or (iv)
if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements
issued by the staff of the Commission) (&ldquo;Effective Date&rdquo;). The Company shall cause its counsel to issue a legal opinion to
the transfer agent promptly after the Effective Date if required by the transfer agent to effect the removal of the legend hereunder.
If all or any portion of a Warrant is exercised at a time when there is an effective registration statement with a current prospectus
to cover the resale of the Warrant Shares, or if such Warrant Shares may be sold under Rule 144 and the Company is then in compliance
with the current public information required under Rule 144, or if the Warrant Shares may be sold under Rule 144 without the requirement
for the Company to be in compliance with the current public information required under Rule 144 as to such Warrant Shares or if such
legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements
issued by the staff of the Commission) then such Warrant Shares shall be issued free of all legends. The Company agrees that following
the Effective Date and at such time as such legend is no longer required under this Section 4.1(c), it will, no later than the earlier
of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following
the delivery by a Purchaser to the Company or the transfer agent of a certificate representing Warrant Shares, as applicable, issued
with a restrictive legend (such date, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be delivered to such Purchaser
a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation on
its records or give instructions to the transfer agent that enlarge the restrictions on transfer set forth in this Section 4. Certificates
for Warrant Shares subject to legend removal hereunder shall be transmitted by the transfer agent to the Purchaser by crediting the account
of the Purchaser&rsquo;s prime broker with the Depository Trust Company System as directed by such Purchaser. &ldquo;<U>Standard Settlement
Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading
Market with respect to the ADSs as in effect on the date of delivery of a certificate representing Warrant Shares issued with a restrictive
legend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
In addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated
damages and not as a penalty, for each $1,000 of Warrant ADSs (based on the VWAP of the ADSs on the date such securities are submitted
to the transfer agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10 per Trading Day (increasing
to $20 per Trading Day three (3) Trading Days after the Legend Removal Date) for each Trading Day after the Legend Removal Date until
such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to a
Purchaser by the Legend Removal Date a certificate representing the securities so delivered to the Company by such Purchaser that is
free from all restrictive and other legends and (b) if after the Legend Removal Date such Purchaser purchases (in an open market transaction
or otherwise) ADSs to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of ADSs, or a sale of a
number of ADSs equal to all or any portion of the number of ADSs, that such Purchaser anticipated receiving from the Company without
any restrictive legend, then an amount equal to the excess of such Purchaser&rsquo;s total purchase price (including brokerage commissions
and other out-of-pocket expenses, if any) for the ADSs so purchased (including brokerage commissions and other out-of-pocket expenses,
if any) (the &ldquo;<B><U>Buy-In Price</U></B>&rdquo;) over the product of (A) such number of Warrant ADSs that the Company was required
to deliver to such Purchaser by the Legend Removal Date multiplied by (B) the lowest closing sale price of the ADSs on any Trading Day
during the period commencing on the date of the delivery by such Purchaser to the Company of the applicable Warrant ADSs (as the case
may be) and ending on the date of such delivery and payment under this Section 4.1(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Furnishing of Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Until the earliest of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to timely
file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company
after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
At any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the
Warrant ADSs (assuming cashless exercise) may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1)
and otherwise without restriction or limitation pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current
public information requirement under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an issuer
in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &ldquo;<U>Public Information Failure</U>&rdquo;)
then, in addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, as partial liquidated
damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Warrant ADSs, an amount in cash
equal to two percent (2.0%) of the aggregate Exercise Price of such Purchaser&rsquo;s Warrants on the day of a Public Information Failure
and on every thirtieth (30<SUP>th</SUP>) day (pro rated for periods totaling less than thirty days) thereafter until the earlier of (a)
the date such Public Information Failure is cured and (b) such time that such public information is no longer required for the Purchasers
to transfer the Warrant ADSs pursuant to Rule 144. The payments to which a Purchaser shall be entitled pursuant to this Section 4.2(b)
are referred to herein as &ldquo;<U>Public Information Failure Payments</U>.&rdquo; Public Information Failure Payments shall be paid
on the earlier of (i) the last day of the calendar month during which such Public Information Failure Payments are incurred and (ii)
the third (3<SUP>rd</SUP>) Trading Day after the event or failure giving rise to the Public Information Failure Payments is cured. In
the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments
shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein shall limit such Purchaser&rsquo;s
right to pursue actual damages for the Public Information Failure, and such Purchaser shall have the right to pursue all remedies available
to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would
require the registration under the Securities Act of the sale of the Warrants or Warrant Shares or that would be integrated with the
offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder
approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent
transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b) file a Report on Form 8-K, including the Transaction Documents as exhibits thereto,
with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents
to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the
Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents, including, without limitation,
the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance
of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement,
whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees
or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates including, without limitation, the Placement Agent,
on the other hand, shall terminate. The Company and each Purchaser shall consult with each other in issuing any other press releases
with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor
otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser,
or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably
be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other
party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose
the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading
Market, without the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with the
filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market
regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause
(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by
the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt of such information
and agreed with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be
relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company delivers any
material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that
such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers,
directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors,
agents, employees or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall
remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains,
material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the
Commission pursuant to a Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing
covenant in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Use of Proceeds</U>. Except as set forth on <U>Schedule 4.7</U> attached hereto, the Company shall use the net proceeds from the sale
of the Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion of
the Company&rsquo;s debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices),
(b) for the redemption of any Ordinary Shares or Ordinary Share Equivalents, (c) for the settlement of any outstanding litigation or
(d) in violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;Purchaser Party&rdquo;) harmless from any and all
losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result
of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents or (b) any action instituted against the Purchaser Party in any capacity, or any of them or their
respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the
transactions contemplated by the Transaction Documents (unless such action is solely based upon a breach of such Purchaser Party&rsquo;s
representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may
have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser
Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought
against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly
notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably
acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate
in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent
that (x) the employment thereof has been specifically authorized by the Company in writing, (y) the Company has failed after a reasonable
period of time to assume such defense and to employ counsel or (z) in such action there is, in the reasonable opinion of counsel, a material
conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company
shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to
any Purchaser Party under this Agreement (1) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written
consent, which shall not be unreasonably withheld or delayed; or (2) to the extent, but only to the extent that a loss, claim, damage
or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements
made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8
shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received
or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser
Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Authority to Allot Ordinary Shares</U>. As of the date hereof, the directors of the Company have authority to allot a sufficient number
of Ordinary Shares to enable the Company to issue the Placed Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise
of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Listing of ADSs</U>. The Company hereby agrees to use reasonable efforts to maintain the listing or quotation of the ADSs on the Trading
Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Placed
ADSs on such Trading Market and promptly secure the listing of all of the Shares on such Trading Market. The Company further agrees,
if the Company applies to have the ADSs traded on any other Trading Market, it will then include in such application all of the Placed
ADSs, and will take such other action as is necessary to cause all of the Placed ADSs to be listed or quoted on such other Trading Market
as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its ADSs on
a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or
rules of the Trading Market. The Company agrees to maintain the eligibility of the ADSs for electronic transfer through the Depository
Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository
Trust Company or such other established clearing corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Shareholder Meeting</U>. The Company shall take all action reasonably necessary to call, give notice of, convene and hold a meeting
of its shareholders (the &ldquo;<U>Shareholder Meeting</U>&rdquo;) within sixty (60) days of the Closing Date for the purpose of considering
and obtaining the Shareholder Approval, with the recommendation of the Company&rsquo;s Board of Directors that such proposal be approved,
and shall not adjourn, recess or postpone such meeting, except (a) to the extent required by applicable law, (b) to solicit additional
proxies if Company reasonably believes there will be insufficient Ordinary Shares represented (either in person or by proxy) to (i) constitute
a quorum necessary to conduct the business of the Shareholder Meeting or (ii) obtain the Shareholder Approval, and (c) to the extent
reasonably necessary to ensure that any required supplement or amendment to the proxy statement or other materials delivered by the Company
to shareholders in connection with the Shareholder Meeting. The Company&rsquo;s Board of Directors shall use best efforts to obtain the
Shareholder Approval. The Company shall solicit proxies from its shareholders in connection therewith in the same manner as all the other
management proposals in such proxy statement and all management-appointed proxyholders shall vote their proxies in favor of such proposal.
If the Company does not obtain Shareholder Approval at the first meeting, the Company shall call a meeting every forty (40) days thereafter
to seek Shareholder Approval until the earlier of the date on which Shareholder Approval is obtained or the Warrants are no longer outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>Subsequent Equity Sales.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof until thirty (30) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any ADSs, Ordinary Shares or Ordinary Share Equivalents or (ii)
file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or as contemplated pursuant
to Section 4.16 herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
From the date hereof until one (1) year after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement
to effect any issuance by the Company or any of its Subsidiaries of ADSs, Ordinary Shares or Ordinary Share Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which
the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include
the right to receive additional ADSs or Ordinary Shares either (A) at a conversion price, exercise price or exchange rate or other price
that is based upon and/or varies with the trading prices of or quotations for the ADSs at any time after the initial issuance of such
debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after
the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly
related to the business of the Company or the market for the ADSs or (ii) enters into, or effects a transaction under, any agreement,
including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the Company may issue securities
at a future determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether
such agreement is subsequently canceled; <U>provided</U>, <U>however</U>, that, (A) after thirty (30) days after the Closing Date, the
entry into and/or issuance of ADSs or Ordinary Shares in an &ldquo;at the market&rdquo; offering with the Placement Agent as sales agent
shall not be deemed a Variable Rate Transaction and (B) after five (5) months after the Closing Date, the issuance of ADSs or Ordinary
Shares pursuant to the August 2025 Purchase Agreement shall not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled
to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect
damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction
shall be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at
such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included
in the Disclosure Schedules. Notwithstanding the foregoing, and notwithstanding anything contained in this Agreement to the contrary,
the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will
not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement
are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted
or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the
Company to the Company or its Subsidiaries after the issuance of the initial press release as described in Section 4.4. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect
to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
<U>Exercise Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required
of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required
of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to
exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms,
conditions and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15
<U>Form D; Blue Sky Filings</U>. The Company agrees to timely file a Form D with respect to the Warrants, the Warrant Shares and Warrant
ADSs as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such
action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Warrant, the Warrant
Shares and Warrant ADSs for, sale to the Purchasers at the Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the
states of the United States, and shall provide evidence of such actions promptly upon request of any Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16
<U>Registration Statement</U>. As soon as reasonably practicable, but in no event later than the 30 day anniversary of the Closing Date,
the Company shall file a registration statement on Form S-3 (or other appropriate form if the Company is not then S-3 eligible) providing
for the resale by the Purchasers of the Warrant Shares and Warrant ADSs issued and issuable upon exercise of the Warrants. The Company
shall use commercially reasonable efforts to cause such registration to become effective within seventy-five (75) days following the
Closing Date, <I>provided, however, </I>that this deadline shall be tolled by one Business Day for each Business Day that the Commission
is closed due to a shutdown of the United States government<I>,</I> and to keep such registration statement effective at all times until
(a) the Warrant Shares and Warrant and to keep such registration statement effective at all times until (a) the Warrant Shares and Warrant
ADSs are sold under such registration statement or pursuant to Rule 144 or other exemption under the Securities Act, (b) the Warrant
Shares and Warrant ADSs may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 under the Securities Act, and
(c) the Warrants are no longer outstanding, whichever is the earliest to occur. Subject to the accuracy of the information provided by
the Purchasers to the Company, the Company shall ensure that such registration statement (including any amendments or supplements thereto
and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein, or necessary to make the statements therein (in the case of prospectuses, in the light of the circumstances in
which they were made) not misleading. After the date hereof and during any period in which a prospectus or prospectus supplement relating
to any of the Warrant Shares and Warrant ADSs subject to registration under this Section 4.16 is required to be delivered by any Purchaser
pursuant to the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172 of the Securities
Act), (i) the Company will notify the Purchasers promptly of the time when any subsequent amendment to such registration statement, other
than documents incorporated by reference, has been filed with the Commission or has become effective or any subsequent supplement to
the prospectus regarding such Securities or any of the Purchasers or any subsequent amendment to the prospectus or any supplement or
amendment to the prospectus supplement has been filed with the Commission and of any comment letter from the Commission or any request
by the Commission for any amendment or supplement to such registration statement, any amendment to the prospectus, any supplement to
the prospectus that relates to the Securities subject to such registration statement under this Section or any of the Purchasers, or
any amendment or supplement to the prospectus supplement, provided that no notification of the Purchasers shall be required if such amendment,
supplement, or comment, or request would not, and would not seek, to limit the rights of the Purchasers or the Warrant Shares and Warrant
ADSs, (ii) the Company will prepare and file with the Commission, promptly upon a Purchaser&rsquo;s request, any amendments or supplements
to such registration statement, prospectus or prospectus supplement that, in the Company&rsquo;s reasonable opinion, may be necessary
in connection with any resale of the Warrant Shares and Warrant ADSs by such Purchaser (provided, however, that the failure of such Purchaser
to make such request shall not relieve the Company of any obligation or liability hereunder), (iii) the Company will not file any amendment
or supplement to a registration statement, prospectus or prospectus supplement, other than documents incorporated by reference, relating
to the Warrant Shares subject to registration under this Section 4.16 unless a copy thereof has been submitted or made available to each
Purchaser within a reasonable period of time before the filing and no Purchaser has reasonably objected in writing thereto (provided,
however, that (A) the failure of any Purchaser to make such objection shall not relieve the Company of any obligation or liability hereunder,
and (B) the Company has no obligation to provide a Purchaser any advance copy of such filing or to provide such Purchaser an opportunity
to object to such filing if such filing does not name such Purchaser or specifically discuss the Warrant Shares and Warrant ADSs subject
to registration under this Section 4.16 as contemplated hereby) and the Company will furnish or make available to each Purchaser at the
time of filing thereof a copy of any document that upon filing is deemed to be incorporated by reference into a registration statement,
prospectus or prospectus supplement, except for those documents available via EDGAR, and (iv) the Company will cause each amendment or
supplement to the prospectus or prospectus supplement, other than documents incorporated by reference, to be filed with the Commission
as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act. Each Purchaser shall furnish the Company a completed
questionnaire in the form attached hereto as <U>Schedule 4.16</U> prior to the filing of such registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17
<U>Equal Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered
to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser
by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall
not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of
Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18
<U>Lock-Up Agreements</U>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except
to extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If
any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to seek
specific performance of the terms of such Lock-Up Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Depositary fees (including,
without limitation, any fees required for same-day processing of any instruction letter delivered by the Company to issue the Placed
ADSs), stamp taxes and other taxes and duties levied in connection with the delivery of any Placed ADSs to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus
Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>)Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Placed Shares based
on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver,
by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver
disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser
(or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the
rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior
written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon
each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the
transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
<U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations, warranties and
covenants of the Company in this Agreement and the representations, warranties and covenants of the Purchasers in this Agreement. This
Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the
benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section
5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall
be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10
<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11
<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, by other electronic signing created on an electronic platform (such as DocuSign) or by digital
signing (such as Adobe Sign) such signature shall create a valid and binding obligation of the party executing (or on whose behalf such
signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13
<U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in respect of the securities or other matter to which the default relates without prejudice to its future actions and rights; <U>provided</U>,
<U>however</U>, that in the case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any
ADSs subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid
to the Company for such shares and the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s
Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14
<U>Replacement of Securities</U>. Subject to compliance with the Company&rsquo;s articles of association, if any certificate or instrument
evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution
for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument,
but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new
certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated
with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15
<U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that
a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16
<U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17
<U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as
a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of
this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to
communicate with the Company through the legal counsel of the Placement Agent. The legal counsel of the Placement Agent does not represent
any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms
and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers.
It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between
the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18
<U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts
have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19
<U>Saturdays, Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
this Agreement, the Lock-Up Agreement and the Warrants and, therefore, the normal rule of construction to the effect that any ambiguities
are to be resolved against the drafting party shall not be employed in the interpretation of the Agreement, the Lock-Up Agreement and
the Warrants or any amendments thereto. In addition, each and every reference to share prices and ADSs or Ordinary Shares in this Agreement,
the Lock-Up Agreement or the Warrants shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the ADSs or Ordinary Shares that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21
<B><U>WAIVER OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Akari
    Therapeutics PLC</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
    for Notice:</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 5%; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 2%; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 49%; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy to (which shall not constitute notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO AKTX SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser: ______________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>: _________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory:_________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile
Number of Authorized Signatory: __________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Warrants to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $__________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of ADSs:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Series E Warrants:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Series F Warrants:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number: ____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of ADSs to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DWAC
for ADSs:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC
Participant name and number: ________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact
of DTC Participant: _______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
Number of Participant Contact: _____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to
purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the
Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii)
the Closing shall occur by the first (1st) Trading Day following the date of this Agreement and (iii) any condition to Closing contemplated
by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any
agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be
an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or
the like or purchase price (as applicable) to such other party on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit
A</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit
B</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>ex10-2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLACEMENT
AGENCY AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-indent: 4in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
14, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladenburg
Thalmann &amp; Co. Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">640
Fifth Avenue, 4<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Introduction</B>.
Subject to the terms and conditions herein (this &ldquo;<U>Agreement</U>&rdquo;), Akari Therapeutics, Plc, a public company with limited
liability incorporated under the laws of England and Wales (the &ldquo;<U>Company</U>&rdquo;), hereby agrees to sell up to an aggregate
of $2,500,000 of securities of the Company, including, but not limited to, registered American Depositary Shares (the &ldquo;<U>Shares</U>&rdquo;),
each represented by 2,000 ordinary shares, par value $0.0001 of the Company (&ldquo;<U>Ordinary Shares</U>&rdquo;), and unregistered
Series E warrants and Series F warrants, each to purchase Ordinary Shares represented by American Depositary Shares (the &ldquo;<U>Warrants</U>&rdquo;,
and the American Depositary Shares issuable upon exercise of the Warrants, the &ldquo;<U>Warrant Shares</U>&rdquo;) (the Shares, Warrants
and Warrant Shares, collectively, the &ldquo;<U>Securities</U>&rdquo;) directly to various investors (each, an &ldquo;<U>Investor</U>&rdquo;
and, collectively, the &ldquo;<U>Investors</U>&rdquo;) through Ladenburg Thalmann &amp; Co. Inc. (the &ldquo;<U>Placement Agent</U>&rdquo;)
as placement agent. The documents executed and delivered by the Company and the Investors in connection with the Offering (as defined
below), including, without limitation, a securities purchase agreement(s) (the &ldquo;<U>Purchase Agreement</U>&rdquo;), shall be collectively
referred to herein as the &ldquo;<U>Transaction Documents</U>.&rdquo; The Placement Agent may retain other brokers or dealers to act
as sub-agents or selected-dealers on its behalf in connection with the Offering (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defined
terms used but not defined herein shall have the meaning set forth in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby confirms its agreement with the Placement Agent as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1. Agreement to Act as Placement Agent.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On the basis of the representations, warranties and agreements of the Company herein contained, and subject to all the terms and conditions
of this Agreement, the Placement Agent shall be the exclusive placement agent in connection with the offering and sale by the Company
of the Shares pursuant to the Company&rsquo;s registration statement on Form S-3 (File No. 333-289056) (the &ldquo;<U>Registration Statement</U>&rdquo;)
(such offering, the &ldquo;<U>Registered Offering</U>&rdquo;) and a concurrent private placement of the Warrants (such private placement,
the &ldquo;<U>Private Placement</U>&rdquo; and, together with the Registered Offering, the &ldquo;<U>Offering</U>&rdquo;) with the terms
of the Offering to be subject to market conditions and negotiations between the Company, the Placement Agent and the prospective Investors.
The Placement Agent will act on a reasonable best efforts basis and the Company agrees and acknowledges that there is no guarantee of
the successful placement of the Securities, or any portion thereof, in the prospective Offering. Under no circumstances will the Placement
Agent or any of its &ldquo;Affiliates&rdquo; (as defined below) be obligated to underwrite or purchase any of the Securities for its
own account or otherwise provide any financing. The Placement Agent shall act solely as the Company&rsquo;s agent and not as principal.
The Placement Agent shall have no authority to bind the Company with respect to any prospective offer to purchase Securities and the
Company shall have the sole right to accept offers to purchase Securities and may reject any such offer, in whole or in part. Subject
to the terms and conditions hereof, payment of the purchase price for, and delivery of, the Securities shall be made at one or more closings
(each a &ldquo;<U>Closing</U>&rdquo; and the date on which each Closing occurs, a &ldquo;<U>Closing Date</U>&rdquo;). As compensation
for services rendered, on each Closing Date, the Company shall pay to the Placement Agent the fees and expenses set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
A cash fee equal to 7.2% of the gross proceeds received by the Company from the sale of the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
A management fee payable in cash equal to 0.5% of the total gross proceeds received by the Company from the sale of the Securities at
the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Such number of warrants (the &ldquo;<U>Placement Agent Warrants</U>&rdquo;) to the Placement Agent, or its designees, at the Closing
to purchase Ordinary Shares represented by ADSs equal to 4.0% of the aggregate number of Shares sold in the Offering. The Placement Agent
Warrants shall have substantially the same terms as the Series E Warrants issued to the Investors in the Offering except that the exercise
price shall be 125% of the offering price per Share and shall have an expiration date of 5 years from the commencement of sales of the
Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
The Company also agrees to reimburse Placement Agent&rsquo;s expenses up to $75,000, which shall be payable immediately upon the Closing
of the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The term of the Placement Agent&rsquo;s exclusive engagement will be as provided in Section 2 of that certain Investment Banking Agreement
dated August 28, 2025 between the Company and the Placement Agent (the &ldquo;<U>Investment Banking Agreement</U>&rdquo;). Notwithstanding
anything to the contrary contained herein, the provisions concerning confidentiality, indemnification and contribution contained herein
and the Company&rsquo;s obligations contained in the indemnification provisions will survive any expiration or termination of this Agreement,
and the Company&rsquo;s obligation to pay fees actually earned and payable and to reimburse expenses actually incurred and reimbursable
pursuant to Section 1 hereof and which are permitted to be reimbursed under FINRA Rule 5110(f)(2)(D)(i), will survive any expiration
or termination of this Agreement. Nothing in this Agreement shall be construed to limit the ability of the Placement Agent or its Affiliates
to pursue, investigate, analyze, invest in, or engage in investment banking, financial advisory or any other business relationship with
Persons (as defined below) other than the Company. As used herein (i) &ldquo;Persons&rdquo; means an individual or corporation, partnership,
trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency
or subdivision thereof) or other entity of any kind and (ii) &ldquo;Affiliate&rdquo; means any Person that, directly or indirectly through
one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed
under Rule 405 under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2. Representations, Warranties and Covenants of the Company</B>. The Company hereby represents, warrants and covenants to the Placement
Agent as of the date hereof, and as of each Closing Date, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Securities Law Filings</U>. The Company has filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
the Registration Statement under the Securities Act, which was filed on July 29, 2025 and declared effective on July 31, 2025 for the
registration of the Shares under the Securities Act. Following the determination of pricing among the Company and the prospective Investors
introduced to the Company by the Placement Agent, the Company will file with the Commission pursuant to Rule 424(b) under the Securities
Act, and the rules and regulations (the &ldquo;<U>Rules and Regulations</U>&rdquo;) of the Commission promulgated thereunder, a prospectus
supplement relating to the placement of the Shares, their respective pricing and the plan of distribution thereof and will advise the
Placement Agent of all further information (financial and other) with respect to the Company required to be set forth therein. Such registration
statement, at any given time, including the exhibits thereto filed at such time, as amended at such time, is hereinafter called the &ldquo;<U>Registration
Statement</U>&rdquo;; such prospectus in the form in which it appears in the Registration Statement at the time of effectiveness, together
with any preliminary prospectus supplement relating to the Offering, if any (the &ldquo;<U>Preliminary Prospectus Supplement</U>&rdquo;)
is hereinafter called the &ldquo;<U>Base Prospectus</U>&rdquo;; and the final prospectus supplement, in the form in which it will be
filed with the Commission pursuant to Rule 424(b) (including the Base Prospectus as it may be amended or supplemented) is hereinafter
called the &ldquo;<U>Final Prospectus Supplement</U>.&rdquo; The Registration Statement at the time it originally became effective is
hereinafter called the &ldquo;<U>Original Registration Statement</U>.&rdquo; Any reference in this Agreement to the Registration Statement,
the Original Registration Statement, the Base Prospectus, the Preliminary Prospectus Supplement, if any or the Final Prospectus Supplement
shall be deemed to refer to and include the documents incorporated by reference therein (the &ldquo;<U>Incorporated Documents</U>&rdquo;),
if any, which were or are filed under the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), at any
given time, as the case may be; and any reference in this Agreement to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo;
with respect to the Registration Statement, the Original Registration Statement, the Base Prospectus, the Preliminary Prospectus Supplement
or the Final Prospectus Supplement shall be deemed to refer to and include the filing of any document under the Exchange Act after the
date of this Agreement, or the issue date of the Base Prospectus, the Preliminary Prospectus Supplement or the Final Prospectus Supplement,
as the case may be, deemed to be incorporated therein by reference. All references in this Agreement to financial statements and schedules
and other information which is &ldquo;contained,&rdquo; &ldquo;included,&rdquo; &ldquo;described,&rdquo; &ldquo;referenced,&rdquo; &ldquo;set
forth&rdquo; or &ldquo;stated&rdquo; in the Registration Statement, the Base Prospectus, the Preliminary Prospectus Supplement or the
Final Prospectus Supplement (and all other references of like import) shall be deemed to mean and include all such financial statements
and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Base Prospectus,
the Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be. As used in this paragraph and elsewhere
in this Agreement, &ldquo;<U>Time of Sale Disclosure Package</U>&rdquo; means the Base Prospectus, any preliminary prospectus supplement,
any securities purchase agreement between the Company and the Investors, and any issuer free writing prospectus as defined in Rule 433
of the Act (each, an &ldquo;<U>Issuer Free Writing Prospectus</U>&rdquo;), if any, that the parties hereto shall hereafter expressly
agree in writing to treat as part of the Time of Sale Disclosure Package. The term &ldquo;<U>any Prospectus Supplement</U>&rdquo; shall
mean, as the context requires, the Base Prospectus, the Final Prospectus Supplement, and any supplement to either thereof. The Company
has not received any notice that the Commission has issued or intends to issue a stop order suspending the effectiveness of the Registration
Statement or the use of the Base Prospectus or any Prospectus Supplement or intends to commence a proceeding for any such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Assurances</U>. The Original Registration Statement, as amended, (and any further documents to be filed with the Commission) contains
all exhibits and schedules as required by the Securities Act. Each of the Registration Statement and any post-effective amendment thereto,
at the time it became effective, complied in all material respects with the Securities Act and the applicable Rules and Regulations and
did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to
make the statements therein not misleading. The Base Prospectus, and the Final Prospectus Supplement, each as of its respective date,
comply or will comply in all material respects with the Securities Act and the applicable Rules and Regulations. Each of the Base Prospectus
and the Final Prospectus Supplement, as amended or supplemented, did not and will not contain as of the date thereof any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. The Incorporated Documents, when they were filed with the Commission, conformed in all material
respects to the requirements of the Exchange Act and the applicable Rules and Regulations promulgated thereunder, and none of such documents,
when they were filed with the Commission, contained any untrue statement of a material fact or omitted to state a material fact necessary
to make the statements therein (with respect to Incorporated Documents incorporated by reference in the Base Prospectus or Final Prospectus
Supplement), in light of the circumstances under which they were made not misleading. No post-effective amendment to the Registration
Statement reflecting any facts or events arising after the date thereof which represent, individually or in the aggregate, a fundamental
change in the information set forth therein is required to be filed with the Commission. There are no documents required to be filed
with the Commission in connection with the transaction contemplated hereby that (x) have not been filed as required pursuant to the Securities
Act or (y) will not be filed within the requisite time period. There are no contracts or other documents required to be described in
the Base Prospectus or Final Prospectus Supplement, or to be filed as exhibits or schedules to the Registration Statement, which have
not been described or filed as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Offering Materials</U>. Neither the Company nor any of its directors and officers has distributed and none of them will distribute,
prior to each Closing Date, any offering material in connection with the offering and sale of the Securities other than the Base Prospectus,
the Final Prospectus Supplement, the Registration Statement, copies of the documents incorporated by reference therein and any other
materials permitted by the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and the Final Prospectus Supplement and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated hereby and thereby
and under the Final Prospectus Supplement have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Company&rsquo;s Board of Directors or an authorized committee thereof (the &ldquo;<U>Board of
Directors</U>&rdquo;) or the Company&rsquo;s stockholders in connection therewith other than in connection with the Required Approvals
(as defined in the Purchase Agreement). This Agreement has been duly executed by the Company and, when delivered in accordance with the
terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its
terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other
laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the transactions contemplated pursuant
to the Final Prospectus Supplement, the issuance and sale of the Securities and the consummation by it of the transactions contemplated
hereby and thereby to which it is a party do not (i) conflict with or violate any provision of the Company&rsquo;s or any subsidiary&rsquo;s
certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a
default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien (as
defined in the Purchase Agreement) upon any of the properties or assets of the Company or any subsidiary, or give to others any rights
of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility,
debt or other instrument (evidencing a Company or subsidiary debt or otherwise) or other understanding to which the Company or any subsidiary
is a party or by which any property or asset of the Company or any subsidiary is bound or affected, or (iii) subject to the Required
Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction
of any court or governmental authority to which the Company or a subsidiary is subject (including federal and state securities laws and
regulations), or by which any property or asset of the Company or a subsidiary is bound or affected; except in the case of each of clauses
(ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect (as defined in the Purchase Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<FONT STYLE="letter-spacing: -0.15pt"><U>Certificates</U>. </FONT>Any certificate signed by an officer of the Company and delivered to
the Placement Agent or to counsel for the Placement Agent shall be deemed to be a representation and warranty by the Company to the Placement
Agent as to the matters set forth therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Reliance</U>. The Company acknowledges that the Placement Agent will rely upon the accuracy and truthfulness of the foregoing representations
and warranties and hereby consents to such reliance.<B>&#9;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Forward-Looking Statements</U>. No forward-looking statements (within the meaning of Section 27A of the Securities Act and Section
21E of the Exchange Act) contained in the Registration Statement, the Base Prospectus or the Final Prospectus Supplement has been made
or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Statistical or Market-Related Data</U>. Any statistical, industry-related and market-related data included or incorporated by reference
in the Registration Statement, the Base Prospectus and the Final Prospectus Supplement, are based on or derived from sources that the
Company reasonably and in good faith believes to be reliable and accurate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>FINRA Affiliations</U>. There are no affiliations with any FINRA member firm that is participating in the Registered Offering among
the Company&rsquo;s officers or directors, or to the knowledge of the Company, any five percent (5%) or greater stockholder of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Representations, Warranties and Covenants Incorporated by Reference</U>. Each of the representations, warranties and covenants (together
with any related disclosure schedules thereto) made by the Company to the Investors in the Purchase Agreement is hereby incorporated
herein by reference (as though fully restated herein) and is hereby made to, and in favor of, the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3. Delivery and Payment</B>. Each Closing shall take place by remote communications and by the exchange of signatures by electronic transmission
(or in such other manner and place as shall be agreed upon by the Placement Agent and the Company). Subject to the terms and conditions
hereof, at each Closing payment of the purchase price for the Securities sold on such Closing Date shall be made by Federal Funds wire
transfer, against delivery of such Securities, and such Securities shall be registered in such name or names and shall be in such denominations,
as the Placement Agent may request at least one business day before the time of purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deliveries
of the documents with respect to the purchase of the Securities, if any, shall be made at the offices of Placement Agent counsel. All
actions taken at a Closing shall be deemed to have occurred simultaneously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4. Covenants and Agreements of the Company</B>. The Company further covenants and agrees with the Placement Agent as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Registration Statement Matters</U>. The Company will advise the Placement Agent promptly after it receives notice thereof of the time
when any amendment to the Registration Statement has been filed or becomes effective or any supplement to any Prospectus Supplement or
any amended Prospectus Supplement has been filed and will furnish the Placement Agent with copies thereof. The Company will file promptly
all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section
13(a), 14 or 15(d) of the Exchange Act subsequent to the date of any Prospectus Supplement and for so long as the delivery of a prospectus
is required in connection with the Registered Offering. The Company will advise the Placement Agent, promptly after it receives notice
thereof (i) of any request by the Commission to amend the Registration Statement or to amend or supplement any Prospectus Supplement
or for additional information, and (ii) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration
Statement or any post-effective amendment thereto or any order directed at any Incorporated Document, if any, or any amendment or supplement
thereto or any order preventing or suspending the use of the Base Prospectus or any Prospectus Supplement or any amendment or supplement
thereto or any post-effective amendment to the Registration Statement, of the suspension of the qualification of the Securities for offering
or sale in any jurisdiction, of the institution or threatened institution of any proceeding for any such purpose, or of any request by
the Commission for the amending or supplementing of the Registration Statement or a Prospectus Supplement or for additional information.
The Company shall use its best efforts to prevent the issuance of any such stop order or prevention or suspension of such use. If the
Commission shall enter any such stop order or order or notice of prevention or suspension at any time prior to the completion of the
Offering, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment, or will file a new
registration statement and use its best efforts to have such new registration statement declared effective as soon as practicable. Additionally,
the Company agrees that in connection with the Offering, it shall comply with the provisions of Rules 424(b), 430A, 430B and 430C, as
applicable, under the Securities Act, including with respect to the timely filing of documents thereunder, and will use its reasonable
efforts to confirm that any filings made by the Company under such Rule 424(b) are received in a timely manner by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Blue Sky Compliance</U>. The Company will cooperate with the Placement Agent and the Investors in endeavoring to qualify the Securities
for sale under the securities laws of such jurisdictions (United States and foreign) as the Placement Agent and the Investors may reasonably
request and will make such applications, file such documents, and furnish such information as may be reasonably required for that purpose,
provided the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in
any jurisdiction where it is not now so qualified or required to file such a consent, and provided further that the Company shall not
be required to produce any new disclosure document other than a Prospectus Supplement. The Company will, from time to time, prepare and
file such statements, reports and other documents as are or may be required to continue such qualifications in effect for so long a period
as the Placement Agent may reasonably request for distribution of the Securities. The Company will advise the Placement Agent promptly
of the suspension of the qualification or registration of (or any such exemption relating to) the Securities for offering, sale or trading
in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order
suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at
the earliest possible moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Amendments and Supplements to a Prospectus Supplement and Other Matters</U>. The Company will comply with the Securities Act and the
Exchange Act, and the rules and regulations of the Commission thereunder, so as to permit the completion of the distribution of the Securities
as contemplated in this Agreement, the Incorporated Documents and any Prospectus Supplement. If during the period in which a prospectus
is required by law to be delivered in connection with the distribution of Shares contemplated by the Incorporated Documents or any Prospectus
Supplement (the &ldquo;<U>Prospectus Delivery Period</U>&rdquo;), any event shall occur as a result of which, in the judgment of the
Company or in the reasonable opinion of the Placement Agent or counsel for the Placement Agent, it becomes necessary to amend or supplement
the Incorporated Documents or any Prospectus Supplement in order to make the statements therein, in the light of the circumstances under
which they were made, as the case may be, not misleading, or if it is necessary at any time to amend or supplement the Incorporated Documents
or any Prospectus Supplement or to file under the Exchange Act any Incorporated Document to comply with any law, the Company will promptly
prepare and file with the Commission, and furnish at its own expense to the Placement Agent and to dealers, an appropriate amendment
to the Registration Statement or supplement to the Registration Statement, the Incorporated Documents or any Prospectus Supplement that
is necessary in order to make the statements in the Incorporated Documents and any Prospectus Supplement as so amended or supplemented,
in the light of the circumstances under which they were made, as the case may be, not misleading, or so that the Registration Statement,
the Incorporated Documents or any Prospectus Supplement, as so amended or supplemented, will comply with law. Before amending the Registration
Statement or supplementing the Incorporated Documents or any Prospectus Supplement in connection with the Registered Offering, the Company
will furnish the Placement Agent with a copy of such proposed amendment or supplement and will not file any such amendment or supplement
to which the Placement Agent reasonably objects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Copies of any Amendments and Supplements to a Prospectus Supplement</U>. The Company will furnish the Placement Agent, without charge,
during the period beginning on the date hereof and ending on the later of the last Closing Date of the Registered Offering, as many copies
of the Incorporated Documents and any Prospectus Supplement and any amendments and supplements thereto (including any Incorporated Documents,
if any) as the Placement Agent may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Free Writing Prospectus</U>. The Company covenants that it will not, unless it obtains the prior written consent of the Placement
Agent, make any offer relating to the Shares that would constitute a Company Free Writing Prospectus or that would otherwise constitute
a &ldquo;<U>free writing prospectus</U>&rdquo; (as defined in Rule 405 of the Securities Act) required to be filed by the Company with
the Commission or retained by the Company under Rule 433 of the Securities Act. In the event that the Placement Agent expressly consents
in writing to any such free writing prospectus (a &ldquo;<U>Permitted Free Writing Prospectus</U>&rdquo;), the Company covenants that
it shall (i) treat each Permitted Free Writing Prospectus as a Company Free Writing Prospectus, and (ii) comply with the requirements
of Rule 164 and 433 of the Securities Act applicable to such Permitted Free Writing Prospectus, including in respect of timely filing
with the Commission, legending and record keeping.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Depositary</U>. The Company will maintain, at its expense, a depositary for the Ordinary Shares and American Depositary Shares until
such date as no Warrants are outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>No Manipulation of Price</U><I>. </I>The Company will not take, directly or indirectly, any action designed to cause or result in,
or that has constituted or might reasonably be expected to constitute, the stabilization or manipulation of the price of any securities
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Acknowledgment</U>. The Company acknowledges that any advice given by the Placement Agent to the Company is solely for the benefit
and use of the Board of Directors of the Company and may not be used, reproduced, disseminated, quoted or referred to, without the Placement
Agent&rsquo;s prior written consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Announcement of Offering</U>. The Company acknowledges and agrees that the Placement Agent may, subsequent to the Closing, make public
its involvement with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Reliance on Others</U>. The Company confirms that it will rely on its own counsel and accountants for legal and accounting advice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Research Matters</U><FONT STYLE="font-variant: small-caps">.</FONT> By entering into this Agreement, the Placement Agent does not
provide any promise, either explicitly or implicitly, of favorable or continued research coverage of the Company and the Company hereby
acknowledges and agrees that the Placement Agent&rsquo;s selection as a placement agent for the Offering was in no way conditioned, explicitly
or implicitly, on the Placement Agent providing favorable or any research coverage of the Company. In accordance with FINRA Rule 2711(e),
the parties acknowledge and agree that the Placement Agent has not directly or indirectly offered favorable research, a specific rating
or a specific price target, or threatened to change research, a rating or a price target, to the Company or inducement for the receipt
of business or compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5. Conditions of the Obligations of the Placement Agent</B>. The obligations of the Placement Agent hereunder shall be subject to the
accuracy of the representations and warranties on the part of the Company set forth in Section 2 hereof, in each case as of the date
hereof and as of each Closing Date as though then made, to the timely performance by each of the Company of its covenants and other obligations
hereunder on and as of such dates, and to each of the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Compliance with Registration Requirements; No Stop Order; No Objection from the FINRA.</U> Each Prospectus Supplement (in accordance
with Rule 424(b)) and &ldquo;<U>free writing prospectus</U>&rdquo; (as defined in Rule 405 of the Securities Act), if any, shall have
been duly filed with the Commission, as appropriate; no stop order suspending the effectiveness of the Registration Statement or any
part thereof shall have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission; no
order preventing or suspending the use of any Prospectus Supplement shall have been issued and no proceeding for that purpose shall have
been initiated or threatened by the Commission; no order having the effect of ceasing or suspending the distribution of the Securities
or any other securities of the Company shall have been issued by any securities commission, securities regulatory authority or stock
exchange and no proceedings for that purpose shall have been instituted or shall be pending or, to the knowledge of the Company, contemplated
by any securities commission, securities regulatory authority or stock exchange; all requests for additional information on the part
of the Commission shall have been complied with; and the FINRA shall have raised no objection to the fairness and reasonableness of the
placement terms and arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Corporate Proceedings</U>. All corporate proceedings and other legal matters in connection with this Agreement, the Registration Statement
and each Prospectus Supplement, and the registration, sale and delivery of the Securities, shall have been completed or resolved in a
manner reasonably satisfactory to the Placement Agent&rsquo;s counsel, and such counsel shall have been furnished with such papers and
information as it may reasonably have requested to enable such counsel to pass upon the matters referred to in this Section 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>No Material Adverse Effect</U>. Subsequent to the execution and delivery of this Agreement and prior to each Closing Date, in the
Placement Agent&rsquo;s sole judgment after consultation with the Company, there shall not have occurred any Material Adverse Effect
(as defined in the Purchase Agreement) or development involving a prospective material adverse change in the condition or the business
activities, financial or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration
Statement and Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Opinions of Counsel for the Company</U>. The Placement Agent shall have received on each Closing Date the favorable opinion of Company
US Counsel and Company UK Counsel (each as defined in the Purchase Agreement), dated as of such Closing Date, including, without limitation,
a negative assurance letter from Company US Counsel addressed to the Placement Agent and in form and substance reasonably satisfactory
to the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Officers&rsquo; Certificate</U>. The Placement Agent shall have received on each Closing Date a certificate of the Company, dated
as of such Closing Date, signed by the Chief Executive Officer and Chief Financial Officer of the Company, to the effect that, and the
Placement Agent shall be satisfied that, the signers of such certificate have reviewed the Registration Statement, the Incorporated Documents,
any Prospectus Supplement, and this Agreement and to the further effect that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The representations and warranties of the Company in the Purchase Agreement and this Agreement are true and correct, as if made on and
as of such Closing Date, and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed
or satisfied at or prior to such Closing Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
No stop order suspending the effectiveness of the Registration Statement or the use of the Base Prospectus or any Prospectus Supplement
has been issued and no proceedings for that purpose have been instituted or are pending or, to the Company&rsquo;s knowledge, threatened
under the Securities Act; no order having the effect of ceasing or suspending the distribution of the Securities or any other securities
of the Company has been issued by any securities commission, securities regulatory authority or stock exchange in the United States and
no proceedings for that purpose have been instituted or are pending or, to the knowledge of the Company, contemplated by any securities
commission, securities regulatory authority or stock exchange in the United States;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
When the Registration Statement became effective, at the time of sale, and at all times subsequent thereto up to the delivery of such
certificate, the Registration Statement and the Incorporated Documents, if any, when such documents became effective or were filed with
the Commission, and any Prospectus Supplement, contained all material information required to be included therein by the Securities Act
and the Exchange Act, as applicable, and the applicable rules and regulations of the Commission thereunder, as the case may be, and in
all material respects conformed to the requirements of the Securities Act and the Exchange Act and the applicable rules and regulations
of the Commission thereunder, as the case may be, and the Registration Statement and the Incorporated Documents, if any, and any Prospectus
Supplement, did not and do not include any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading (provided,
however, that the preceding representations and warranties contained in this paragraph (iii) shall not apply to any statements or omissions
made in reliance upon and in conformity with information furnished in writing to the Company by the Placement Agent expressly for use
therein) and, since the effective date of the Registration Statement, there has occurred no event required by the Securities Act and
the rules and regulations of the Commission thereunder to be set forth in the Incorporated Documents which has not been so set forth;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Subsequent to the respective dates as of which information is given in the Registration Statement, the Incorporated Documents and any
Prospectus Supplement, there has not been: (a) any Material Adverse Effect; (b) any transaction that is material to the Company and the
subsidiaries taken as a whole, except transactions entered into in the ordinary course of business; (c) any obligation, direct or contingent,
that is material to the Company and the subsidiaries taken as a whole, incurred by the Company or any subsidiary, except obligations
incurred in the ordinary course of business; (d) any material change in the capital stock (except changes thereto resulting from the
exercise of outstanding stock options or warrants) or outstanding indebtedness of the Company or any subsidiary; (e) any dividend or
distribution of any kind declared, paid or made on the capital stock of the Company; or (f) any loss or damage (whether or not insured)
to the property of the Company or any subsidiary which has been sustained or will have been sustained which has a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Stock Exchange Listing</U>. The Shares shall be registered under the Exchange Act and shall be listed on the Trading Market, and the
Company shall not have taken any action designed to terminate, or likely to have the effect of terminating, the registration of the Ordinary
Shares and ADSs under the Exchange Act or delisting or suspending from trading the Ordinary Shares and ADSs from the Trading Market,
nor shall the Company have received any information suggesting that the Commission or the Trading Market is contemplating terminating
such registration or listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Additional Documents</U>. On or before each Closing Date, the Placement Agent and counsel for the Placement Agent shall have received
such information and documents as they may reasonably require for the purposes of enabling them to pass upon the issuance and sale of
the Securities as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction
of any of the conditions or agreements, herein contained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any condition specified in this Section 5 is not satisfied when and as required to be satisfied, this Agreement may be terminated by
the Placement Agent by notice to the Company at any time on or prior to a Closing Date, which termination shall be without liability
on the part of any party to any other party, except that Section 6 (Payment of Expenses), Section 7 (Indemnification and Contribution)
and Section 8 (Representations and Indemnities to Survive Delivery) shall at all times be effective and shall survive such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6. Payment of Expenses</B>. The Company agrees to pay all costs, fees and expenses incurred by the Company in connection with the
performance of its obligations hereunder and in connection with the transactions contemplated hereby, including, without limitation:
(i) all expenses incident to the issuance, delivery and qualification of the Securities (including all printing and engraving costs);
(ii) all fees and expenses of the registrar and depositary and/or transfer agent of the Company; (iii) all necessary issue, transfer
and other stamp taxes in connection with the issuance and sale of the Securities; (iv) all fees and expenses of the Company&rsquo;s counsel,
independent public or certified public accountants and other advisors; (v) all costs and expenses incurred in connection with the preparation,
printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents
and certificates of experts), the Base Prospectus, the Final Prospectus Supplement and each Prospectus Supplement, and all amendments
and supplements thereto, and this Agreement; (vi) all filing fees, reasonable attorneys&rsquo; fees and expenses incurred by the Company
or the Placement Agent in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of)
all or any part of the Securities for offer and sale under the state securities or blue sky laws or the securities laws of any other
country, and, if requested by the Placement Agent, preparing and printing a &ldquo;<U>Blue Sky Survey</U>,&rdquo; an &ldquo;<U>International
Blue Sky Survey</U>&rdquo; or other memorandum, and any supplements thereto, advising the Placement Agent of such qualifications, registrations
and exemptions; (vii) if applicable, the filing fees incident to the review and approval by the FINRA of the Placement Agent&rsquo;s
participation in the offering and distribution of the Shares; (viii) the fees and expenses associated with including the Shares and the
Warrant Shares on the Trading Market; (ix) all costs and expenses incident to the travel and accommodation of the Company&rsquo;s and
the Placement Agent&rsquo;s employees on the &ldquo;<U>roadshow</U>,&rdquo; if any; and (x) all other fees, costs and expenses of the
Company related to the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7. Indemnification and Contribution.</B> The Company agrees to indemnify the Placement Agent in accordance with the provisions of <U>Exhibit
A</U> to the Investment Banking Agreement, which is incorporated by reference herein and made a part hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8. Representations and Indemnities to Survive Delivery</B>. The respective indemnities, agreements, representations, warranties and other
statements of the Company or any person controlling the Company, of its officers, and of the Placement Agent set forth in or made pursuant
to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Placement Agent,
the Company, or any of its or their partners, officers or directors or any controlling person, as the case may be, and will survive delivery
of and payment for the Securities sold hereunder and any termination of this Agreement. A successor to a Placement Agent, or to the Company,
its directors or officers or any person controlling the Company, shall be entitled to the benefits of the indemnity, contribution and
reimbursement agreements contained in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9. Notices</B>. All communications hereunder shall be in writing and shall be mailed, hand delivered, telecopied or e-mailed and confirmed
to the parties hereto as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Placement Agent to the address set forth above, attention: General Counsel, facsimile: (305) 572-4220</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
a copy to: </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ellenoff
Grossman &amp; Schole LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1345
Avenue of the Americas, 11th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10105</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:
capmkts@egsllp.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company, 22 Boston Wharf Road, FL 7 Boston, MA 02210, attention: Abizer Gaslightwala (E-Mail: abizer.gaslightwala@akaritx.com).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
a copy to: </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greenburg
Traurig LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
Vanderbilt Avenue, New York, NY 10017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:
Gary.Emmanuel@gtlaw.com; rutherfurdw@gtlaw.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Gary Emmanuel, Esq., Win Rutherfurd, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
party hereto may change the address for receipt of communications by giving written notice to the others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
10. Successors</B>. This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees,
officers and directors and controlling persons referred to in Section 7 hereof, and to their respective successors, and personal representative,
and no other person will have any right or obligation hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
11. Partial Unenforceability</B>. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not
affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of
this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and
only such minor changes) as are necessary to make it valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
12. Governing Law Provisions</B>. This Agreement shall be deemed to have been made and delivered in New York City and both this Agreement
and the transactions contemplated hereby shall be governed as to validity, interpretation, construction, effect and in all other respects
by the internal laws of the State of New York, without regard to the conflict of laws principles thereof. Each of the Placement Agent
and the Company: (i) agrees that any legal suit, action or proceeding arising out of or relating to this Agreement and/or the transactions
contemplated hereby shall be instituted exclusively in New York Supreme Court, County of New York, or in the United States District Court
for the Southern District of New York, (ii) waives any objection which it may have or hereafter to the venue of any such suit, action
or proceeding, and (iii) irrevocably consents to the jurisdiction of the New York Supreme Court, County of New York, and the United States
District Court for the Southern District of New York in any such suit, action or proceeding. Each of the Placement Agent and the Company
further agrees to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding in
the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York and agrees
that service of process upon the Company mailed by certified mail to the Company&rsquo;s address shall be deemed in every respect effective
service of process upon the Company, in any such suit, action or proceeding, and service of process upon the Placement Agent mailed by
certified mail to the Placement Agent&rsquo;s address shall be deemed in every respect effective service process upon the Placement Agent,
in any such suit, action or proceeding. Notwithstanding any provision of this Agreement to the contrary, the Company agrees that neither
the Placement Agent nor its affiliates, and the respective officers, directors, employees, agents and representatives of the Placement
Agent, its affiliates and each other person, if any, controlling the Placement Agent or any of its affiliates, shall have any liability
(whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection with the engagement and transaction
described herein except for any such liability for losses, claims, damages or liabilities incurred by the Company that are finally judicially
determined to have resulted from the willful misconduct or gross negligence of such individuals or entities. If either party shall commence
an action or proceeding to enforce any provision of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed
by the other party for its reasonable attorney&rsquo;s fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
13. General Provisions. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous
oral agreements, understandings and negotiations with respect to the subject matter hereof. Notwithstanding anything herein to the contrary,
the Investment Banking Agreement between the Company and the Placement Agent, shall continue to be effective and the terms therein shall
continue to survive and be enforceable by the Placement Agent in accordance with its terms, including, without limitation, Section 4(d)
and Section 5 therein with respect to future offerings. This Agreement may be executed in two or more counterparts, each one of which
shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may
not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived
unless waived in writing by each party whom the condition is meant to benefit. Section headings herein are for the convenience of the
parties only and shall not affect the construction or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company acknowledges that in connection with the offering of the Securities: (i) the Placement Agent has acted at arms length, are
not agents of, and owe no fiduciary duties to the Company or any other person, (ii) the Placement Agent owes the Company only those duties
and obligations set forth in this Agreement and (iii) the Placement Agent may have interests that differ from those of the Company. The
Company waives to the full extent permitted by applicable law any claims it may have against the Placement Agent arising from an alleged
breach of fiduciary duty in connection with the offering of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>The
remainder of this page has been intentionally left blank.</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing is in accordance with your understanding of our agreement, please sign below whereupon this instrument, along with all
counterparts hereof, shall become a binding agreement in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>akari
    therapeutics, PLC</B>,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing Placement Agency Agreement is hereby confirmed and accepted as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LADENBURG
    THALMANN &amp; CO. INC.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nicholas
    Stergis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing
    Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>ex10-3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.3 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, AND IN THE CASE OF A TRANSACTION EXEMPT FROM REGISTRATION,
UNLESS THE COMPANY AND DEPOSITARY HAVE RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO EACH OF THEM THAT SUCH TRANSACTION DOES
NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &ldquo;ACCREDITED
INVESTOR&rdquo; AS DEFINED IN RULE 501(A) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERIES
E WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES AKARI THERAPEUTICS, PLC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    No. [&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    Date: October [&#9679;], 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of American Depositary Shares: [&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SERIES E WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the &ldquo;<U>Warrant</U>&rdquo;) certifies that,
for value received, [&#9679;] or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations
on exercise and the conditions hereinafter set forth, at any time on or after the date Shareholder Approval is received and effective
(the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on the five (5) year anniversary of
the Initial Exercise Date (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Akari Therapeutics,
Plc., a public company with limited liability incorporated under the laws of England and Wales (the &ldquo;<U>Company</U>&rdquo;), up
to [&#9679;] Ordinary Shares (the &ldquo;<U>Warrant Shares</U>&rdquo;) represented by [&#9679;] American Depositary Shares (&ldquo; <U>ADSs</U>&rdquo;),
as subject to adjustment hereunder (the &ldquo;<U>Warrant ADSs</U>&rdquo;). The purchase price of one Warrant ADS shall be equal to the
Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in that
certain Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated October [&#9679;], 2025 among the Company and
the purchasers signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency
of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books
of the Company) and the Depositary of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in
the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii) the number
of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid
the Holder shall deliver to the Company the aggregate applicable Exercise Price of the Warrant ADSs thereby purchased by wire transfer
or cashier&rsquo;s check drawn on a United States bank, in either case in immediately available funds, unless the cashless exercise procedure
specified in Section 2(c) below is properly specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. The
Company shall have no obligation to inquire with respect to or otherwise confirm the authenticity of the signature(s) contained on any
Notice of Exercise nor the authority of the person so executing such Notice of Exercise. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant
ADSs available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company
for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises
of this Warrant resulting in purchases of a portion of the total number of Warrant ADSs available hereunder shall have the effect of
lowering the outstanding number of Warrant ADSs purchasable hereunder in an amount equal to the applicable number of Warrant ADSs purchased.
The Holder and the Company shall maintain records showing the number of Warrant ADSs purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. The Holder and any assignee,
by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a
portion of the Warrant ADSs hereunder, the number of Warrant ADSs available for purchase hereunder at any given time may be less than
the amount stated on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. Subject to Section 2(c) hereof, the exercise price per ADS under this Warrant shall be $[&#9679;], subject to adjustment
hereunder (or, if higher, the aggregate nominal value of the Ordinary Shares underlying an ADS at the time of issue) (the &ldquo;<U>Exercise
Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If following the date that is 6 months following the original issuance date of the Warrants, at the time of
exercise hereof, there is no effective registration statement registering with a current prospectus available for the resale of the Warrant
ADSs by the Holder, then this Warrant may (if permitted by applicable law and the Company&rsquo;s articles of association) also be exercised,
in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Warrant ADSs equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both
executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the
option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or
(z) the Bid Price of the ADSs on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) as of the time
of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular
trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the
close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the
applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed
and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
= the Exercise Price of this Warrant for cash exercise, as adjusted hereunder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
= the number of Warrant ADSs that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if
such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Warrant ADSs are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant ADSs being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs are then
listed or quoted on a Trading Market, the bid price of the ADSs for the time in question (or the nearest preceding date) on the Trading
Market on which the ADSs are then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time)
to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the ADSs for
such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs are not then listed or quoted for trading
on OTCQB or OTCQX and if prices for the ADSs are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc.
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the ADSs
so reported, or (d) in all other cases, the fair market value of an ADSs as determined by an independent appraiser selected in good faith
by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the reasonable
fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs then listed or quoted on
a Trading Market, the daily volume weighted average price of the ADSs for such date (or the nearest preceding date) on the Trading Market
on which the ADSs then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02
p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the ADSs for such date
(or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs are not then listed or quoted for trading on OTCQB or
OTCQX and if prices for the ADSs are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per ADS so reported, or (d) in all
other cases, the fair market value of an ADS as determined by an independent appraiser selected in good faith by the Holders of a majority
in interest of the Securities then outstanding and reasonably acceptable to the Company, the reasonable fees and expenses of which shall
be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant ADSs Upon Exercise</U>. Subject to the Company&rsquo;s receipt of the Exercise Price, the Company shall deposit
the Warrant Shares subject to such exercise with Deutsche Bank Trust Company Americas, the Depositary for the ADSs (the &ldquo;<U>Depositary</U>&rdquo;)
and instruct the Depositary to credit the Holder&rsquo;s prime broker with The Depository Trust Company through its Deposit/Withdrawal
At Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Depositary is then a participant in such system and either (A) there is an effective
registration statement with a current prospectus registering for resale of the Warrant Shares represented by the Warrant ADSs by the
Holder or (B) this Warrant is being exercised via cashless exercise and the Warrant ADSs have been sold by the Holder prior to the Warrant
ADS Delivery Date (as defined below), and otherwise by electronic (registered in book-entry format) or physical delivery to the address
specified by the Holder in the Notice of Exercise, by the date that is the earliest of (i) one (1) Trading Day after the delivery to
the Company of the Notice of Exercise, and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise and the aggregate Exercise Price (such date, the &ldquo;<U>Warrant ADS Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Company shall treat the Holder for all corporate purposes as if it were the beneficial owner
of the Warrant ADSs with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier
of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice
of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant ADSs subject to a Notice of Exercise by the Warrant
ADS Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant
ADSs subject to such exercise (based on the VWAP of the ADSs on the date of the applicable Notice of Exercise), $10.00 per Trading Day
(increasing to $20.00 per Trading Day on the third Trading Day after the Warrant ADS Delivery Date) for each Trading Day after such Warrant
ADS Delivery Date until such Warrant ADSs are delivered or the Holder rescinds such exercise. The Company agrees to use commercially
reasonable efforts to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;Standard Settlement Period&rdquo; means the standard settlement period, expressed in a number
of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the ADSs as in effect on the date of delivery of the Notice
of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant ADSs, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant ADSs called for by this Warrant, which new Warrant shall in all
other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Depositary to transmit to the Holder the Warrant ADSs pursuant to Section
2(d)(i) by the Warrant ADS Delivery Date, then the Holder will have the right to rescind such exercise in respect of the untransmitted
Warrant ADSs (with the effect that the Holder&rsquo;s right to acquire such Warrant ADSs pursuant to this Warrant shall be restored)
and the Company shall return to the Holder the aggregate Exercise Price paid to the Company for such Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant ADSs Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Depositary to deliver to the Holder the Warrant ADSs in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant ADS Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, ADSs
to deliver in satisfaction of a sale by the Holder of the Warrant ADSs which the Holder anticipated receiving upon such exercise (a &ldquo;Buy-In&rdquo;),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including
brokerage commissions, if any) for the ADSs so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant ADSs
that the Company failed to deliver to the Holder in connection with the exercise at issue by (2) the price at which the sell order giving
rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant in respect
of the Warrant ADSs for which such exercise was not honored and return any amount received by the Company in respect of the Exercise
Price for those Warrant ADSs (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of ADSs that
would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder
purchases ADSs having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of the Warrant with an
aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company
shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the
Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver ADSs upon exercise of the Warrant
as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional Warrant Shares or Warrant ADSs shall be issued upon the exercise of this Warrant.
As to any fraction of an ADS which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole ADS; provided, however, the fraction of an ADS shall not be rounded up to the next whole ADS if such rounding
results in the issue price being lower than the nominal value of the ADS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant ADSs shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of Warrant ADSs, all of which taxes and expenses shall be paid by the Company,
and such Warrant ADSs shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event that Warrant ADSs are to be issued in a name other than the name of the Holder, this Warrant when surrendered
for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all
Depositary fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established
clearing corporation performing similar functions) required for same-day electronic issuance and delivery of the Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof; provided, however, that the foregoing shall not be deemed or construed to limit any rights
of the Depositary under the terms and provisions of the deposit agreement among, inter alia, the Company and the Depositary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. Notwithstanding anything to the contrary contained herein, the Company shall not effect the
exercise of any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant to
the terms and conditions of this Warrant and any such exercise shall be null and void and treated if never made, to the extent that after
giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially own in excess
of 9.99% (the &ldquo;<U>Maximum Percentage</U>&rdquo;) of the number of Ordinary Shares outstanding immediately after giving effect to
such exercise. For purposes of the foregoing sentence, the aggregate number of Ordinary Shares beneficially owned by the Holder and the
other Attribution Parties shall include the number of Ordinary Shares underlying ADSs held by the Holder and all other Attribution Parties
plus the number of Ordinary Shares underlying ADSs issuable upon exercise of this Warrant with respect to which the determination of
such sentence is being made, but shall exclude the number of Ordinary Shares underlying ADSs which would be issuable upon (A) exercise
of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution Parties and (B)
exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by the Holder
or any other Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained in this Section
2(e). For purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act.
For purposes of this Warrant, in determining the number of Ordinary Shares underlying ADSs the Holder may acquire upon the exercise of
this Warrant without exceeding the Maximum Percentage, the Holder may rely on the number of Ordinary Shares as reflected in (x) the Company&rsquo;s
most recent Annual Report on Form 10-K, Current Report on Form 8-K or other public filing with the Commission, as the case may be, (y)
a more recent public announcement by the Company or (3) any other written notice by the Company setting forth the number of Ordinary
Shares outstanding (the &ldquo;<U>Reported Outstanding Share Number</U>&rdquo;). If the Company receives an Exercise Notice from the
Holder at a time when the actual number of outstanding Ordinary Shares is less than the Reported Outstanding Share Number, the Company
shall (i) notify the Holder in writing of the number of Ordinary Shares then outstanding and, to the extent that such Exercise Notice
would otherwise cause the Holder&rsquo;s beneficial ownership, as determined pursuant to this Section 2(e), to exceed the Maximum Percentage,
the Holder must notify the Company of a reduced number of Warrant ADSs to be purchased pursuant to such Exercise Notice (the number of
shares by which such purchase is reduced, the &ldquo;<U>Reduction Shares</U>&rdquo;) and (ii) as soon as reasonably practicable, the
Company shall return to the Holder any exercise price paid by the Holder for the Reduction Shares. For any reason at any time, upon the
written or oral request of the Holder, the Company shall within one (1) Business Day confirm orally and in writing or by electronic mail
to the Holder the number of Ordinary Shares then outstanding. In any case, the number of outstanding Ordinary Shares shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and any other Attribution
Party since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of Ordinary Shares
to the Holder upon exercise of this Warrant results in the Holder and the other Attribution Parties being deemed to beneficially own,
in the aggregate, more than the Maximum Percentage of the number of outstanding Ordinary Shares (as determined under Section 13(d) of
the Exchange Act), the Company and the Holder shall use commercially reasonable efforts to procure that the number of shares so issued
by which the Holder&rsquo;s and the other Attribution Parties&rsquo; aggregate beneficial ownership exceeds the Maximum Percentage (the
&ldquo;<U>Excess Shares</U>&rdquo;) are repurchased by the Company (out of its distributable reserves pursuant to a contract duly authorized
in accordance with the law, or as it may otherwise be legally permitted from time to time) for a price equal to the applicable Exercise
Price, and pending such repurchase the Holder agrees it shall not exercise any rights relating to the power to vote or to transfer the
Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase (with such increase not effective
until the sixty-first (61st) day after delivery of such notice) or decrease the Maximum Percentage to any other percentage not in excess
of 9.99% as specified in such notice; provided that (i) any such increase in the Maximum Percentage will not be effective until the sixty-first
(61st) day after such notice is delivered to the Company and (ii) any such increase or decrease will apply only to the Holder and the
other Attribution Parties and not to any other holder of Warrants that is not an Attribution Party of the Holder. For purposes of clarity,
the Ordinary Shares issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially
owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act. The provisions of
this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e)
to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended
beneficial ownership limitation contained in this Section 2(e) or to make changes or supplements necessary or desirable to properly give
effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this
Warrant. &ldquo;<U>Attribution Parties</U>&rdquo; means, collectively, the following Persons and entities: (i) any investment vehicle,
including, any funds, feeder funds or managed accounts, currently, or from time to time after the issuance date, directly or indirectly
managed or advised by the Holder&rsquo;s investment manager or any of its Affiliates or principals, (ii) any direct or indirect Affiliates
of the Holder or any of the foregoing, (iii) any Person acting or who could be deemed to be acting as a group together with the Holder
or any of the foregoing and (iv) any other Persons whose beneficial ownership of the Company&rsquo;s Ordinary Shares would or could be
aggregated with the Holder&rsquo;s and the other Attribution Parties for purposes of Section 13(d) of the Exchange Act. For clarity,
the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will
have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Share Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or otherwise
makes a distribution or distributions on its Ordinary Shares or ADSs or any other equity or equity equivalent securities payable in Ordinary
Shares or ADSs (which, for avoidance of doubt, shall not include any ADSs issued by the Company upon exercise of this Warrant), as applicable,
(ii) subdivides outstanding Ordinary Shares or ADSs into a larger number of shares or ADSs, as applicable, (iii) combines (including
by way of reverse share split) outstanding Ordinary Shares or ADSs into a smaller number of shares or ADSs, as applicable, (iv) redesignates
any other securities as Ordinary Shares or ADSs or (v) issues Ordinary Shares or ADSs by way of capitalization of profits or reserves,
then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of ADSs (excluding
treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of ADSs outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted so that
the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective
immediately after the record date or (if there is no record date) the effective date of the transaction giving rise to the adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
[RESERVED].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time that this Warrant is
outstanding the Company grants, issues or sells any Ordinary Share Equivalents or rights to purchase shares, warrants, securities or
other property pro rata to the record holders of any class of Ordinary Shares or ADSs (the &ldquo;<U>Purchase Rights</U>&rdquo;), then
the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder
could have acquired if the Holder had held the number of Ordinary Shares or ADSs acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Maximum Percentage) immediately before the date on which
a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record
holders of Ordinary Shares or ADSs are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Maximum Percentage,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such ADSs as a
result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such
time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Pro Rata Distributions</U>. Except to the extent that the adjustments pursuant to Section 3(a) above apply, during such time as this
Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its
assets) to holders of Ordinary Shares or ADSs, by way of return of capital or otherwise (including, without limitation, any distribution
of cash, shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme
of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant, then,
in each such case, the Holder shall be entitled to receive at the time such Distribution is made the amount of cash or assets that are
distributed in the Distribution per Ordinary Share or ADS multiplied by the number of Ordinary Shares or ADSs acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Maximum Percentage)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of Ordinary Shares or ADSs are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
that the Holder shall not be entitled to receive any Ordinary Shares or ADSs pursuant to the foregoing right to the extent that this
would result in the Holder exceeding the Maximum Percentage, and any such Ordinary Shares or ADSs shall be held in abeyance for the benefit
of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly
or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of
its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer
(whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares are permitted to sell, tender or
exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary
Shares, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or
recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50%
of the outstanding Ordinary Shares (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e)
on the exercise of this Warrant), the number of shares of the successor or acquiring corporation or of the Company, if it is the surviving
corporation, and/or any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental
Transaction by a holder of the number of Ordinary Shares for which this Warrant is exercisable immediately prior to such Fundamental
Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the
determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one Ordinary Share in such Fundamental Transaction, and the Company shall apportion the Exercise
Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate
Consideration. If holders of Ordinary Shares are given any choice as to the securities, cash or property to be received in a Fundamental
Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant
following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company
or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within
30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental
Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined
below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided,
however, that, if the Fundamental Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s
Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration
(and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to
the holders of Ordinary Shares of the Company in connection with the Fundamental Transaction, whether that consideration be in the form
of cash, stock or any combination thereof, or whether the holders of Ordinary Shares are given the choice to receive from among alternative
forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Ordinary Shares of the Company
are not offered or paid any consideration in such Fundamental Transaction, such holders of Ordinary Shares will be deemed to have received
Ordinary Shares of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental
Transaction. &ldquo;Black Scholes Value&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained
from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for
pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time
between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to 100-day volatility obtained from the Company&rsquo;s historical volatility using the HVT Function on Bloomberg (determined
utilizing a 365-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental
Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash,
if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, (D) a remaining option time
equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination
Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds
(or such other consideration) within the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation
of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not
the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant
in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to
the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of
the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the Ordinary Shares acquirable and receivable upon exercise of this Warrant (without regard
to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an Exercise price which applies the
Exercise Price hereunder to such shares of capital stock (but taking into account the relative value of the Ordinary Shares pursuant
to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the
case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall
be the sum of the number of Ordinary Shares (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant ADSs and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Ordinary Shares, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares or
ADSs, (C) the Company shall authorize the granting to all holders of the Ordinary Shares or ADSs rights or warrants to subscribe for
or purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required
in connection with any reclassification of the Ordinary Shares or ADSs, any consolidation or merger to which the Company is a party,
any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Ordinary
Shares are converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the
Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the
applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose
of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of
the Ordinary Shares or ADSs of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Ordinary Shares of record shall be entitled to exchange their Ordinary
Shares for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share
exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity
of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file
the material terms of such notice with the Commission pursuant to a Report on Form 8-K. The Holder shall remain entitled to exercise
this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except
as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Voluntary Adjustment By Company.</U> Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and
for any period of time deemed appropriate by the Board of Directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Change in ADS Ratio.</U> If after the Issuance Date the ratio of ADSs to Ordinary Shares is increased or reduced, then the number
of Warrant ADSs to be delivered upon exercise of this Warrant and the Exercise Price per Warrant ADS will each be proportionately adjusted
so that the aggregate Exercise Price remains unchanged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws, and the conditions set forth in Section 4(d) hereof
and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to
pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company
assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase
of Warrant ADSs without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date and shall be
identical with this Warrant except as to the number of Warrant ADSs issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or
transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant ADSs issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant ADSs or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Shareholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting the rights of a Holder to receive Warrant ADSs on a &ldquo;cashless exercise,&rdquo; and to
receive the cash payments contemplated pursuant to Sections 2(d)(i), 2(d)(iv) and 2(d)(v), in no event will the Company be required to
net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant ADSs,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, its directors will have authority to allot a sufficient number
of shares to provide for the issuance of the Warrant ADSs and underlying Ordinary Shares upon the exercise of any purchase rights under
this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are
charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant ADSs may be issued as provided herein without violation
of any applicable law or regulation, or of any requirements of the applicable Trading Market upon which the Ordinary Shares and ADSs
may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant ADSs in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the
Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its articles of association or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at
all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant ADSs for which this Warrant is exercisable or in the Exercise
Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public
regulatory body or bodies having jurisdiction thereof. Unless required by law, the Company shall not do anything that would require the
Exercise Price to be adjusted to an amount that is less than the aggregate nominal value of the Ordinary Shares underlying an ADS at
that time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies, notwithstanding the fact that
all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of
this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient
to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Ordinary Shares or ADSs or as a shareholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Depositary</U>. For the avoidance of doubt, notwithstanding anything to the contrary contained herein, the Depositary&rsquo;s rights
and obligations with respect to the Company and the ADSs (including the Warrant ADSs) shall be as set forth in, and subject to, the terms
and provisions of the deposit agreement among, <I>inter alia</I>, the Company and the Depositary and in no event shall this Warrant be
deemed or construed to impose any additional obligations or liabilities on the Depositary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Company Acknowledgement</U>. The Company acknowledges that the Company has received the aggregate par value amount of the Warrant
Shares underlying the Warrant ADSs upon exercise of this Warrant and the Company shall hold such aggregate nominal amount in trust and
shall apply it as applicable in connection with exercises of this Warrant pursuant to Section 2(c) herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p)
<U>Electronic Signatures</U>. Electronically scanned and transmitted signatures, including by email attachment, shall be deemed originals
for all purposes of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AKARI
    THERAPEUTICS, PLC</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TO:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AKARI
    THERAPEUTICS, PLC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEUTSCHE
    BANK TRUST COMPANY AMERICAS, AS DEPOSITARY</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase _________ Warrant ADSs of the Company pursuant to the terms of the attached Warrant (only if
exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
if permitted the cancellation of such number of Warrant ADSs as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant ADSs purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please register and issue said Warrant ADSs in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC
Participant name and number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
and account number of DTC Participant Client:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact
of DTC Participant:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact
of Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
Number of DTC Participant:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ____________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
of Authorized Signatory of Investing Entity: ______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase Warrant ADSs.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    _________________________________________________________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:
    _______________________________________________________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    ____________, ______</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: _____________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address: ______________________________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>6
<FILENAME>ex10-4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.4 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, AND IN THE CASE OF A TRANSACTION EXEMPT FROM REGISTRATION,
UNLESS THE COMPANY AND DEPOSITARY HAVE RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO EACH OF THEM THAT SUCH TRANSACTION DOES
NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &ldquo;ACCREDITED
INVESTOR&rdquo; AS DEFINED IN RULE 501(A) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERIES
F WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES AKARI THERAPEUTICS, PLC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    No. [&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    Date: October [&#9679;], 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of American Depositary Shares: [&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SERIES F WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the &ldquo;<U>Warrant</U>&rdquo;) certifies that,
for value received, [&#9679;] or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations
on exercise and the conditions hereinafter set forth, at any time on or after the date Shareholder Approval is received and effective
(the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on the thirty (30) month anniversary of
the Initial Exercise Date (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Akari Therapeutics,
Plc., a public company with limited liability incorporated under the laws of England and Wales (the &ldquo;<U>Company</U>&rdquo;), up
to [&#9679;] Ordinary Shares (the &ldquo;<U>Warrant Shares</U>&rdquo;) represented by [&#9679;] American Depositary Shares (&ldquo; <U>ADSs</U>&rdquo;),
as subject to adjustment hereunder (the &ldquo;<U>Warrant ADSs</U>&rdquo;). The purchase price of one Warrant ADS shall be equal to the
Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in that
certain Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated October [&#9679;], 2025 among the Company and
the purchasers signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency
of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books
of the Company) and the Depositary of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in
the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii) the number
of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid
the Holder shall deliver to the Company the aggregate applicable Exercise Price of the Warrant ADSs thereby purchased by wire transfer
or cashier&rsquo;s check drawn on a United States bank, in either case in immediately available funds, unless the cashless exercise procedure
specified in Section 2(c) below is properly specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. The
Company shall have no obligation to inquire with respect to or otherwise confirm the authenticity of the signature(s) contained on any
Notice of Exercise nor the authority of the person so executing such Notice of Exercise. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant
ADSs available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company
for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises
of this Warrant resulting in purchases of a portion of the total number of Warrant ADSs available hereunder shall have the effect of
lowering the outstanding number of Warrant ADSs purchasable hereunder in an amount equal to the applicable number of Warrant ADSs purchased.
The Holder and the Company shall maintain records showing the number of Warrant ADSs purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. The Holder and any assignee,
by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a
portion of the Warrant ADSs hereunder, the number of Warrant ADSs available for purchase hereunder at any given time may be less than
the amount stated on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. Subject to Section 2(c) hereof, the exercise price per ADS under this Warrant shall be $[&#9679;], subject to adjustment
hereunder (or, if higher, the aggregate nominal value of the Ordinary Shares underlying an ADS at the time of issue) (the &ldquo;<U>Exercise
Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If following the date that is 6 months following the original issuance date of the Warrants, at the time of
exercise hereof, there is no effective registration statement registering with a current prospectus available for the resale of the Warrant
ADSs by the Holder, then this Warrant may (if permitted by applicable law and the Company&rsquo;s articles of association) also be exercised,
in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Warrant ADSs equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both
executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the
option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or
(z) the Bid Price of the ADSs on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) as of the time
of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular
trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the
close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the
applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed
and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
= the Exercise Price of this Warrant for cash exercise, as adjusted hereunder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
= the number of Warrant ADSs that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if
such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Warrant ADSs are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant ADSs being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs are then
listed or quoted on a Trading Market, the bid price of the ADSs for the time in question (or the nearest preceding date) on the Trading
Market on which the ADSs are then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time)
to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the ADSs for
such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs are not then listed or quoted for trading
on OTCQB or OTCQX and if prices for the ADSs are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc.
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the ADSs
so reported, or (d) in all other cases, the fair market value of an ADSs as determined by an independent appraiser selected in good faith
by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the reasonable
fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs then listed or quoted on
a Trading Market, the daily volume weighted average price of the ADSs for such date (or the nearest preceding date) on the Trading Market
on which the ADSs then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02
p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the ADSs for such date
(or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs are not then listed or quoted for trading on OTCQB or
OTCQX and if prices for the ADSs are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per ADS so reported, or (d) in all
other cases, the fair market value of an ADS as determined by an independent appraiser selected in good faith by the Holders of a majority
in interest of the Securities then outstanding and reasonably acceptable to the Company, the reasonable fees and expenses of which shall
be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant ADSs Upon Exercise</U>. Subject to the Company&rsquo;s receipt of the Exercise Price, the Company shall deposit
the Warrant Shares subject to such exercise with Deutsche Bank Trust Company Americas, the Depositary for the ADSs (the &ldquo;<U>Depositary</U>&rdquo;)
and instruct the Depositary to credit the Holder&rsquo;s prime broker with The Depository Trust Company through its Deposit/Withdrawal
At Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Depositary is then a participant in such system and either (A) there is an effective
registration statement with a current prospectus registering for resale of the Warrant Shares represented by the Warrant ADSs by the
Holder or (B) this Warrant is being exercised via cashless exercise and the Warrant ADSs have been sold by the Holder prior to the Warrant
ADS Delivery Date (as defined below), and otherwise by electronic (registered in book-entry format) or physical delivery to the address
specified by the Holder in the Notice of Exercise, by the date that is the earliest of (i) one (1) Trading Day after the delivery to
the Company of the Notice of Exercise, and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise and the aggregate Exercise Price (such date, the &ldquo;<U>Warrant ADS Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Company shall treat the Holder for all corporate purposes as if it were the beneficial owner
of the Warrant ADSs with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier
of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice
of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant ADSs subject to a Notice of Exercise by the Warrant
ADS Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant
ADSs subject to such exercise (based on the VWAP of the ADSs on the date of the applicable Notice of Exercise), $10.00 per Trading Day
(increasing to $20.00 per Trading Day on the third Trading Day after the Warrant ADS Delivery Date) for each Trading Day after such Warrant
ADS Delivery Date until such Warrant ADSs are delivered or the Holder rescinds such exercise. The Company agrees to use commercially
reasonable efforts to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;Standard Settlement Period&rdquo; means the standard settlement period, expressed in a number
of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the ADSs as in effect on the date of delivery of the Notice
of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant ADSs, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant ADSs called for by this Warrant, which new Warrant shall in all
other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Depositary to transmit to the Holder the Warrant ADSs pursuant to Section
2(d)(i) by the Warrant ADS Delivery Date, then the Holder will have the right to rescind such exercise in respect of the untransmitted
Warrant ADSs (with the effect that the Holder&rsquo;s right to acquire such Warrant ADSs pursuant to this Warrant shall be restored)
and the Company shall return to the Holder the aggregate Exercise Price paid to the Company for such Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant ADSs Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Depositary to deliver to the Holder the Warrant ADSs in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant ADS Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, ADSs
to deliver in satisfaction of a sale by the Holder of the Warrant ADSs which the Holder anticipated receiving upon such exercise (a &ldquo;Buy-In&rdquo;),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including
brokerage commissions, if any) for the ADSs so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant ADSs
that the Company failed to deliver to the Holder in connection with the exercise at issue by (2) the price at which the sell order giving
rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant in respect
of the Warrant ADSs for which such exercise was not honored and return any amount received by the Company in respect of the Exercise
Price for those Warrant ADSs (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of ADSs that
would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder
purchases ADSs having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of the Warrant with an
aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company
shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the
Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver ADSs upon exercise of the Warrant
as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional Warrant Shares or Warrant ADSs shall be issued upon the exercise of this Warrant.
As to any fraction of an ADS which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole ADS; provided, however, the fraction of an ADS shall not be rounded up to the next whole ADS if such rounding
results in the issue price being lower than the nominal value of the ADS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant ADSs shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of Warrant ADSs, all of which taxes and expenses shall be paid by the Company,
and such Warrant ADSs shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event that Warrant ADSs are to be issued in a name other than the name of the Holder, this Warrant when surrendered
for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all
Depositary fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established
clearing corporation performing similar functions) required for same-day electronic issuance and delivery of the Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof; provided, however, that the foregoing shall not be deemed or construed to limit any rights
of the Depositary under the terms and provisions of the deposit agreement among, inter alia, the Company and the Depositary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. Notwithstanding anything to the contrary contained herein, the Company shall not effect the
exercise of any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant to
the terms and conditions of this Warrant and any such exercise shall be null and void and treated if never made, to the extent that after
giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially own in excess
of 9.99% (the &ldquo;<U>Maximum Percentage</U>&rdquo;) of the number of Ordinary Shares outstanding immediately after giving effect to
such exercise. For purposes of the foregoing sentence, the aggregate number of Ordinary Shares beneficially owned by the Holder and the
other Attribution Parties shall include the number of Ordinary Shares underlying ADSs held by the Holder and all other Attribution Parties
plus the number of Ordinary Shares underlying ADSs issuable upon exercise of this Warrant with respect to which the determination of
such sentence is being made, but shall exclude the number of Ordinary Shares underlying ADSs which would be issuable upon (A) exercise
of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution Parties and (B)
exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by the Holder
or any other Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained in this Section
2(e). For purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act.
For purposes of this Warrant, in determining the number of Ordinary Shares underlying ADSs the Holder may acquire upon the exercise of
this Warrant without exceeding the Maximum Percentage, the Holder may rely on the number of Ordinary Shares as reflected in (x) the Company&rsquo;s
most recent Annual Report on Form 10-K, Current Report on Form 8-K or other public filing with the Commission, as the case may be, (y)
a more recent public announcement by the Company or (3) any other written notice by the Company setting forth the number of Ordinary
Shares outstanding (the &ldquo;<U>Reported Outstanding Share Number</U>&rdquo;). If the Company receives an Exercise Notice from the
Holder at a time when the actual number of outstanding Ordinary Shares is less than the Reported Outstanding Share Number, the Company
shall (i) notify the Holder in writing of the number of Ordinary Shares then outstanding and, to the extent that such Exercise Notice
would otherwise cause the Holder&rsquo;s beneficial ownership, as determined pursuant to this Section 2(e), to exceed the Maximum Percentage,
the Holder must notify the Company of a reduced number of Warrant ADSs to be purchased pursuant to such Exercise Notice (the number of
shares by which such purchase is reduced, the &ldquo;<U>Reduction Shares</U>&rdquo;) and (ii) as soon as reasonably practicable, the
Company shall return to the Holder any exercise price paid by the Holder for the Reduction Shares. For any reason at any time, upon the
written or oral request of the Holder, the Company shall within one (1) Business Day confirm orally and in writing or by electronic mail
to the Holder the number of Ordinary Shares then outstanding. In any case, the number of outstanding Ordinary Shares shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and any other Attribution
Party since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of Ordinary Shares
to the Holder upon exercise of this Warrant results in the Holder and the other Attribution Parties being deemed to beneficially own,
in the aggregate, more than the Maximum Percentage of the number of outstanding Ordinary Shares (as determined under Section 13(d) of
the Exchange Act), the Company and the Holder shall use commercially reasonable efforts to procure that the number of shares so issued
by which the Holder&rsquo;s and the other Attribution Parties&rsquo; aggregate beneficial ownership exceeds the Maximum Percentage (the
&ldquo;<U>Excess Shares</U>&rdquo;) are repurchased by the Company (out of its distributable reserves pursuant to a contract duly authorized
in accordance with the law, or as it may otherwise be legally permitted from time to time) for a price equal to the applicable Exercise
Price, and pending such repurchase the Holder agrees it shall not exercise any rights relating to the power to vote or to transfer the
Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase (with such increase not effective
until the sixty-first (61st) day after delivery of such notice) or decrease the Maximum Percentage to any other percentage not in excess
of 9.99% as specified in such notice; provided that (i) any such increase in the Maximum Percentage will not be effective until the sixty-first
(61st) day after such notice is delivered to the Company and (ii) any such increase or decrease will apply only to the Holder and the
other Attribution Parties and not to any other holder of Warrants that is not an Attribution Party of the Holder. For purposes of clarity,
the Ordinary Shares issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially
owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act. The provisions of
this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e)
to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended
beneficial ownership limitation contained in this Section 2(e) or to make changes or supplements necessary or desirable to properly give
effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this
Warrant. &ldquo;<U>Attribution Parties</U>&rdquo; means, collectively, the following Persons and entities: (i) any investment vehicle,
including, any funds, feeder funds or managed accounts, currently, or from time to time after the issuance date, directly or indirectly
managed or advised by the Holder&rsquo;s investment manager or any of its Affiliates or principals, (ii) any direct or indirect Affiliates
of the Holder or any of the foregoing, (iii) any Person acting or who could be deemed to be acting as a group together with the Holder
or any of the foregoing and (iv) any other Persons whose beneficial ownership of the Company&rsquo;s Ordinary Shares would or could be
aggregated with the Holder&rsquo;s and the other Attribution Parties for purposes of Section 13(d) of the Exchange Act. For clarity,
the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will
have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Share Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or otherwise
makes a distribution or distributions on its Ordinary Shares or ADSs or any other equity or equity equivalent securities payable in Ordinary
Shares or ADSs (which, for avoidance of doubt, shall not include any ADSs issued by the Company upon exercise of this Warrant), as applicable,
(ii) subdivides outstanding Ordinary Shares or ADSs into a larger number of shares or ADSs, as applicable, (iii) combines (including
by way of reverse share split) outstanding Ordinary Shares or ADSs into a smaller number of shares or ADSs, as applicable, (iv) redesignates
any other securities as Ordinary Shares or ADSs or (v) issues Ordinary Shares or ADSs by way of capitalization of profits or reserves,
then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of ADSs (excluding
treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of ADSs outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted so that
the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective
immediately after the record date or (if there is no record date) the effective date of the transaction giving rise to the adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
[RESERVED].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time that this Warrant is
outstanding the Company grants, issues or sells any Ordinary Share Equivalents or rights to purchase shares, warrants, securities or
other property pro rata to the record holders of any class of Ordinary Shares or ADSs (the &ldquo;<U>Purchase Rights</U>&rdquo;), then
the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder
could have acquired if the Holder had held the number of Ordinary Shares or ADSs acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Maximum Percentage) immediately before the date on which
a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record
holders of Ordinary Shares or ADSs are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Maximum Percentage,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such ADSs as a
result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such
time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Pro Rata Distributions</U>. Except to the extent that the adjustments pursuant to Section 3(a) above apply, during such time as this
Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its
assets) to holders of Ordinary Shares or ADSs, by way of return of capital or otherwise (including, without limitation, any distribution
of cash, shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme
of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant, then,
in each such case, the Holder shall be entitled to receive at the time such Distribution is made the amount of cash or assets that are
distributed in the Distribution per Ordinary Share or ADS multiplied by the number of Ordinary Shares or ADSs acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Maximum Percentage)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of Ordinary Shares or ADSs are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
that the Holder shall not be entitled to receive any Ordinary Shares or ADSs pursuant to the foregoing right to the extent that this
would result in the Holder exceeding the Maximum Percentage, and any such Ordinary Shares or ADSs shall be held in abeyance for the benefit
of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly
or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of
its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer
(whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares are permitted to sell, tender or
exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary
Shares, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or
recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50%
of the outstanding Ordinary Shares (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e)
on the exercise of this Warrant), the number of shares of the successor or acquiring corporation or of the Company, if it is the surviving
corporation, and/or any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental
Transaction by a holder of the number of Ordinary Shares for which this Warrant is exercisable immediately prior to such Fundamental
Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the
determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one Ordinary Share in such Fundamental Transaction, and the Company shall apportion the Exercise
Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate
Consideration. If holders of Ordinary Shares are given any choice as to the securities, cash or property to be received in a Fundamental
Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant
following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company
or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within
30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental
Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined
below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided,
however, that, if the Fundamental Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s
Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration
(and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to
the holders of Ordinary Shares of the Company in connection with the Fundamental Transaction, whether that consideration be in the form
of cash, stock or any combination thereof, or whether the holders of Ordinary Shares are given the choice to receive from among alternative
forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Ordinary Shares of the Company
are not offered or paid any consideration in such Fundamental Transaction, such holders of Ordinary Shares will be deemed to have received
Ordinary Shares of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental
Transaction. &ldquo;Black Scholes Value&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained
from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for
pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time
between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to 100-day volatility obtained from the Company&rsquo;s historical volatility using the HVT Function on Bloomberg (determined
utilizing a 365-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental
Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash,
if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, (D) a remaining option time
equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination
Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds
(or such other consideration) within the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation
of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not
the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant
in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to
the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of
the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the Ordinary Shares acquirable and receivable upon exercise of this Warrant (without regard
to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an Exercise price which applies the
Exercise Price hereunder to such shares of capital stock (but taking into account the relative value of the Ordinary Shares pursuant
to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the
case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall
be the sum of the number of Ordinary Shares (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant ADSs and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Ordinary Shares, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares or
ADSs, (C) the Company shall authorize the granting to all holders of the Ordinary Shares or ADSs rights or warrants to subscribe for
or purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required
in connection with any reclassification of the Ordinary Shares or ADSs, any consolidation or merger to which the Company is a party,
any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Ordinary
Shares are converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the
Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the
applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose
of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of
the Ordinary Shares or ADSs of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Ordinary Shares of record shall be entitled to exchange their Ordinary
Shares for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share
exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity
of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file
the material terms of such notice with the Commission pursuant to a Report on Form 8-K. The Holder shall remain entitled to exercise
this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except
as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Voluntary Adjustment By Company.</U> Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and
for any period of time deemed appropriate by the Board of Directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Change in ADS Ratio.</U> If after the Issuance Date the ratio of ADSs to Ordinary Shares is increased or reduced, then the number
of Warrant ADSs to be delivered upon exercise of this Warrant and the Exercise Price per Warrant ADS will each be proportionately adjusted
so that the aggregate Exercise Price remains unchanged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws, and the conditions set forth in Section 4(d) hereof
and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to
pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company
assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase
of Warrant ADSs without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date and shall be
identical with this Warrant except as to the number of Warrant ADSs issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or
transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant ADSs issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant ADSs or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Shareholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting the rights of a Holder to receive Warrant ADSs on a &ldquo;cashless exercise,&rdquo; and to
receive the cash payments contemplated pursuant to Sections 2(d)(i), 2(d)(iv) and 2(d)(v), in no event will the Company be required to
net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant ADSs,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, its directors will have authority to allot a sufficient number
of shares to provide for the issuance of the Warrant ADSs and underlying Ordinary Shares upon the exercise of any purchase rights under
this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are
charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant ADSs may be issued as provided herein without violation
of any applicable law or regulation, or of any requirements of the applicable Trading Market upon which the Ordinary Shares and ADSs
may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant ADSs in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the
Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its articles of association or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at
all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant ADSs for which this Warrant is exercisable or in the Exercise
Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public
regulatory body or bodies having jurisdiction thereof. Unless required by law, the Company shall not do anything that would require the
Exercise Price to be adjusted to an amount that is less than the aggregate nominal value of the Ordinary Shares underlying an ADS at
that time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies, notwithstanding the fact that
all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of
this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient
to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Ordinary Shares or ADSs or as a shareholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Depositary</U>. For the avoidance of doubt, notwithstanding anything to the contrary contained herein, the Depositary&rsquo;s rights
and obligations with respect to the Company and the ADSs (including the Warrant ADSs) shall be as set forth in, and subject to, the terms
and provisions of the deposit agreement among, <I>inter alia</I>, the Company and the Depositary and in no event shall this Warrant be
deemed or construed to impose any additional obligations or liabilities on the Depositary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Company Acknowledgement</U>. The Company acknowledges that the Company has received the aggregate par value amount of the Warrant
Shares underlying the Warrant ADSs upon exercise of this Warrant and the Company shall hold such aggregate nominal amount in trust and
shall apply it as applicable in connection with exercises of this Warrant pursuant to Section 2(c) herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p)
<U>Electronic Signatures</U>. Electronically scanned and transmitted signatures, including by email attachment, shall be deemed originals
for all purposes of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AKARI
    THERAPEUTICS, PLC</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TO:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AKARI
    THERAPEUTICS, PLC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEUTSCHE
    BANK TRUST COMPANY AMERICAS, AS DEPOSITARY</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase _________ Warrant ADSs of the Company pursuant to the terms of the attached Warrant (only if
exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
if permitted the cancellation of such number of Warrant ADSs as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant ADSs purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please register and issue said Warrant ADSs in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC
Participant name and number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
and account number of DTC Participant Client:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact
of DTC Participant:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact
of Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
Number of DTC Participant:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ____________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
of Authorized Signatory of Investing Entity: ______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase Warrant ADSs.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    _________________________________________________________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:
    _______________________________________________________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    ____________, ______</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: _____________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address: ______________________________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>7
<FILENAME>ex10-5.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.5 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, AND IN THE CASE OF A TRANSACTION EXEMPT FROM REGISTRATION,
UNLESS THE COMPANY AND DEPOSITARY HAVE RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO EACH OF THEM THAT SUCH TRANSACTION DOES
NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &ldquo;ACCREDITED
INVESTOR&rdquo; AS DEFINED IN RULE 501(A) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLACEMENT
AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES AKARI THERAPEUTICS, PLC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    No. [&#9679;]</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
Date: October 16, 2025</FONT></TD>
    <TD STYLE="width: 8%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of American Depositary Shares: [&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the &ldquo;<U>Warrant</U>&rdquo;) certifies
that, for value received, [&#9679;] or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations
on exercise and the conditions hereinafter set forth, at any time on or after the date Shareholder Approval is received and effective
(the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on October 14, 2030 (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Akari Therapeutics, Plc., a public company with limited liability
incorporated under the laws of England and Wales (the &ldquo;<U>Company</U>&rdquo;), up to [&#9679;] Ordinary Shares (the &ldquo;<U>Warrant
Shares</U>&rdquo;) represented by [&#9679;] American Depositary Shares (&ldquo; <U>ADSs</U>&rdquo;), as subject to adjustment hereunder
(the &ldquo;<U>Warrant ADSs</U>&rdquo;). The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section
2(b). This Warrant is being issued pursuant to the certain placement agency agreement, dated as of October 14, 2025, by and between the
Company and Ladenburg Thalmann &amp; Co. Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in that
certain Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated October 14, 2025 among the Company and the
purchasers signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency
of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books
of the Company) and the Depositary of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in
the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii) the number
of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid
the Holder shall deliver to the Company the aggregate applicable Exercise Price of the Warrant ADSs thereby purchased by wire transfer
or cashier&rsquo;s check drawn on a United States bank, in either case in immediately available funds, unless the cashless exercise procedure
specified in Section 2(c) below is properly specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. The
Company shall have no obligation to inquire with respect to or otherwise confirm the authenticity of the signature(s) contained on any
Notice of Exercise nor the authority of the person so executing such Notice of Exercise. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant
ADSs available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company
for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises
of this Warrant resulting in purchases of a portion of the total number of Warrant ADSs available hereunder shall have the effect of
lowering the outstanding number of Warrant ADSs purchasable hereunder in an amount equal to the applicable number of Warrant ADSs purchased.
The Holder and the Company shall maintain records showing the number of Warrant ADSs purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. The Holder and any assignee,
by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a
portion of the Warrant ADSs hereunder, the number of Warrant ADSs available for purchase hereunder at any given time may be less than
the amount stated on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. Subject to Section 2(c) hereof, the exercise price per ADS under this Warrant shall be $1.00, subject to adjustment
hereunder (or, if higher, the aggregate nominal value of the Ordinary Shares underlying an ADS at the time of issue) (the &ldquo;<U>Exercise
Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If following the date that is 6 months following the original issuance date of the Warrants, at the time of
exercise hereof, there is no effective registration statement registering with a current prospectus available for the resale of the Warrant
ADSs by the Holder, then this Warrant may (if permitted by applicable law and the Company&rsquo;s articles of association) also be exercised,
in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Warrant ADSs equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)&thinsp;=
as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and
delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in
Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder,
either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the
ADSs on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) as of the time of the Holder&rsquo;s execution
of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day
and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo;
on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such
Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after
the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)&thinsp;=
the Exercise Price of this Warrant for cash exercise, as adjusted hereunder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)&thinsp;=
the number of Warrant ADSs that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Warrant ADSs are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant ADSs being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs are then
listed or quoted on a Trading Market, the bid price of the ADSs for the time in question (or the nearest preceding date) on the Trading
Market on which the ADSs are then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time)
to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the ADSs for
such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs are not then listed or quoted for trading
on OTCQB or OTCQX and if prices for the ADSs are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc.
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the ADSs
so reported, or (d) in all other cases, the fair market value of an ADSs as determined by an independent appraiser selected in good faith
by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the reasonable
fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs then listed or quoted on
a Trading Market, the daily volume weighted average price of the ADSs for such date (or the nearest preceding date) on the Trading Market
on which the ADSs then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02
p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the ADSs for such date
(or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs are not then listed or quoted for trading on OTCQB or
OTCQX and if prices for the ADSs are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per ADS so reported, or (d) in all
other cases, the fair market value of an ADS as determined by an independent appraiser selected in good faith by the Holders of a majority
in interest of the Securities then outstanding and reasonably acceptable to the Company, the reasonable fees and expenses of which shall
be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant ADSs Upon Exercise</U>. Subject to the Company&rsquo;s receipt of the Exercise Price, the Company shall deposit
the Warrant Shares subject to such exercise with Deutsche Bank Trust Company Americas, the Depositary for the ADSs (the &ldquo;<U>Depositary</U>&rdquo;)
and instruct the Depositary to credit the Holder&rsquo;s prime broker with The Depository Trust Company through its Deposit/Withdrawal
At Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Depositary is then a participant in such system and either (A) there is an effective
registration statement with a current prospectus registering for resale of the Warrant Shares represented by the Warrant ADSs by the
Holder or (B) this Warrant is being exercised via cashless exercise and the Warrant ADSs have been sold by the Holder prior to the Warrant
ADS Delivery Date (as defined below), and otherwise by electronic (registered in book-entry format) or physical delivery to the address
specified by the Holder in the Notice of Exercise, by the date that is the earliest of (i) one (1) Trading Day after the delivery to
the Company of the Notice of Exercise, and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise and the aggregate Exercise Price (such date, the &ldquo;<U>Warrant ADS Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Company shall treat the Holder for all corporate purposes as if it were the beneficial owner
of the Warrant ADSs with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier
of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice
of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant ADSs subject to a Notice of Exercise by the Warrant
ADS Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant
ADSs subject to such exercise (based on the VWAP of the ADSs on the date of the applicable Notice of Exercise), $10.00 per Trading Day
(increasing to $20.00 per Trading Day on the third Trading Day after the Warrant ADS Delivery Date) for each Trading Day after such Warrant
ADS Delivery Date until such Warrant ADSs are delivered or the Holder rescinds such exercise. The Company agrees to use commercially
reasonable efforts to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;Standard Settlement Period&rdquo; means the standard settlement period, expressed in a number
of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the ADSs as in effect on the date of delivery of the Notice
of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant ADSs, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant ADSs called for by this Warrant, which new Warrant shall in all
other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Depositary to transmit to the Holder the Warrant ADSs pursuant to Section
2(d)(i) by the Warrant ADS Delivery Date, then the Holder will have the right to rescind such exercise in respect of the untransmitted
Warrant ADSs (with the effect that the Holder&rsquo;s right to acquire such Warrant ADSs pursuant to this Warrant shall be restored)
and the Company shall return to the Holder the aggregate Exercise Price paid to the Company for such Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant ADSs Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Depositary to deliver to the Holder the Warrant ADSs in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant ADS Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, ADSs
to deliver in satisfaction of a sale by the Holder of the Warrant ADSs which the Holder anticipated receiving upon such exercise (a &ldquo;Buy-In&rdquo;),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including
brokerage commissions, if any) for the ADSs so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant ADSs
that the Company failed to deliver to the Holder in connection with the exercise at issue by (2) the price at which the sell order giving
rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant in respect
of the Warrant ADSs for which such exercise was not honored and return any amount received by the Company in respect of the Exercise
Price for those Warrant ADSs (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of ADSs that
would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder
purchases ADSs having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of the Warrant with an
aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company
shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the
Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver ADSs upon exercise of the Warrant
as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional Warrant Shares or Warrant ADSs shall be issued upon the exercise of this Warrant.
As to any fraction of an ADS which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole ADS; provided, however, the fraction of an ADS shall not be rounded up to the next whole ADS if such rounding
results in the issue price being lower than the nominal value of the ADS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant ADSs shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of Warrant ADSs, all of which taxes and expenses shall be paid by the Company,
and such Warrant ADSs shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event that Warrant ADSs are to be issued in a name other than the name of the Holder, this Warrant when surrendered
for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all
Depositary fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established
clearing corporation performing similar functions) required for same-day electronic issuance and delivery of the Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof; provided, however, that the foregoing shall not be deemed or construed to limit any rights
of the Depositary under the terms and provisions of the deposit agreement among, inter alia, the Company and the Depositary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. Notwithstanding anything to the contrary contained herein, the Company shall not effect the
exercise of any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant to
the terms and conditions of this Warrant and any such exercise shall be null and void and treated if never made, to the extent that after
giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially own in excess
of 4.99% (the &ldquo;<U>Maximum Percentage</U>&rdquo;) of the number of Ordinary Shares outstanding immediately after giving effect to
such exercise. For purposes of the foregoing sentence, the aggregate number of Ordinary Shares beneficially owned by the Holder and the
other Attribution Parties shall include the number of Ordinary Shares underlying ADSs held by the Holder and all other Attribution Parties
plus the number of Ordinary Shares underlying ADSs issuable upon exercise of this Warrant with respect to which the determination of
such sentence is being made, but shall exclude the number of Ordinary Shares underlying ADSs which would be issuable upon (A) exercise
of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution Parties and (B)
exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by the Holder
or any other Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained in this Section
2(e). For purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act.
For purposes of this Warrant, in determining the number of Ordinary Shares underlying ADSs the Holder may acquire upon the exercise of
this Warrant without exceeding the Maximum Percentage, the Holder may rely on the number of Ordinary Shares as reflected in (x) the Company&rsquo;s
most recent Annual Report on Form 10-K, Current Report on Form 8-K or other public filing with the Commission, as the case may be, (y)
a more recent public announcement by the Company or (3) any other written notice by the Company setting forth the number of Ordinary
Shares outstanding (the &ldquo;<U>Reported Outstanding Share Number</U>&rdquo;). If the Company receives an Exercise Notice from the
Holder at a time when the actual number of outstanding Ordinary Shares is less than the Reported Outstanding Share Number, the Company
shall (i) notify the Holder in writing of the number of Ordinary Shares then outstanding and, to the extent that such Exercise Notice
would otherwise cause the Holder&rsquo;s beneficial ownership, as determined pursuant to this Section 2(e), to exceed the Maximum Percentage,
the Holder must notify the Company of a reduced number of Warrant ADSs to be purchased pursuant to such Exercise Notice (the number of
shares by which such purchase is reduced, the &ldquo;<U>Reduction Shares</U>&rdquo;) and (ii) as soon as reasonably practicable, the
Company shall return to the Holder any exercise price paid by the Holder for the Reduction Shares. For any reason at any time, upon the
written or oral request of the Holder, the Company shall within one (1) Business Day confirm orally and in writing or by electronic mail
to the Holder the number of Ordinary Shares then outstanding. In any case, the number of outstanding Ordinary Shares shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and any other Attribution
Party since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of Ordinary Shares
to the Holder upon exercise of this Warrant results in the Holder and the other Attribution Parties being deemed to beneficially own,
in the aggregate, more than the Maximum Percentage of the number of outstanding Ordinary Shares (as determined under Section 13(d) of
the Exchange Act), the Company and the Holder shall use commercially reasonable efforts to procure that the number of shares so issued
by which the Holder&rsquo;s and the other Attribution Parties&rsquo; aggregate beneficial ownership exceeds the Maximum Percentage (the
&ldquo;<U>Excess Shares</U>&rdquo;) are repurchased by the Company (out of its distributable reserves pursuant to a contract duly authorized
in accordance with the law, or as it may otherwise be legally permitted from time to time) for a price equal to the applicable Exercise
Price, and pending such repurchase the Holder agrees it shall not exercise any rights relating to the power to vote or to transfer the
Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase (with such increase not effective
until the sixty-first (61st) day after delivery of such notice) or decrease the Maximum Percentage to any other percentage not in excess
of 9.99% as specified in such notice; provided that (i) any such increase in the Maximum Percentage will not be effective until the sixty-first
(61st) day after such notice is delivered to the Company and (ii) any such increase or decrease will apply only to the Holder and the
other Attribution Parties and not to any other holder of Warrants that is not an Attribution Party of the Holder. For purposes of clarity,
the Ordinary Shares issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially
owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act. The provisions of
this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e)
to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended
beneficial ownership limitation contained in this Section 2(e) or to make changes or supplements necessary or desirable to properly give
effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this
Warrant. &ldquo;<U>Attribution Parties</U>&rdquo; means, collectively, the following Persons and entities: (i) any investment vehicle,
including, any funds, feeder funds or managed accounts, currently, or from time to time after the issuance date, directly or indirectly
managed or advised by the Holder&rsquo;s investment manager or any of its Affiliates or principals, (ii) any direct or indirect Affiliates
of the Holder or any of the foregoing, (iii) any Person acting or who could be deemed to be acting as a group together with the Holder
or any of the foregoing and (iv) any other Persons whose beneficial ownership of the Company&rsquo;s Ordinary Shares would or could be
aggregated with the Holder&rsquo;s and the other Attribution Parties for purposes of Section 13(d) of the Exchange Act. For clarity,
the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will
have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Share Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or otherwise
makes a distribution or distributions on its Ordinary Shares or ADSs or any other equity or equity equivalent securities payable in Ordinary
Shares or ADSs (which, for avoidance of doubt, shall not include any ADSs issued by the Company upon exercise of this Warrant), as applicable,
(ii) subdivides outstanding Ordinary Shares or ADSs into a larger number of shares or ADSs, as applicable, (iii) combines (including
by way of reverse share split) outstanding Ordinary Shares or ADSs into a smaller number of shares or ADSs, as applicable, (iv) redesignates
any other securities as Ordinary Shares or ADSs or (v) issues Ordinary Shares or ADSs by way of capitalization of profits or reserves,
then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of ADSs (excluding
treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of ADSs outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted so that
the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective
immediately after the record date or (if there is no record date) the effective date of the transaction giving rise to the adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
[RESERVED].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time that this Warrant is
outstanding the Company grants, issues or sells any Ordinary Share Equivalents or rights to purchase shares, warrants, securities or
other property pro rata to the record holders of any class of Ordinary Shares or ADSs (the &ldquo;<U>Purchase Rights</U>&rdquo;), then
the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder
could have acquired if the Holder had held the number of Ordinary Shares or ADSs acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Maximum Percentage) immediately before the date on which
a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record
holders of Ordinary Shares or ADSs are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Maximum Percentage,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such ADSs as a
result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such
time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Pro Rata Distributions</U>. Except to the extent that the adjustments pursuant to Section 3(a) above apply, during such time as this
Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its
assets) to holders of Ordinary Shares or ADSs, by way of return of capital or otherwise, other than cash (including, without limitation,
any distribution of shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to receive at the time such Distribution is made the amount of cash or assets that
are distributed in the Distribution per Ordinary Share or ADS multiplied by the number of Ordinary Shares or ADSs acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Maximum Percentage)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of Ordinary Shares or ADSs are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
that the Holder shall not be entitled to receive any Ordinary Shares or ADSs pursuant to the foregoing right to the extent that this
would result in the Holder exceeding the Maximum Percentage, and any such Ordinary Shares or ADSs shall be held in abeyance for the benefit
of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly
or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of
its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer
(whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares are permitted to sell, tender or
exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary
Shares, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or
recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50%
of the outstanding Ordinary Shares (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e)
on the exercise of this Warrant), the number of shares of the successor or acquiring corporation or of the Company, if it is the surviving
corporation, and/or any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental
Transaction by a holder of the number of Ordinary Shares for which this Warrant is exercisable immediately prior to such Fundamental
Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the
determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one Ordinary Share in such Fundamental Transaction, and the Company shall apportion the Exercise
Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate
Consideration. If holders of Ordinary Shares are given any choice as to the securities, cash or property to be received in a Fundamental
Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant
following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company
or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within
30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental
Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined
below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided,
however, that, if the Fundamental Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s
Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration
(and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to
the holders of Ordinary Shares of the Company in connection with the Fundamental Transaction, whether that consideration be in the form
of cash, stock or any combination thereof, or whether the holders of Ordinary Shares are given the choice to receive from among alternative
forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Ordinary Shares of the Company
are not offered or paid any consideration in such Fundamental Transaction, such holders of Ordinary Shares will be deemed to have received
Ordinary Shares of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental
Transaction. &ldquo;Black Scholes Value&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained
from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for
pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time
between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to 100-day volatility obtained from the Company&rsquo;s historical volatility using the HVT Function on Bloomberg (determined
utilizing a 365-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental
Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash,
if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, (D) a remaining option time
equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination
Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds
(or such other consideration) within the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation
of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not
the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant
in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to
the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of
the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the Ordinary Shares acquirable and receivable upon exercise of this Warrant (without regard
to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an Exercise price which applies the
Exercise Price hereunder to such shares of capital stock (but taking into account the relative value of the Ordinary Shares pursuant
to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the
case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall
be the sum of the number of Ordinary Shares (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant ADSs and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Ordinary Shares, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares or
ADSs, (C) the Company shall authorize the granting to all holders of the Ordinary Shares or ADSs rights or warrants to subscribe for
or purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required
in connection with any reclassification of the Ordinary Shares or ADSs, any consolidation or merger to which the Company is a party,
any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Ordinary
Shares are converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the
Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the
applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose
of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of
the Ordinary Shares or ADSs of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Ordinary Shares of record shall be entitled to exchange their Ordinary
Shares for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share
exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity
of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file
the material terms of such notice with the Commission pursuant to a Report on Form 8-K. The Holder shall remain entitled to exercise
this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except
as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Voluntary Adjustment By Company.</U> Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and
for any period of time deemed appropriate by the Board of Directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Change in ADS Ratio.</U> If after the Issuance Date the ratio of ADSs to Ordinary Shares is increased or reduced, then the number
of Warrant ADSs to be delivered upon exercise of this Warrant and the Exercise Price per Warrant ADS will each be proportionately adjusted
so that the aggregate Exercise Price remains unchanged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws, and the conditions set forth in Section 4(d) hereof,
this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of
the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall
issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three
(3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly
assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant ADSs without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date and shall be
identical with this Warrant except as to the number of Warrant ADSs issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or
transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant ADSs issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant ADSs or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Shareholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting the rights of a Holder to receive Warrant ADSs on a &ldquo;cashless exercise,&rdquo; and to
receive the cash payments contemplated pursuant to Sections 2(d)(i), 2(d)(iv) and 2(d)(v),in no event will the Company be required to
net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant ADSs,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, its directors will have authority to allot a sufficient number
of shares to provide for the issuance of the Warrant ADSs and underlying Ordinary Shares upon the exercise of any purchase rights under
this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are
charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant ADSs may be issued as provided herein without violation
of any applicable law or regulation, or of any requirements of the applicable Trading Market upon which the Ordinary Shares and ADSs
may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant ADSs in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the
Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its articles of association or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at
all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant ADSs for which this Warrant is exercisable or in the Exercise
Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public
regulatory body or bodies having jurisdiction thereof. Unless required by law, the Company shall not do anything that would require the
Exercise Price to be adjusted to an amount that is less than the aggregate nominal value of the Ordinary Shares underlying an ADS at
that time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies, notwithstanding the fact that
all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of
this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient
to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered to the address of the Holder in the Warrant Register.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Ordinary Shares or ADSs or as a shareholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Depositary</U>. For the avoidance of doubt, notwithstanding anything to the contrary contained herein, the Depositary&rsquo;s rights
and obligations with respect to the Company and the ADSs (including the Warrant ADSs) shall be as set forth in, and subject to, the terms
and provisions of the deposit agreement among, <I>inter alia</I>, the Company and the Depositary and in no event shall this Warrant be
deemed or construed to impose any additional obligations or liabilities on the Depositary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Company Acknowledgement</U>. The Company acknowledges that the Company has received the aggregate par value amount of the Warrant
Shares underlying the Warrant ADSs upon exercise of this Warrant and the Company shall hold such aggregate nominal amount in trust and
shall apply it as applicable in connection with exercises of this Warrant pursuant to Section 2(c) herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p)
<U>Electronic Signatures</U>. Electronically scanned and transmitted signatures, including by email attachment, shall be deemed originals
for all purposes of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">q)
<U>Piggy Back Registration Rights</U>. If, at any time while this Warrant is outstanding, there is not an effective registration statement
covering all of the Warrant Shares and the Company shall determine to prepare and file with the Commission a registration statement relating
to an offering for its own account or the account of others under the Securities Act of any of its equity securities, other than on Form
S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely
in connection with any acquisition of any entity or business or equity securities issuable in connection with the Company&rsquo;s stock
option or other employee benefit plans, then the Company shall deliver to the Holder a written notice of such determination and, if within
fifteen days after the date of the delivery of such notice, Holder shall so request in writing, the Company shall include in such registration
statement all or any part of such Warrant Shares that the Holder requests to be registered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AKARI
    THERAPEUTICS, PLC</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TO:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AKARI
    THERAPEUTICS, PLC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEUTSCHE
    BANK TRUST COMPANY AMERICAS, AS DEPOSITARY</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase _________ Warrant ADSs of the Company pursuant to the terms of the attached Warrant (only if
exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
in lawful money of the United States; or </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
if permitted the cancellation of such number of Warrant ADSs as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant ADSs purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please register and issue said Warrant ADSs in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC
Participant name and number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
and account number of DTC Participant Client:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact
of DTC Participant:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact
of Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
Number of DTC Participant:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ____________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
of Authorized Signatory of Investing Entity: _____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase Warrant ADSs.) </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
____________, ______</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Signature: _____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Address: ______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  P 2@# 2(  A$! Q$!_\0
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MW,<;Y5@0?E8T >X45E>%;^;5?"^CWMRP>XN;.&:1@, LR DX[<FM6@ HHHH
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M7N?[>G_)MW[+7_8MG_TFLZ\,_8H_Y.N^&/\ V&(__06H#H?LC^U+\6)?@C\
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M _KFOG'P#96UY_P4U^(%_P"'7$EC;^%(8M=>W;]V+PM"%1L<%]J*?8AL\YH
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=:Z'=K?6.@VEBEE8F=3E'E5>'P>V,]LXR"4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>aktx-20251014.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaGAqbP9z5Z8yekhvWBxbanqvy8pk1C67yyrYe7mwTsL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:AKTX="http://akaritherapeuticsplc.com/20251014" elementFormDefault="qualified" targetNamespace="http://akaritherapeuticsplc.com/20251014">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://akaritherapeuticsplc.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="aktx-20251014_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aktx-20251014_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aktx-20251014_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
    <element id="AKTX_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember" name="AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AKTX_OrdinarySharesParValue0.0001PerShareMember" name="OrdinarySharesParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>aktx-20251014_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="aktx-20251014.xsd#Cover" roleURI="http://akaritherapeuticsplc.com/role/Cover" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://akaritherapeuticsplc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aktx-20251014.xsd#AKTX_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember" xlink:label="loc_AKTXAmericanDepositorySharesEachRepresenting2000OrdinarySharesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AKTXAmericanDepositorySharesEachRepresenting2000OrdinarySharesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aktx-20251014.xsd#AKTX_OrdinarySharesParValue0.0001PerShareMember" xlink:label="loc_AKTXOrdinarySharesParValue0.0001PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AKTXOrdinarySharesParValue0.0001PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>aktx-20251014_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aktx-20251014.xsd#AKTX_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember" xlink:label="AKTX_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AKTX_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember" xlink:to="AKTX_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AKTX_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember_lbl" xml:lang="en-US">American Depository Shares, each representing 2000 Ordinary Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aktx-20251014.xsd#AKTX_OrdinarySharesParValue0.0001PerShareMember" xlink:label="AKTX_OrdinarySharesParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AKTX_OrdinarySharesParValue0.0001PerShareMember" xlink:to="AKTX_OrdinarySharesParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AKTX_OrdinarySharesParValue0.0001PerShareMember_lbl" xml:lang="en-US">Ordinary Shares, par value $0.0001 per share*</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>aktx-20251014_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="aktx-20251014.xsd#Cover" roleURI="http://akaritherapeuticsplc.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://akaritherapeuticsplc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aktx-20251014.xsd#AKTX_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember" xlink:label="loc_AKTXAmericanDepositorySharesEachRepresenting2000OrdinarySharesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AKTXAmericanDepositorySharesEachRepresenting2000OrdinarySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aktx-20251014.xsd#AKTX_OrdinarySharesParValue0.0001PerShareMember" xlink:label="loc_AKTXOrdinarySharesParValue0.0001PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AKTXOrdinarySharesParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 14,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AKARI
THERAPEUTICS, PLC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001541157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1034922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">22
Boston Wharf Road FL 7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(929)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">274-7510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AKTX_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember', window );">American Depository Shares, each representing 2000 Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American
    Depository Shares, each representing 2000 Ordinary Shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AKTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AKTX_OrdinarySharesParValue0.0001PerShareMember', window );">Ordinary Shares, par value $0.0001 per share*</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary
    Shares, par value $0.0001 per share*<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AKTX_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AKTX_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AKTX_OrdinarySharesParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AKTX_OrdinarySharesParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akaritherapeuticsplc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aktx-20251014.xsd</File>
    <File>aktx-20251014_def.xml</File>
    <File>aktx-20251014_lab.xml</File>
    <File>aktx-20251014_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "AKTX",
   "nsuri": "http://akaritherapeuticsplc.com/20251014",
   "dts": {
    "schema": {
     "local": [
      "aktx-20251014.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "aktx-20251014_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "aktx-20251014_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aktx-20251014_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 25
   },
   "report": {
    "R1": {
     "role": "http://akaritherapeuticsplc.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-10-14",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-10-14",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "AKTX_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://akaritherapeuticsplc.com/20251014",
     "localname": "AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "American Depository Shares, each representing 2000 Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "AKTX_OrdinarySharesParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://akaritherapeuticsplc.com/20251014",
     "localname": "OrdinarySharesParValue0.0001PerShareMember",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares, par value $0.0001 per share*"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://akaritherapeuticsplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001493152-25-018269-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-018269-xbrl.zip
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M+T:BL0$[<(?D+W(&Q7>4 4\B(0K4*GL>"-UJ^2M)@_H[RGDOF")J:Y:]?8N
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MBN*+$(NE[@9_%_Q1K=*-O%7"6P,Z8 #,&S3"Z<KAB\W3BP6278V5+I307;#
M3AK2_[WC;;-CWS=+39(Q 0N0 !R \:WVH(8VZ(*C-/G*O$<X/RJ+J9G*5"T$
MJ8MJM2.-R(.^.$V3\Z]YJ+PMYW"MUAZ@"ZKM- N^CN:4^)>4H\IQ?P[6 :WW
MV8)2.\U\/R%V+Z*U\K?7@OL8FXDAN;LF&R1?C0KH@#W-ZP$:YW8K+@]#LQ6,
M^_?)RSRO(A7_X1;-MO+!145<!VRJI0^ZX_A55/)IRQX./FUO\ (+LWCC%F_4
M)WVB^^K!56UXJ[TZK!:@9;G4^^-@KX+Z]/?ZN_2X^6'^U(P^\G]02P,$%
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M)$2NJOF<) $+U^*N;U,Y*C+KE6XP6:O[DL8O!.K&8!)*6D<-^SU9ADG*Y&.
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MT)QR8;XMOK$_[-]+,$?^ 5!+ P04    " "+2E!;>T%!UN6W  #5<@0 "@
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M 4S*5EH*L*Z]Z6@#%%/8]E([M0D!%W"G\H'S@@X<9K01,1ZD]S%+;]5++D'
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M6G0>RE3ROQSDX[')1Y^5%,08[V4B)3TFTK#6CVRM;WFIR^[^S(MU'G*G?U"
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MQ>+VM$SD)W!F3X0#R?5T QEC%A3TOIA^HUIW="=3#!K;5)3N9E;9G0=[0]Q
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M[/'MF&L.7MI%T@6W3VRS;HE[OQSBW@\9]WXYQ+V'N/<7?C;.^&P\_82=P8U
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MX!O46&UKZS%XQ-#98IX& CZ>HR/ T_8K<K+*01L[VU.0M+7Q )?:W/H9"3D
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MY[/"09Z1 B:/,G$#!ZX<P()H^#4.0,2^D"><BI.H1K5YD0H)P9<*+<%05Y4
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M8NZ:AX''*IOF?#7*QDV;!ZY5#[B12"+MGLC;%=!SE%>,H49T[?N5X"R#!JM
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M@/-*QF'8*?N$PS??PN??DBX'MO6: ]*V0DL+M-:VZ#E1MYKUE)#7%A9<5ES
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M@/L4X"[?D-_@#?D#I2V<3?4FO>9$H+O\I**TYCJ40K(C7+PR(?C5E6OT-&\
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M=?H+QVMYN;<!^RK@$0N,KFQHI:^'X68R-@]O#_QR$2$ZH 60\/'&A<G-8%0
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M'O$_7\'^TF?J+545GNE*876@+G$*Y7C3*15!99$^,^>69G]I38:37]H*'EN
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M3E;= 05R-4,C$A8.Q9$TUGT+'=AY.&\F5CD1H<(-43>H8?E12-!F"U5I")D
MJ2%KG"Q^VJX%D8^.^:&P/TYM0<$9O)O2O4],]@$W0H=+CD<S0B-.Z@7T/SK^
M&T>3]\%(SEYLGV^MXV_3ZYKVXJN\0@P CXL9B3B\I3H3Y(MWVJPJ\'AS.*P
ML[$".N=)228V8H&VH.@ \A[C[,$)E%041C>SRRR9)U/>V,4ZKXID4M,7[:?[
MB*\V'B+PC;Y2[I)#JOV>H'DT9V4-EO YXS/!.0,G/LH"G./\L0,=7Z8YA&F
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MZHX'29P=JM@AZC]-C*4-K,045)$F$C4 #0>E%4;9I&JBEKT^!3+?1$DR<.S
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MH2;#I7JQ-7_ 5>4LD4A4%10)W=;::6>$F;-G-_AEKI&?FYCM:*8Z2\3A_2J
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M%VA.B%+$UF'8,#]21E_'(^7ZIY!(2$/<[.QXU.KMBHL2T=Z'9T_@TW5<_$'
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MO'[V.RZI[__Q_I>7C_\_4$L#!!0    ( (M*4%LX^[ J>4L  '[! 0 *
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MQ+DA+%!4V0P>Q2A5EO $XEU>@@[Z_)OMX]J;/0'&FB>X:D6>!-9O@NHRRK(
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MZ!SMKA5G\=N"_+.$LE-,L@3F:Z!(0O!%YWV,%O!R+$0^NZ?X\^A]0O%_*KI
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M0J4JE,1J6J+\09[6N3%.?E7<K6$?:/@"1<\J(?F#NU=&H,>P#RH#Z<U+>5&
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MY'1A;"LY;.HDTWEH:<&S$AJ1L14\\U[UX>T0D>[5N!;;^K0(7I=L,(%0DZ(
M8)G)O$Q7;"G#)0MSB5<_4'B6MI8/(K;U^(JN9DT@8U@I"UP]QZJG:UAFK!^L
MS+X+CJ*%8--6ZPI;D=;(V,8 LTVT. HU:?RTAA"X$H=NS\A[FO1VS#F^4ETC
M-I-5.>"W,X/^*>$.N(#JV.3 $((X POSO9*F(.@NB^OD2N%&M:RAB[&(MTVZ
M;ZSA$>A"MI4( K!2N2.VN%@/<>4'H?5QCIANV 98!;?>'?;[.NP2S3J$0WN!
M%TZC#Y(>'DE]IWC%"A[*+U#3YQH1G;4VFM/]/,M.)<V93;C&F/.2=?2!L&I9
M*R)4"+XPP4\2$2WZ/.T@*%1XGB(?]/OH>M5MW1$AAY&:D2A?? G'Y]$R\8+%
MK*@9+3%B"&O\/R40I0<Q!NTWK_WJ()I[HLXNKGI(6R-GF#X(5.,D"<XKG<QM
MI)KKPJ4U$EI,R48[]:$;9KM&1U6'YM&[I]1XP[S'^ 2NGR6WA@0'2:+Q-0%$
M$Z:T08AVD:E=1]R/Y.&RB=& !0V8/]"CB_!"O*%J.]7%*^#BKY?P+R)X$\H5
MQ3?3Y0R,C@1M+,6.-A?:O"<W=O/PIN""@O9V76.26*8-!0QA>1_%!#-4S).J
M$G"A#B!.ZHZ%>R\DSV_%BYJ%BE0/G_-V@A$;20D]8L (7KBJ2<(E$LN/C'=I
MY-*%\8,.FJVB.'W47,>IZ9ONQ/B]B7$EQ\$]$38[0*1X%MXV U/D'S4^@]V@
MB5-9,[P(7SZ@XE#&JTTY?+!$@'<5> !?$&5/I7-Q?)0E7.#9<>%6,[_#6I%H
M"H8G+PKB6]M2D6@"(KD45!7,%I[X7UB61:%:'3^Q3JG!W3)CTWR(V4251'/5
M#0D4&J03<HL%'-,T<FW&)O[^PST+V^L]OM[5>^SJ/7;U'E^\2DBXX\=+"&AK
MX\3,AE3.? =6OP?2;\T/4'5]S4P&RFF=_4TLM%@Q?YS0MP,-+G*T,0.@F:NV
MPKE;;FCI'D[6&;%O3;_T:TX4IGE'-#M?T[B(.+@J4@%IQ]+PA/)D.>HPF6\C
M:P<[K4UU2J/U>Q*F58M4M 4D=/7)14*&GLYRL-TWK.LRG3&\X;G K: TX"IP
M4,D*'4O5G<-'Q37%(3![4[%^_&[_N^_^[/?AO(T^I$NPGL^!'#2&+]RQEZ(E
M393>QYRV.PV=P2&40_3?W8/9XN"[KJ377<[:%)#X<P,-NY,<?PFZ' Y5A-.V
MLJI8!P.OR0VO;T%N"]A\HX%%6?N=#^SW5MFZ^L@'W1(&K:O)P+2:JQR!;(T.
M^>N6'N9OG'_*"P,<]0D+PP_N0''#1(1G5292>4R1[W5NZL\ZSO_-.R\^H-R]
M>_LES6>+,K(^<::LE<2S:8(+P,FB2VJ71), L$!?W3S$C913O,3<R*=YXW8:
MF.Q P"A%FN[2%J115EP4:^U^6K\R4C\56&VK"BD9M)U9!_T(2_K]#ICJ,ET9
MH0H&R1S1<B5@T8$,]?0Y-F#K%"6VLX)Q,9QCN+B5!*T)TEQS=W/^QDV,:G$,
M!B-4Q5);$!O5C'?6,"+&"7/UY*: #?UGE"@PY?;=A%(Z96'ZQ54A@)>SZ??L
M+O=AGF/T>4Q][50M@Q&:IT\>_3T,#J5OT/OROQ_]71=HJ!'%BS33 .[R3"DA
M"+EC0#J"..H58JT AFZ66',BE,B=P+DLX*RPJ^5EIK&S\/G 8G4O,>A=CHT"
MTN H9#47K]]KT5.>"APK (,SZQKZ67!*-W0GF'EU?Y)FIY9-;7-)T(<0*.QD
M)5H%7-)ZK0I#HGF]=B;FV)3Z/ #<IL>-T*]OI-VQV53N%JN&<$T7?LNB&F%W
MH]JO6U &6HT@4BK>NJ@$OS762M=-^55 +8(D]  6&J6#KBPB Q)/9-=Q=&91
M+3'V9JV-U<D8P5['ZSG<J NHE$*QIG+&)JQM'9@1]<UH=\B(V=AE'SJ;1;57
M1(#?$3G&C^F56^9SZY8ZG*I=($I*9>-!K"A7). A=7-866M5)7[M#T2Q0NQ6
M%H"9U"6/58C55&?-@333[H%+Y/BC-$+<="^/;\U_\)P2;]+1P;H"1H%C@\U=
M:H(:WC$3D&Z+\4NO31BG).JVUM:ZE9N.!M<9 FUF-MCM#KM54J-X'81JJUVM
M_+8V78\YRB[;(S3U!9X.;;%AVRR0?D],D%25B5#%8&1AA=Q*3%%-DT)?H17S
M\AY^(LA;+'^+MEO%7C+3RT5TFX9L$$M,DDZ[:[GQ1!#'5PE9"6J!W90_36&[
MC2GV7-G'04[?9&*)9MM,@_8@IN-\^^V&07NW(:8XUF5BML40+O*K*B0?126B
M?O;>3%JY:;WE2LOQ:[4K58%BQ_+ND2RQQQVA1]PJ*<E:<89LVHNVA\9=L:!
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MI%G.2>)+=U^A_X3_NP*A@8@71C*HGD?@S&9&LU0H'.B.RDP!+%-2(?*X6,]
M>)FX@2II(=!>5432C'-NC9T/0@]P'G'Z8!G!Y.3%J[:&KQ71X!)3L0+VCI3-
M"+)<YC]+7(UYL9QA0L?M;]^ "TI. I8LEUS$A5 CR"Z#CR&J6B*VST=1=86U
M]>AN7^3L.K76?41;F6/O:L ;TGV5><=YM +_/-/ ^(C17RR0_1CME\+1"G\
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MJ7@$&!A)KU*R /ZY,WRT#V+A'X-_X><[PT$(9, FO]@>_UTXV+<2 <L[;3J
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M6EH8!(5;9.&_K'O00_!RL,0^QA)"Y+MEM*;]5!4SG5M1F%RG\/5,U=XWS_C
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M9>J54B"]JL.$@_SM6Q8X\TI-[$E?C@WO]O7ZW+E(M"BPO9"3BEQT'[#6.45
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M?P*T?\TI;S,)4<L@WS%F.SZ:4M% PJ#\^JG-KA8'>$4N4RD^NX#'J48+.5I
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M_>[NUF2P]?T+BB.<T>]I&,?OQJCIYLOLPD,1S!+X$^S1RF3S$%A @ F:<VO
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MWH.4JN9B-I#&BRQMI\H([50 ^EE9XCG*3B:/C?H%<O5%TEXBEB<YY>)H5G]
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MC^ RR79M2C45-JK9WV,YN76I74.[V0)A ZGVL1Q62Y&-0?(E0 /?;T #&]#
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M$Q3OT@KC: SRV:0F[IMVC%0MC^J[!4?@V."D@_?41D&EIW\,CK$?3UUG;'^
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M'>%<\!*N^)%DJO3T./8;#M>?&DJ@R)0*7@K)=56F!\8C;=#6!%^;\XV3F'Y
M@"'EZ?)8HI^1P>_:(Z5YR=)DZ0^9+-3&[3=ZY=[I%=76-ZJ7)9:FP)5(48)_
M>$M ?/Q34D]U$1WM<BQJ0?E8+ ID&(R)VE %\6J=&R?'0>]_/M<7::F%7-=[
M605;Q-$?T4TE,>N$7"*'<$R5 W&Y)C])<5!2@8OB->.G-)*(DLW/88X5S0L.
M73T"&=H>)2IU/73OAPUT;P/=>T#0O:\:JQZJZL=8(,T;]_B^K=2Y;1JYYF_8
M4A9DVYF-UK,(<-/E"V1F<;=SE@)N.X"!;"(;-- R"\0N]= ('N*2+GUPNKU-
M/9]3)P.8M]7'T6MDFNW3D5NM MGBWTI"P7'W'/] N*Q]/R&5G'E;\U55=*LK
MT0COXTX*138)38$3=UD$5+\'0RLO%$J#T$=+)F?$1VGX1((D8/BR3F^;CI=V
M0$#V2P>=[]SOL?=,!G.6J>)$36"I:/HJ94&8$0G=I^JTTPR[*B2%\.)4II!/
MS!N=D5&!6)(2+^::1=<<WU4E1*%=,F^G853YM/FM6V3$D[:F@Q7(&0Z\WY.1
M9QB\C=?ZD)$!5FBJ<0=&PB]_Z^72X7EJ=K!R90V7*FRK]EA[G\"_#=/DKQ26
MK67E'#A)OV>P:(@)66(]B%;](=>!(E15(#NX 5:*R!UC^#G6\E>5)M<D>FZF
M"R31^X@:#%RIG)> -T858&F,P;4:->9VD%':(]&1_2VKM31C6-U?N#G0J::?
MX(A44>IZ3@.CH0=\N1ZI7^=L>(SGW4C5G>:QB:=243&HG^N(VN%PG;#L#<2>
MV*FT-C07^5\KRZ6SNG1T]'V#O153R2+!U- LS[C@'+9",4TCXQB6Q?)"$7.X
MK>(<M@QBP^@L$K<))F0WX+XFVHV9DZ]RZ%T,0X6FF+TJTIAC1,D'TO#T <Y)
M,:F2\DHUK 2#@9+A%LVH;$9=\NRFII%4EC.$N#RX[VEI86M>%&!YS")*\U45
MJ%P3<2I+.O%Q>H4RA!/D] @+P&WYW>H:U3:Q[>1B_UT5:1*7DO"_>N%P19+A
MA>!=;7J!I6[("0LJKZ1T>7N4_2+)DS+*+ IFW:>Z+8:%T J)JU&-(*OYJ'39
MX[VS)YH45TZ?=@7?)^6(RGY]WSM.11C:7OUPKIC@9ZO^J([-L,90<*>;^C26
ML>J=XJ,DU&E"A;99<L%5$"32:P^6V]E'WBG(W5"1+X4*XLLI%UU8]D\RPU6O
M:$:XC8+URG((1L*QP?E=C1YA'5,I8MR5XM072P8#K9,B7BE4]K]@CU8QPT_4
M61::^0S-A-)@DERMJYX^%&/>EFQR6GRT+5;@XU+\C_$PVZ- "JPV:S<KI,@F
MIM^]'JL43'%^:M<0-R"WM^N :"A!O(9Z;<?D^NUA !#T-RW@]DX1U&_8JD6\
M;43 2V<?(1BLB!%*L69'[03ON0I%)P@G!!WK.O?CPE3+6 U%Y=>LMIN$ 1BM
MM5LJZJ9GJF^5%,)$TC]1UU$S1#Y;SZYN^<),KDIG*FM3A*T^KEWP&'>V8+K^
MQQ)00\?[[V52\2;!/H%)F2L#@H(,.JNGZ'?@W$%<HO1H8:,(#"1P_^KVC*-!
M]UM43[=LMG&WZ,!-:NOWT3T?%SGY/)S.''U<8$-Z01,?8X',LF3#*$ZB3'!T
M3 R51:1/+1XI;4>9S)6IMA5;BP!VQFR60D@L=!.VKBB0\:B<*=](X66NN:%%
M\B]PK:8VY$:WTU$4B43.7W%<"(U7G(S<JW(D"SN:LM)EGZ-1)JPZYB;J%?RF
M6SKQ9]OF;(CBG'[(";>+Y$\P594N.UH9N+5-+^L&'T,Y@?D$YZ@+6<%"'A5'
M\^@BJ3R<?\M!A:6[+@DM'\!TYI +I/>\"<R2%8G1+,6H6 DD-!$YL9U<]-[P
M."2'1AI"V%%"J;^J9*&"&57<FEZ68 E(7':QH PZJ19).B*<(>6.J'X5,T'8
M,]7BS?#P5$&\M,J%I"":S14C2JP8U2\QM%JO$R$.=)%@/$:=MC[S^71WD_K<
MI#XWJ<\;WLGACE<]%#1584B.05*9(PT<B"DS!6B'@Z-G<ZR:5<R(W)R@*"U.
MIP:I>$/M4P>#Q@\4?:M#=J:\.+]0[C&JN0<N8,*W=Z2CR;B21ZG#N7)<6%:%
M<J1EB:G0SP1E(SCNJ6;I2N?RW!/6-NW<<@\,)RECWP$?2O0-CE>0;($T*0[1
MF1-!11K4]"K-DHO$D\A03)(+J@Y+*\VSEZE7U70>;SM8#KBCE[QG)V-N>1/Z
MVO1R)J/)/#\E;@JFBE;UYQ;A"TSC%/9=NF'S>PC;*E555&SJ-2NFT/B.I2*/
ME#*:C6W<JC;?D(+KJ1B2,7BQPI@H=-&[8CN>*Z1(:SN\S4PO,_53*L96O2F'
MS^TM)2$]+_*$2<?%>^" E<(0QM@"%G,>Z*: F1^I!LN\^8J*S'YMBK.-SY4!
M:.(@.^#* CVW-..TX^O"Q:[&5[#[ITN[$)O/6XP!$,D,'0_E!YGFS^USQ/EW
MMMZ)+Q21 ORVUIMN]N*]VXO_XKUXD"R**D59Y=WX1A0\I1S5+HB+Y:1N^O8F
M)NN6L"L&:(TQ87?9/,J+)'"FV,Z4D-^NT (^R8\0EM')LF5[M^X).3#^MI<Z
M#%431R$I"4W*E(?2#+C%/';3PQ9=8/3)7QV^ID@?**0T>O7D\'78.ECS[BIC
MJ@MG>)1NGWA0#<)C*Y'YNERRHDKG1%! ]Q9-B8QH=M?#4A^?5)V=>P/8[,5[
MMQ<_" A>=9L4%!1Q4E4-AK]U;'ZMG+.J ,[;9*;5L)P0BC,MEV@C_G:2Y,DL
M%<@.Z?2);I4AHE6YPS9N%9-J-;JDJ&'=]#O"H:G.JN<WG'-E0A'W/-;NG#)5
MG3=0/7F:/".M1Z=Q\22\3[/>X/@S)JVM@#8;[=YMM$S8I$42AU,,'8,)>$$Z
MO5FK%ID+JB92 HGSI+@R]E*(!B(B.4<74JO;5UA9Q ;B]G:$TFX0&B51XLZ-
M=*:,!%W4$N:;P1VZM4Q&%J5#S]C&7:+&T]R"+?6CP;.MZ>"+MQ78I#IO?*>Y
MU H@(LZ6]":%W;R(F683G9$YZU/E\QOU*R!/P?+I1&4'U[^E^&T"N8U^O'=R
MDHLADEQY!,._X(ICE@JLR"HEZE;R0YMM&QL);IT(MVC\F/-'..DF=G,35&N4
M5$>F4H+].2!T3H*ELXZ>D8V'PR67Z225\ !W!,.[!^TW9UI<?5MS_(,SHX?H
M0EI5$E4]23"E\AR"!BAPJGP6F9)_8NB/K52L;>*4UC4$8^VV?S9;Z=YMI8*W
MTMN$BA^L6->E?(*(QV8W)31DE>5*3?+R5$62RP0)I^@ON62^-40JU-$C89OC
M*@'R(<&GU:" NQ&:S8E\XSLM6#Q&F%4OBSR=!F-B+5^J"K[ ?$5PV&J*.C,6
MXL,HK\19JO3/[,BGZ7]+=.7,BVUACB2VD%Z@95A),QT$,?AMP.]"5FZS MMJ
M"4Q.]A%(P;]9"D[3BXM5L(<)_#.;HX_9=!SB0=V.Z?HRS=QD4:-8D-"6J@?B
M+9@ ,1Y]Q6W$"$KJ5@%:]5E-OT.CV+BN,%E0BUDL,TJS]EYK41<=H:+<H-Q7
MA&?[C,?4QD^FHI7JKS-.^%;=I(:F3@+OA>G@>N5T$+0*EZ3U&WAKVR_P4=0'
M;KS]UV"+C!\NIILOLXMH':'80$:9TG]S>N85MN.D"C'#+](8B\/"C+".!,E/
M.@@EB?.M,F2&2 Z'"0Y.DRG. L3_-AZC6>%:;FTMM8[:$J\&0LJ4L<-3ADQ"
MQ2HQ$9=%%N65U4G)%YFVQMT-*FME&2D)8W%1'0V84A[T5SJK$_@1=3<U#:'L
M5GFZGV+A]-<+/2;[0J,'L#:RI,J1-KB78EI)=2])(\W@5FMQIIUD4=_YW"JR
MK7R221F$D@'#8;<I[;[-\*=86%9^SM'_W]9_'NK;O#I\O:4-CGZ/4$QO"B1
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M4D0@2>88)7K0/#Y\>( _YYW\16\B.H#AR:.!1]CG2F^9*S$S6\<@LTL*DL-
M=F4543KWS4M+*E)34#D<ZHG85)V%!@-D<V1BY3E^BIO#.<>Q+'!?6:]Z^7+>
M#)"JM1RP1(\Y!B3C*TUY"<9MB1>SWT7F]*B+8DR+>;A/\0Y?QV4.^T]XS<SJ
M2H\#<E'4PH.;P=TN_,4RA823_3>?]I^:IS#>P_WW6HBT*W2?76D..Z7?82 0
M6^GA$_PYJ:6(BP?T>&!FY1-JR$$/:/35<UE=F7XP#VPZ,_?*[;'QST)L?(B-
M7UYL_'?';\W:&+/#N9HSB00F(-U=<HD7@>Y[\P/=[\7CNJ-!++%,[<>/QV='
M)_]>7=E^<W@!<SJXO/STQ\<KR]]ZZYGQX.;ZB\,\'[I=;W/GCLWXM_6W3+%I
M>W/*\/6@S7F7T"'/"]TVH )M.A5#N[^VP&##?Z0>.X_BMEJZ[/HB+60J4G3;
MH=\^29BI0(*MR31*"J( %!B'I%4JH\8-ZQW,Z4]L0K_)^3 +SOP #5Y!@S>Q
M1:VA@1?Y +TW$;( V<C-89:(? PLXJH^F2FZ0YD[,M."XBF5EGTDT"@)/WB.
MWVDWBEB(V+CN"Y3[,X[1FC=""R:^BJAPM! &E@[=1X.1P3<=G5S#@$4!BWS"
M(F\"BPY:HT %,S%%, JN$UD&%*(+CH*HY[@8;56KNE[5M10W(G9DRBTQ,8H*
M9+KI5&!H.913RI9%T(GL)Z+7P[AMHN2Y=70!HP)&^811L2\8U5I>BE2*0@=*
M2U4(32D!-0#L>P2G6/,>WJJAT4PN8JTAJH#O$> HD&)ZF &6 BSY!$O"%UCZ
M =$)2X9_S36/+ K=BD 6=RQ7(M$/DI"3*9U3E%[YW79#07@$B6CMX]&[]1(N
MRY"O2E?LU,KB? 2U(IT+ FN/D,CLR",CX1'82<*(C!4/B6[0%"Y5T*X'*9L5
MFHY!:<#)@),^X63/%YR\:LV$*CA*0C;.$PEAKV5<H.WJ9J!8E' Y-*Y(#JB<
MJM>345F&1S0YML>_C5\>MAL&81XS&+$ZWFG,!BJ);0^V_YGWXDT!E0(J^81*
M?7]0J:52:2/57: Z$L%9Z](,9QPF40BN31GO7E_H)BKZ4F;E'BTDN3E@JT=#
MS8NXEM7J[FX:5 N5(HR<VFE5/*P4I7C><CFHJU(2#"@7PHZ\##O:\2SLZ**B
MVU_ DD5\,3*GKX- Y;*)0Q!2$'(\$W(>;Q#2H>(Z9@V4L!:7N"#^66-JSB9[
MYQSVW -\]3 3CUV5M[8;1ST"%'C&/'S0FR:''JIAW)9,)5,1B&1I; L?:F$B
M2;^XNJIC;L'VR&=]B$'*"3#G$\P]WH JXMM&\PS(+XYB;@[H\5AE>8UZE)5L
M)$"1:30Q87QJCR\5.=3M0.9RJ&<&. 1P"N#D$SAY$V%US*.6O)"Q1 %'3=FT
M4=J)I8D290@01K8^FC"Y\\+51FAD!2%0<28HIZNU#J/(!4A>/)\4^YKBV6P)
M<)H\Q,["\34L%D91BI5UO6O7=KEBDTA,2S:V4!B?BK[*A19$?"7J4.<GA7<)
MN2HRH9W+UBU1)?P&1 Z([!$B/]YXLIE%6JQXF"2JW/O<UFUIEK1T:$2@V8$;
M['>*?*"T! Q?1#<'79C@AJ!^JL4*"3N(=.1'Q:S=3E.#[\S [/;\HB7*=:;!
MG>UL;3TGC%ZK&'^,L+4U9TUBP?4HI[INCP"1B)K+F;P38[W4"X,#:U!>O6)K
M!^O5PRL'P]M7,QTG*MK;VYYY\M'BO+:K<UCWFRG0.2:;>+&U4$'3&0\#73WX
MJD[7'((#4O;J+I_?,NJVCR>V/%!99CG *1 2!T&55ANA1>A0<P.8+2W8/8?B
MB$R+EHLA4Z<J%6FI5]GD%^1 $]?T#B!<A-,ZG-8^G=;>A%FV#Q]*%:@?8@-4
M%ZK:C"H1QA=RS302A!I;\YY1V>8RSC#2@M0<Y<H[CY<W1A5BX=*!3<;M:ER
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M5:06W4O/&U9SUS@T.A3Z *&6&\<F;Z!X.D8P0;$G '8VB66!*!J9]O LJ>T
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MM"K9V,8)K[$U0]GSO!EHAX']2'#'CM-^PIVR]YDG<W+XZT-/E < G=:"BCG
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M.#(82@4Y36QD,95C>;:<"1IQLN](Y#FB">2EK/);,HZP_S!XK&OXHJ<SFW#
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M\-\?C$\D+!-$6U3+,.C( 7#\GW@T<->U'S[^+;-=7:6&SP2N-9*AQ5U72X2
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M,V<W!B#RF &J#D2>:?'$MN<PW@H0D"=$\'9.G2M#\4D%9#0^ES'%;< U)&X
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M+3(P,C4Q,#$T+GAS9%!+ 0(4 Q0    ( (M*4%OA<AU %PD  .9H   5
M          "  0L$  !A:W1X+3(P,C4Q,#$T7V1E9BYX;6Q02P$"% ,4
M" "+2E!;:_Q7[PX,  "FD   %0              @ %5#0  86MT>"TR,#(U
M,3 Q-%]L86(N>&UL4$L! A0#%     @ BTI06WS/CN]A"   @&,  !4
M         ( !EAD  &%K='@M,C R-3$P,31?<')E+GAM;%!+ 0(4 Q0    (
M (M*4%M[04'6Y;<  -5R!  *              "  2HB  !E>#$P+3$N:'1M
M4$L! A0#%     @ BTI06XJ(P$G^/P  >I8!  H              ( !-]H
M &5X,3 M,BYH=&U02P$"% ,4    " "+2E!;./NP*GE+  !^P0$ "@
M        @ %=&@$ 97@Q,"TS+FAT;5!+ 0(4 Q0    ( (M*4%NNA 98>$L
M (+! 0 *              "  ?YE 0!E>#$P+30N:'1M4$L! A0#%     @
MBTI06P0F_#9J30  :,@!  H              ( !GK$! &5X,3 M-2YH=&U0
M2P$"% ,4    " "+2E!;>G.O!H8F  "["@( "0              @ $P_P$
M97@U+3$N:'1M4$L! A0#%     @ BTI06\-/9+!!(@  TO$   L
K     ( !W24" &9O<FTX+6LN:'1M4$L%!@     +  L D (  $=( @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:AKTX="http://akaritherapeuticsplc.com/20251014"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aktx-20251014.xsd" xlink:type="simple"/>
    <context id="AsOf2025-10-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001541157</identifier>
        </entity>
        <period>
            <startDate>2025-10-14</startDate>
            <endDate>2025-10-14</endDate>
        </period>
    </context>
    <context id="From2025-10-142025-10-14_custom_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001541157</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AKTX:AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-14</startDate>
            <endDate>2025-10-14</endDate>
        </period>
    </context>
    <context id="From2025-10-142025-10-14_custom_OrdinarySharesParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001541157</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AKTX:OrdinarySharesParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-14</startDate>
            <endDate>2025-10-14</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-10-14" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-10-14" id="Fact000004">0001541157</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-10-14" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-10-14" id="Fact000010">2025-10-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-10-14" id="Fact000011">AKARI THERAPEUTICS, PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-10-14" id="Fact000012">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-10-14" id="Fact000013">001-36288</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-10-14" id="Fact000014">98-1034922</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-10-14" id="Fact000015">22 Boston Wharf Road FL 7</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-10-14" id="Fact000016">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-10-14" id="Fact000017">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-10-14" id="Fact000018">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-10-14" id="Fact000019">(929)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-10-14" id="Fact000020">274-7510</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-10-14" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-10-14" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-10-14" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-10-14" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From2025-10-142025-10-14_custom_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember"
      id="Fact000025">American     Depository Shares, each representing 2000 Ordinary Shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-10-142025-10-14_custom_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember"
      id="Fact000026">AKTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-10-142025-10-14_custom_AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember"
      id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2025-10-142025-10-14_custom_OrdinarySharesParValue0.0001PerShareMember"
      id="Fact000028">Ordinary     Shares, par value $0.0001 per share*</dei:Security12bTitle>
    <dei:NoTradingSymbolFlag
      contextRef="From2025-10-142025-10-14_custom_OrdinarySharesParValue0.0001PerShareMember"
      id="Fact000029">true</dei:NoTradingSymbolFlag>
    <dei:SecurityExchangeName
      contextRef="From2025-10-142025-10-14_custom_OrdinarySharesParValue0.0001PerShareMember"
      id="Fact000030">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-10-14" id="Fact000031">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
